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Abstract 
Earlier detection and improvements in treatment for cancer have contributed to a 
decline in mortality rates. With an increase in survival, however, comes a growing 
group of survivors experiencing immediate and delayed physical and psychosocial 
side effects of cancer diagnosis and treatment.  One of the most feared and 
problematic effects is cancer-related lymphoedema, estimated to occur in 20% of 
breast cancer survivors and 15% or more of other cancer survivors (e.g., melanoma, 
gynaecological, bowel).  Lymphoedema is associated with a range of additional 
physical and psychosocial side effects.  Progressive exercise has been found to help 
minimise many of the adverse effects of cancer and its treatment, and does not 
exacerbate lymphoedema.  Lymphoedema organisations now promote exercise for 
women with breast cancer-related lymphoedema, yet the majority of women fall 
below the national recommended physical activity levels.  This may be related to an 
individual’s exercise barriers self-efficacy (that is, their confidence to overcome 
exercise barriers).  However, little is known about whether specific lymphoedema-
related barriers exist, and no scale is available to measure self-efficacy in this sub-
group of survivors.  More research is also needed on how to reduce these barriers.  
Further, exercise is promoted for those with lymphoedema (specifically breast 
cancer-related lymphoedema) and there is a growing perception that resistance-based 
exercise is best, despite limited research comparing resistance- and aerobic-based 
exercise directly.  The aims of this research were therefore to: 
1) identify and examine potential barriers to exercise for individuals with 
cancer-related lymphoedema; 
2) evaluate and compare the effects of resistance- versus aerobic-based exercise 
on lymphoedema status, physical outcomes (muscular strength and 
endurance, aerobic fitness, self-reported upper-body functioning, body 
composition and bone mineral density), exercise barriers self-efficacy and 
quality of life (QoL), specifically in women with breast cancer-related 
lymphoedema. 
 
Two studies were conducted to address these broad research questions.  Study one 
had two components, with the first involving the development and testing of 
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psychometric characteristics of a scale to measure exercise barriers self-efficacy in 
those with cancer-related lymphoedema.  This part of study one resulted in a 
lymphoedema-specific sub-scale containing five items addressing lymphoedema-
related exercise barriers that can be used in conjunction with a well-established nine-
item general exercise barriers scale for cancer patients.  Principal components 
analysis revealed these items loaded highly (> 0.75) on one factor when tested with 
the general barriers scale, and demonstrated good construct and criterion validity, 
high internal consistency (Cronbach’s alpha=0.93) and test-retest reliability (Pearson 
r=0.68, p< 0.01).     
 
The second part of study one used this scale to assess exercise barriers self-efficacy 
in individuals with cancer-related lymphoedema, and to determine if personal, 
cancer- and lymphoedema-related characteristics were associated with self-efficacy.  
Use of this 14-item scale (five lymphoedema-specific and nine general barriers 
items) indicated individuals with cancer-related lymphoedema (n=109, 79% with 
breast cancer-related lymphoedema) have only moderate confidence to engage in 
exercise when faced with potential exercise barriers, with an average exercise 
barriers self-efficacy, out of 100%, of 48% for general barriers and 51% for 
lymphoedema-specific barriers.  People who did not do any physical activity 
(sedentary) reported lower general and lymphoedema-specific exercise barriers self-
efficacy (42.0% [95% confidence interval=26.4, 57.5] and 34.4% [20.0, 48.8], 
respectively) compared to insufficiently (62.0% [51.2, 72.9] and 50.6% [41.4, 59.9], 
respectively) or sufficiently (59.7% [49.5, 69.9] and 51.4% [43.5, 59.3], respectively) 
physically active individuals.  General and lymphoedema-specific self-efficacy was 
also lower in individuals with moderate (48.4% [37.1, 59.7] and 40.9% [31.8, 50.0], 
respectively) or severe lymphoedema-related symptoms (45.0% [33.6, 56.5] and 
42.2% [33.3, 51.0], respectively) compared to those with mild symptoms (62.2% 
[49.1, 75.3] and 54.4% [40.5, 66.3], respectively), as well as in those with three to 
four (54.7% [42.1, 67.3] and 47.9% [35.7, 60.0], respectively) or five or more 
(45.3% [35.2, 55.5] and 40.3% [32.3, 48.2], respectively) lymphoedema-related 
symptoms compared to those with one to two symptoms (65.0% [52.3, 77.6] and 
52.1% [40.2, 64.0], respectively).  Additionally, females reported lower general 
exercise barriers self-efficacy than males (48.2% [42.4, 53.9] versus 61.1% [42.9, 
79.2]) and individuals with lymphoedema for over two years reported lower general 
self-efficacy compared to those who had developed lymphoedema within the 
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previous two years (51.3% [41.0, 61.1] versus 58.8% [47.7, 69.8]).  Individuals who 
developed lymphoedema following treatment for gynaecological or other cancers, 
compared to breast cancer, reported lower lymphoedema-specific self-efficacy 
(gynaecological=39.6% [27.0, 52.3]; other=45.5 [30.3, 60.8]; breast=51.3% [44.8, 
57.9]).   
 
Study two involved the development, implementation and analysis of a 12-week 
supervised, progressive exercise intervention, with a 12-week follow-up period, 
designed to examine the effect of exercise mode (resistance- versus aerobic-based 
exercise) on lymphoedema status, as well as physical outcomes, exercise barriers 
self-efficacy and QoL, in women with breast cancer-related lymphoedema.  Women 
with unilateral, stable lymphoedema were randomly allocated to a resistance- or 
aerobic-based exercise group, with 16 supervised sessions.  Assessments were 
completed at baseline, post-intervention and 12-week follow-up, at Queensland 
University of Technology, Brisbane, Australia.      
 
Results from study two demonstrated neither resistance- nor aerobic-based exercise 
influenced lymphoedema status, reflected by no change in bioimpedance 
spectroscopy scores (BIS) or circumference measurements (two different methods 
used to assess lymphoedema status).  Participation in aerobic-based exercise led to a 
significant reduction in the number of lymphoedema-related symptoms reported (-1.5 
[-2.6, -0.3]).  For secondary outcomes, participation in the resistance- or aerobic-
based exercise intervention led to improvements in general (8.6% [-3.8, 21.0] and 
9.1% [-3.1, 21.4], respectively) and lymphoedema-specific (9.4% [-1.3, 20.1] and 
12.6% [1.9, 23.3], respectively) exercise barriers self-efficacy.  There were 
significant upper-body strength improvements observed in the resistance-based 
exercise group (5.1 [3.8, 6.4] kg; p< 0.01).  Clinically relevant improvements were 
also observed in muscular endurance in both groups (squat test; resistance-based 
exercise group=9.4 [1.7, 17.0]; aerobic-based exercise group=9.4 [0.3, 18.4]) and 
aerobic fitness (6-Minute Walk Test; resistance-based exercise group=34.6 [10.4, 
58.8] meters; aerobic-based exercise group=26.9 [3.1, 50.7] meters).  Finally, 
clinically meaningful improvements in QoL were associated with resistance- and 
aerobic-based exercise (14.6 [9.6, 19.7] and 14.0 [7.3, 20.6], respectively).  Exercise 
participation was not associated with exacerbations in lymphoedema or other adverse 
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events.  The program was highly accepted by participants, as evidenced by high 
adherence to supervised and unsupervised exercise sessions (median [min, 
max]=100% [50%, 100%] and 100% [65%, 100%], respectively).  Further, 
participation in sufficient levels of assigned exercise was maintained during the 12-
week follow-up period (100% [0%, 100%]). 
 
Findings from this work highlight that assessing potential barriers to exercise can 
enable healthcare professionals to better assist patients in identifying ways to 
overcome exercise barriers and engage in regular exercise.  Based on the findings of 
study two, self-efficacy levels may be improved with initially supervised resistance- 
or aerobic-based exercise, at least in women with breast cancer-related 
lymphoedema.  Importantly, evidence from this study highlights that both resistance- 
and aerobic-based exercise are safe for those with lymphoedema, may assist in the 
prevention of lymphoedema progression and may contribute to improvements in 
lymphoedema or lymphoedema-associated symptoms, as well as produce other 
physical and self-reported benefits.  Given these findings, exercise prescription for 
women with breast cancer-related lymphoedema should consider individuals’ 
preferred mode, as well as which type of exercise presents with fewer exercise 
barriers for the individual. 
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always supported my crazy ideas and helped me pursue my dreams, whether it has 
been moving a few states away, or to the opposite side of the world.  I love you and 
cannot thank you enough for always believing in me and supporting my (often 
slightly crazy) ideas.  Don’t worry, I promise I’m done with school after this!  To my 
brother Cody and his wife Megan, I love you two, your Skype sessions, messages 
and mail always made my day.    
 
This is dedicated to the memory of Raphael Faith, a beautiful soul and incredible 
friend who lost her battle to bowel cancer during the final stages of this thesis.  
Thank you for reminding me of what is truly important, and teaching me so much.  I 
love and miss you gorgeous, we’ll never stop fighting.   
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Chapter 1: Introduction 
In 2012, 120,710 new cases of cancer (excluding basal and squamous cell 
carcinomas) were diagnosed in Australia (16).  It is expected that by 2020, yearly 
incidence may reach 150,000 (14).  The five most common cancers reported were 
prostate, bowel, breast, lung and melanoma of the skin, accounting for over 60% of 
all diagnoses (16).  Fortunately, earlier detection and improvements in treatment 
have contributed to a decline in mortality rates over recent years.  Specifically, five-
year survival rates for all cancers have increased from 47% in 1982-1987 to 66% in 
2006-2010, with even higher rates reported in some of the most common cancers 
including prostate (92%), breast (88%) and melanoma (92%) (16).  While cancer 
continues to be a significant cause of illness, both in Australia and worldwide, 
associated mortality is decreasing.  This trend has important implications for the 
healthcare system as an increasing population of cancer survivors emerges.   
 
1.1 CANCER AND TREATMENT-RELATED SIDE EFFECTS      
Despite declining mortality rates, morbidity following cancer is common.  Cancer 
diagnosis and treatment regimes have been associated with both immediate and 
delayed physical and psychosocial side effects.  These issues may occur in isolation 
or as clusters (38; 294), with some symptoms most common following a certain 
treatment type, such as surgery (e.g., range of motion [ROM] limitations) or 
chemotherapy (e.g,, peripheral neuropathy), while others may not be directly 
attributable to a specific treatment component.  Additionally, the experience of 
certain side effects (such as pain) may increase the risk of developing other side 
effects (such as insomnia) and/or further exacerbate existing comorbidities.  Physical 
issues following cancer treatment often include weight changes (83; 110), fatigue 
(27), pain (103), muscle loss and weakness (140), impaired bone health (296) and 
lymphoedema (132).  While some physical side effects dissipate over time (110; 
140), other issues, including cancer-related lymphoedema, muscle loss and fatigue, 
may persist into long-term survivorship (246).   
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Cancer and its associated treatments have also been associated with psychosocial 
side effects, such as distress, anxiety and symptoms of depression (6; 140; 240), 
particularly at transition points (i.e., point of diagnosis, beginning/ending treatment, 
yearly follow-up).  Psychosocial issues are often associated with the physical 
sequelae experienced.  Pain, fatigue and depression are a commonly-identified 
symptom cluster (227).  Altered sexual, bowel/bladder or physical function may 
contribute to feelings of anxiety, sexual issues and body image concerns (110; 140), 
which may also be affected by physical changes (e.g., scarring, radiation burns, 
cancer-related lymphoedema) (82; 251).  
 
Quality of life (QoL) has been observed to change following cancer (110; 111; 140), 
although direction of change may vary among subgroups of cancer survivors.  For 
example, research in breast cancer survivors found QoL improves for the majority of 
survivors within the first year post-treatment (89; 251; 258).  Further, women post-
breast cancer on average report higher QoL levels than individuals experiencing 
other medical conditions (111), even many years post-diagnosis (32; 51; 89; 112).  It 
has been hypothesised that this may be an effect of additional support provided or a 
reflection of response bias, where people judge their personal QoL compared to a 
now different cancer-affected standard (a phenomenon called response shift) (42).  
However, a proportion of survivors may continue to decline following treatment (10; 
111; 258).  These include younger survivors (109; 291) and those reporting greater 
post-cancer treatment declines in areas such as physical and sexual functioning and 
body image (17; 90; 109; 111; 163; 192) and experience of other general and cancer-
related comorbidities (e.g., lymphoedema, musculoskeletal problems, diabetes) (163; 
258).  
 
The physical, psychosocial and QoL effects related to experiencing cancer have been 
associated with impaired functioning and declines in recreational, leisure and/or 
occupational tasks.  Issues such as fatigue and cancer-related lymphoedema have 
been reported to adversely affect physical activity levels.  Consequently, declines in 
activity levels exacerbate issues including fatigue and weight gain.  This results in a 
detrimental cycle whereby physical impairments result in and are worsened by 
declining physical activity levels (Figure 1.1) (119; 125).  The negative effects of 
cancer and its associated treatment regime, and the potential adverse effect of these 
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sequelae on physical activity levels, may ultimately impact overall survival (142; 
144; 147).  
 
Figure 1.1 Physical activity and side effects cycle 
 
1.2 CANCER-RELATED LYMPHOEDEMA 
One of the most feared and problematic side effects of cancer treatment is cancer-
related lymphoedema (194; 206).  This potentially chronic condition results 
following an alteration to the lymphatic system, whereby lymph fluid no longer 
properly drains from the interstitial space (58; 65) and typically presents as swelling 
in areas such as the arm, leg, groin or torso.  Lymphoedema is transient for some, 
chronic for others and may fluctuate with factors such as the weather, travel and 
changes in activity levels (50; 78).  Lymphoedema may present early or many years 
following cancer and may be stable, fluctuating or progressive.  Over time, 
lymphoedema may lead to fibrotic changes and adipose tissue depositions that can 
limit treatment options and create additional complications (50; 78; 131).   
 
1.2.1 Lymphatic system and cancer-related lymphoedema 
The lymphatic system is a complex network of lymph vessels and organs distributed 
throughout the body, responsible for filtering and transporting fluid and proteins 
collected from the interstitial space.  Transport is uni-directional, with lymphatics 
collecting plasma fluid and proteins that enter the interstitial space from arterial 
blood flow and predominantly reintegrating them into blood circulation (273).  This 
combination of fluid and proteins, referred to as lymph, is propelled through the 
lymphatic system by internal and external factors.  Internally, movement is primarily 
regulated by one-way valves, smooth muscle lining lymphatic vessels and 
differences in pressure gradients between components of the lymphatic system (105).  
!!side effects 
(fatigue, weight gain, 
lymphoedema) 
" physical 
activity 
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Important external contributors to lymph flow are the musculoskeletal and 
cardiovascular systems owing to their close proximity with lymphatic system vessels.  
Skeletal muscle contractions, respiration (especially deep diaphragmatic breathing) 
and blood flow have all been demonstrated to aid lymph flow (180; 203; 214; 273).       
 
Lymph movement is affected by lymph production and lymph transport, with 
alterations to either or both components capable of impairing transport capacity.  
Reduced transport capacity, in turn, may result in the development of lymphatic 
diseases, such as lymphoedema (105).  Cancer-related lymphoedema, one of the 
most common forms of secondary lymphoedema (105), results when damage occurs 
to the lymphatic system following events such as surgery, infection or injury, 
impairing lymph transport components (62; 105).  Initially, protein-rich fluid 
accumulates in the interstitial space (196).  Continued accumulation of material in 
the interstitial fluid and decreased capacity to clear it may lead to increased fibrosis 
of tissue in the affected region and weakened immune system functioning (131; 219).  
 
Lymphoedema presentation and severity is commonly classified using the 
International Society of Lymphology scale, ranking lymphoedema from stage 0-3 
based on clinical presentation (Table 1.1) (145).  Stage 0 is when lymphoedema is 
‘latent’ with no visible swelling, while stage 1 is when lymphoedema is ‘pitting’ 
(upon applying pressure to the affected area, skin remains indented) with visible 
swelling and results from high-protein fluid accumulating in the interstitial fluid 
(105).  Conversely, stage 2 is primarily non-pitting, with tissue changes and 
hardening of the affected area, and stage 3 is defined by extreme swelling (>50% 
volume) and non-pitting, with changes to skin texture and integrity (105; 145).  
Stages 0 and 1 are considered reversible, while 2 and 3 are classified as non-
reversible.     
 
Table 1.1 International Society of Lymphology lymphoedema staging 
ISL stage 0 A subclinical state where swelling is not evident despite impaired lymph transport.  
This stage may exist for months or years before oedema becomes evident. 
ISL stage 1 This represents early onset of the condition where there is accumulation of tissue fluid 
that subsides with limb elevation.  The oedema may be pitting at this stage. 
ISL stage 2 Limb elevation alone rarely reduces swelling and pitting is manifested. 
ISL stage 3 The tissue is hard (fibrotic) and pitting is absent.  Skin changes such as thickening, 
hyperpigmentation, increased skin folds, fat deposits and warty overgrowths develop. 
ISL=International Society of Lymphology 
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Many types of cancer and their associated treatments may result in the development 
of lymphoedema.  These include prostate, bowel, gynaecological, head and neck 
cancer and melanoma.  However, much of the research on cancer-related 
lymphoedema comes from studying women with breast cancer-related 
lymphoedema.   
 
1.2.2 Breast cancer-related lymphoedema 
1.2.2.1 Incidence and assessment  
Breast cancer-related lymphoedema is estimated to occur in 21% of survivors, with 
rates increasing up to two years after cancer diagnosis (88; 129; 206).  However, 
estimates vary given the diversity in assessment tools and their ability to detect 
different stages of lymphoedema.  In the earlier stages, lymphoedema is 
predominantly characterised by excess interstitial fluid, with little to no change in 
surrounding tissues.  If lymphoedema progresses, presentation becomes characterised 
by deposition of adipose and fibrotic tissues with or without an increase in 
extracellular fluid (66; 132).  As such, assessment methods such as bioimpedance 
spectroscopy (BIS), which measures extracellular fluid (285), as well as subjective 
report (207), are best suited for earlier-stage lymphoedema.  Conversely, volume and 
circumference measures (arm circumferences, water displacement, perometry) are 
best used with later-stage lymphoedema (105; 131; 226).  
 
Certain limitations exist for all of the above-mentioned techniques.  With the 
exception of the subjective survey, assessment is limited to limb lymphoedema, not 
monitoring individuals that present exclusively with breast or trunk lymphoedema 
(77).  One study found 35% of women (out of 194) reported breast and/or trunk 
lymphoedema, with almost half of these cases not reporting lymphoedema in other 
regions (259).  This has important implications for measurement, as changes in 
lymphoedema may not actually be reflected by change in measurement results.  
Additionally, the objective methods only portray lymphoedema at the point in time at 
which measurements were obtained, not allowing for monitoring of daily or weekly 
fluctuations that may exist with variation in activity, temperature and other factors 
(50; 78).  Given the limitations of both objective and subjective measurement 
techniques, it may be most beneficial to use multiple assessment methods, especially 
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if the patient population presents with a combination of early- and later-stage 
lymphoedema.  Additionally, as adequate detection of lymphoedema may be a key 
factor in monitoring treatment success and helping minimise detrimental effects of 
the disease (255), a relevant assessment method needs to be chosen when monitoring 
survivors with breast cancer-related lymphoedema.                
 
1.2.2.2 Risk factors 
A number of treatment factors have been associated with lymphoedema risk, 
specifically undergoing more extensive and aggressive treatments.  Undergoing 
axillary node dissection, compared to sentinel node biopsy, has consistently been 
associated with lymphoedema rates about four times higher, regardless of other 
treatments received (88; 129; 137; 255).  Risk also increases with more extensive 
breast surgery (86; 113; 255) and/or radiation therapy (61; 96; 117; 138; 196; 213),  
and potentially chemotherapy (11; 88; 255), especially when these treatments are 
used in combination.  
 
Specific patient characteristics have also been associated with increased risk of 
developing lymphoedema, although inconsistencies exist in relationships observed. 
Research showing an association between age and risk of developing breast cancer-
related lymphoedema is mixed (255).  Additionally, being overweight or obese has 
also been proposed to increase risk of breast cancer-related lymphoedema, as excess 
weight and fat deposits may increase lymph load and reduce lymphatic transport 
efficiency (197), with this relationship between body mass index (BMI) and 
lymphoedema reported as independent of other personal and treatment-related 
characteristics (59; 60; 88; 137; 150; 213).  Also, once lymphoedema has developed, 
obesity has been associated with the severity of the condition (278; 284).  However, 
these relationships may only be observed when breast cancer-related lymphoedema 
is assessed via specific lymphoedema assessment methods that assess limb size, with 
recent studies reporting no association between BMI and development of 
lymphoedema (107; 179; 246).  
 
1.2.2.3 Lymphoedema side effects 
Breast cancer-related lymphoedema is associated with a range of adverse physical 
and psychosocial effects.  As lymphoedema is a lymphostatic disease, it can impair 
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immune function and increase the risk of infections and susceptibility to illness (131; 
191).  Individuals often develop swelling, as well as issues such as pain, heaviness 
and skin tightness (206).  Lymphoedema is also associated with decreased ROM and 
higher self-reported disability ratings and experience of upper-body symptoms, 
which may already be impaired from breast cancer treatments such as surgery and 
radiation therapy (53).  Survivors with breast cancer-related lymphoedema have also 
reported more comorbid conditions than those without breast cancer-related 
lymphoedema, specifically orthopaedic issues, obesity and the need to use cardiac 
and osteoporosis medications (228).   
 
The burden of coping with lymphoedema, in addition to other side effects from 
cancer and treatment, further increases an individual’s risk of psychosocial distress 
(28), and has been associated with psychosocial issues including distress, depression, 
anxiety and social inhibition (188; 215).  Women with breast cancer-related 
lymphoedema also report body image, self-esteem and sexuality concerns, which 
may be associated with greater physical complications (53) and visible issues such as 
swelling, skin infection and wearing a compression garment (115; 188; 191; 215).  
 
Lymphoedema and its associated complications may limit an individual’s ability to 
perform common daily activities or maintain household and/or occupational roles 
(250).  Additionally, uncertainty about how to care for lymphoedema and avoid 
exacerbating the condition often leads to further declines in function independent of 
actual physical limitations (174; 175; 250).  This, in addition to the physical and 
psychosocial side effects, may contribute to the decline in QoL often reported 
following development of lymphoedema (2; 188).  A cross-sectional survey on breast 
cancer survivors with and without breast cancer-related lymphoedema found those 
with lymphoedema (n=64) reported poorer QoL, especially when experiencing 
physical factors such as pain and arm dysfunction, compared with their age-matched 
peers who had not developed lymphoedema (n=64) (227).  Having lymphoedema 
may also impact quantity of life, with recent research suggesting developing breast 
cancer-related lymphoedema during the initial years post-cancer diagnosis is 
associated with a two to three-fold increase in mortality risk (132), although reverse 
causality cannot be ruled out (i.e., development of lymphoedema as a marker of 
cancer recurrence).  
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1.2.3 Lymphoedema following other cancers 
While incidence information on lymphoedema in other cancers is limited, a meta-
analysis by Cormier and colleagues (65) found that, overall, approximately 15% of 
those diagnosed with melanoma, sarcoma, genitourinary, gynaecological or 
head/neck cancer subsequently developed lymphoedema.  However, rates vary 
depending on type of cancer and diagnostic method.  For example, a study in 
gynaecological cancer survivors found incidence depended on cancer type (vulvar, 
36%; uterine, 8%; cervical, 12%; ovarian, 7%) and also varied with respect to 
whether lymphoedema was assessed via self-report methods (25%) compared with a 
clinical diagnosis (10%) (25).  
 
Lymphoedema assessment for non-breast cancer-related lymphoedema is often 
challenging.  Using circumferences to measure lower-leg lymphoedema does not 
include the groin/pelvic area, and may be difficult in head/neck lymphoedema (65). 
Reference values exist to allow use of BIS in unilateral (286) and bilateral lower-
limb lymphoedema (290), but researchers highlight these are preliminary and require 
further investigation.  Subjective assessment methods are also limited, and have 
primarily included use of tools such as the Common Toxicity Criteria or non-
validated questionnaires (65).   
 
Risk factors are similar for those associated with developing breast cancer-related 
lymphoedema.  Rates are higher in individuals undergoing lymph node dissection 
and more extensive surgery (65; 235; 298).   Radiation therapy and lower-limb 
lymphoedema incidence has been studied in gynaecological patients, with research 
suggesting cervical and vulvar cancer survivors face greater risk, compared to 
ovarian or uterine cancer survivors (1; 25; 235).  Limited research exists on patient 
characteristics associated with development of lymphoedema beyond breast.  
Preliminary findings suggest obesity is associated with higher lymphoedema rates 
(25), but there does not appear to be an association between age and development of 
lower-leg lymphoedema (1; 25; 235), although studies are limited and relate only to 
lymphoedema following gynaecological cancer.   
 
Individuals with cancer-related lymphoedema beyond breast report many of the same 
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physical and psychosocial side effects as survivors with breast cancer-related 
lymphoedema.  These include physical symptoms such as swelling, pain, heaviness 
and limited ROM (25; 235; 276), as well as psychosocial effects including distress 
(28) and sexuality and body image concerns (25; 102).  Further, at least in 
individuals with gynaecological cancer-related lymphoedema, survivors often report 
declines in physical and psychosocial functioning alongside decreased QoL (102).  
The compilation of research on potential effects of cancer-related lymphoedema, 
both breast and non-breast, highlights the need to minimise the development and 
progression of lymphoedema and help those affected to manage the physical and 
psychosocial sequelae of the condition.              
 
1.2.4 Lymphoedema treatment: use and efficacy 
Treatment and management of cancer-related lymphoedema involves both patient-
administered and health care professional-administered approaches, with no single 
‘usual care’ treatment approach (209).  As lymphoedema is considered a chronic 
condition, the main aims of treatment are minimising physical effects, primarily 
swelling, pain and movement limitations, and preventing further complications such 
as skin damage and infection (158).  A variety of modes may be used by health care 
professionals and the patient in managing lymphoedema, both in isolation and 
combination.  These include complex decongestive therapy (CDT), manual 
lymphatic drainage (MLD), massage, compression, elevation, exercise, 
pharmaceuticals and pneumatic pumps (87; 158; 191).  
 
While CDT and its components (e.g., MLD, compression) are often prescribed for 
cancer-related lymphoedema, evidence for their effectiveness in managing 
lymphoedema is graded as weak to moderate (210).  Additionally, the continuous 
phase of this treatment is primarily self-administered, which may result in poor 
adherence and therefore minimal benefit.  A survey by Sierla and colleagues related 
to breast cancer-related lymphoedema found, of the 57% of respondents reporting 
compression garment use, none met recommended clinical guidelines for use and 
garment care (259).  
 
Studies indicate individuals have greater motivation to undertake clinician-
administered rather than self-administered therapies, viewing these as more effective 
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(198; 293).  However, reliance on health professionals for lymphoedema 
management is time-consuming and not always geographically or financially feasible 
for patients (257).  Other therapy options such as pneumatic compression therapy, 
laser, pharmaceuticals and surgery may present time- and finance-related barriers as 
well, and effectiveness data for these methods is also limited and only short-term 
outcomes reported (87; 274).  
 
Given the time and monetary burdens associated with such therapies, as well as only 
moderate evidence on their effectiveness, individuals with cancer-related 
lymphoedema need self-management options that they feel confident in undertaking 
and that offer a cost-effective, time-efficient management strategy.  One of these 
self-management options is exercise, the evidence for which will be reviewed in 
detail in the next chapter.  
 
1.3 SUMMARY 
Recent years have seen a decline in cancer mortality, but morbidity following cancer 
remains prevalent.  This burden will rise with an increasing population of survivors.  
Lymphoedema following cancer treatment is a significant issue with limited 
evidence guiding its prevention or management, with most evidence coming from 
studies in individuals with breast cancer-related lymphoedema.  Certain treatment-
related factors including lymph node removal and extensiveness of surgery and 
adjuvant therapy, in addition to patient characteristics including obesity, may 
increase one’s risk of developing cancer-related lymphoedema.  The physical and 
psychological implications of the condition, combined with side effects of cancer 
irrespective of lymphoedema presence, adversely impact survivors’ overall function, 
well-being and QoL. The physical effects of cancer and cancer-related lymphoedema 
commonly impact functioning and performance of daily activities.  This may have 
significant social, emotional and financial implications and potentially adversely 
affect mortality.  Current and common treatment options are vast and varied but 
typically carry with them significant time and cost implications.  Proven efficacy is 
limited for most, and outcomes other than changes in limb size rarely studied.  Those 
with cancer-related lymphoedema need to be given safe, effective and feasible ways 
to manage their condition and improve their confidence in maintaining their daily 
activities, and ultimately their quality, and potentially quantity, of life.   
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Chapter 2: Literature Review 
2.1 EXERCISE IN CANCER SURVIVORS 
2.1.1 Cancer and treatment-related side effects 
Extensive research has been undertaken on strategies to minimise the adverse 
physiological and psychosocial effects of cancer and associated treatment, with 
participation in regular exercise emerging as an effective approach to counteract 
morbidity.  Given the multitude and diversity of studies investigating exercise for 
cancer survivors, numerous reviews have been conducted to summarise this research 
and highlight key findings, limitations and areas for future research.   
 
First, exercise post-cancer is considered safe.  A meta-analysis by Speck and 
colleagues on exercise interventions in all cancer survivors found 29 of the 36 
interventions reporting on adverse events indicated no harm resulted from exercise 
participation (265).  In the studies reporting incidences, these were primarily not 
attributable to exercise or, those that were, were classified as mild and 
musculoskeletal in nature (e.g., hip pain, pulled muscle).  A meta-analysis of 14 
studies in breast cancer survivors found adverse events reported in four studies, with 
incidences primarily of a musculoskeletal nature and occurring during an 
unsupervised, home-based program (187).  Although two studies reported 
development of lymphoedema, occurrence rates were non-significantly different than 
those observed in the control groups.   
 
Research in during- and post-treatment cancer survivors has consistently found 
exercise produces positive physical effects, with findings coming from low-quality 
single-group studies, as well as randomised controlled trials (RCTs) of high 
methodological quality.  A meta-analysis of 82 studies found small to medium effect 
sizes from exercise interventions conducted during treatment (40% of studies) on 
improving aerobic fitness and physical activity levels and minimising adverse 
changes in body weight and percentage body fat, with significant positive impact of 
exercise on upper- and lower-body strength (265).  Similar effects were observed in 
post-treatment interventions (60% of studies), with the greatest benefits accrued in 
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aerobic fitness, strength, flexibility and lean body mass (265).  Other reviews have 
reported similar physical benefits of exercise, both during and after cancer treatment 
(56; 63; 106; 108).  Evidence also suggests exercise during treatment can reduce the 
development of adverse symptoms and side effects (245).  Additional physiological 
parameters, including immune function markers (i.e., IGF-1, insulin), ROM and 
flexibility or bone health, have been demonstrated to benefit from exercise, but 
evidence is preliminary and thereby further investigation is needed (56; 106; 245; 
249; 265).   
   
Exercise interventions have also assessed the psychosocial impact of exercise.  A 
meta-analysis by Speck and colleagues (265) reported during-treatment interventions 
enhanced mood and functional QoL and decreased anxiety, with the most significant 
improvement related to self-esteem.  Improvements were greater in post-treatment 
exercise programs, with increases in QoL and body image and lower mood 
disturbance, fatigue, confusion and pain.  Other studies have highlighted these 
benefits, especially in QoL (100; 245), also reporting reduced depression, sleep 
disturbances and general psychological and emotional distress (56; 75; 94; 106; 108). 
 
Length of survival may also be impacted by exercise, with recent research suggesting 
cancer-related and overall survival is higher in physically active survivors.  Courneya 
and colleagues (74) found, at an eight-year follow-up, cancer and overall survival 
rates were higher in breast cancer survivors that participated in an exercise 
intervention during chemotherapy, compared to individuals in the control group.  
Additionally, a meta-analysis on four cohort studies conducted in breast cancer 
survivors concluded that all levels of post-diagnosis physical activity (intermediate, 
intermediate-high, high; classified using MET-hours per week) were associated with 
a significantly lower risk of breast cancer-related (34% reduction) and overall (41% 
reduction) mortality (144).  There were no significant increases in risk reduction 
when undertaking more intense exercise (moderate, moderate-high or high).  Similar 
findings relate to colorectal cancer survivors, with higher post-diagnosis levels of 
physical activity associated with lower cancer-related and overall mortality (190).  
However, these findings are yet to be confirmed in an adequately-powered RCT.    
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2.1.2 Exercise guidelines 
Guided by exercise research findings, a variety of professional organisations have 
updated their guidelines on activity recommendations for cancer survivors.  Exercise 
and Sport Science Australia advise the majority of cancer survivors to follow age-
appropriate general population exercise guidelines, combining both resistance- and 
aerobic-based exercise.  However, they highlight the need to monitor individuals for 
development or exacerbation of side effects to help build confidence and assess if the 
program is appropriate (135).  The American College of Sports Medicine consulted 
an expert panel in the field of exercise and cancer (249), who endorsed 
recommendations similar to Exercise and Sport Science Australia, highlighting the 
need to adjust programmes depending on the survivor’s experience of treatment-
related effects and risk for adverse events such as fractures, weight loss or 
lymphoedema.  
 
Given the promising results from research on exercise and cancer, and guidelines on 
exercise from professional organisations, more research is justified on assessing how 
transferable such findings are to cancer patients with greater survivorship concerns, 
such as those with lymphoedema.  To date, the majority of research on individuals 
with cancer-related lymphoedema, one of the most feared and problematic side 
effects of cancer, has focused on breast cancer survivors.  This literature is reviewed 
in the following sections. 
 
2.2 EXERCISE AND BREAST CANCER-RELATED LYMPHOEDEMA 
2.2.1 Guidelines related to breast cancer-related lymphoedema 
Historically, breast cancer survivors have been advised to limit their physical activity 
and use of the affected arm after treatment to reduce lymphoedema risk (5; 272).  
However, as highlighted by the National Lymphoedema Network and reviews of risk 
reduction advice, many recommendations are based on pathophysiology and clinical 
experience rather than evidence-based research (186; 202).  Overall, advice is aimed 
at preventing overload of the lymphatic system by avoiding increased production of 
lymph and further structural damage to the lymphatic network in individuals.  This 
has included recommendations to avoid certain medical procedures on the affected 
limb (e.g., blood pressure readings, needle sticks), minimise limb constriction from 
tight clothing or carrying heavy bags, avoid vigorous activity and heavy lifting and 
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wear a compression sleeve during flying and exercise (186).  With limited research 
supporting these recommendations, lymphoedema education organisations are 
beginning to update their guidelines, endorsing rather than discouraging exercise and 
full use of the affected limb (43; 202).  However, breast cancer survivors with or at 
risk of breast cancer-related lymphoedema report confusion about what activity 
advice to adhere to, and reduce activities such as exercise and affected arm usage due 
to fear and uncertainty of developing or exacerbating lymphoedema (37; 174; 175).  
As limiting activity in the affected arm may actually increase upper-body 
impairments and lymphoedema risk (or worsen the condition) (175; 236; 241), more 
evidence demonstrating safety of exercise for those with breast cancer-related 
lymphoedema is needed to minimise activity avoidance in this population and 
provide support for guidelines endorsing exercise. 
 
2.2.2 Physiological effects of exercise on breast cancer-related lymphoedema 
The most distal lymphatic vessels, responsible for collecting fluid from interstitial 
space, lack the smooth muscle lining found in more proximal lymphatic vessels 
(173).  Therefore, initial movement of lymph into the lymphatic system 
predominantly relies on extrinsic factors, including skeletal muscle contractions, 
respiration and arterial pulsations (12). 
 
Physiologically, exercise may therefore impact the lymphatic system through its 
effects on the musculoskeletal and/or cardiovascular systems.  Additionally, the 
lymphatic system helps the musculoskeletal and cardiovascular systems function 
during exercise by returning fluid and proteins to the cardiovascular system, and both 
systems help remove lactic acid and provide oxygenated blood and energy to the 
musculoskeletal system (173).  Lane and colleagues (171; 173) observed that 
exercise may result in lymphatic changes in the impaired region, including 
lymphangiogenesis (generation of new lymphatic vessels from pre-existing vessels) 
and recruitment of dormant vessels, but further research is warranted.  In a study of 
30 women, they found that breast cancer survivors with (n=10) and without 
lymphoedema (n=10) and controls (n=10) had similar clearance of 
radiopharmaceuticals from the hand during and after arm ergometery.  However, 
survivors with lymphoedema had a greater build-up of fluid in the forearm dermis 
rather than clearance to the axilla, as normally expected.   
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It is also feasible that participation in exercise enhances immune functioning by 
improving immune cell response and reducing inflammatory responses, thereby 
helping decrease stress on the lymphatic system (297).  However, the evidence in 
breast cancer survivors and post-exercise immunological improvement is limited and 
conflicting (99; 205; 245; 249).  For example, Fairey and colleagues (98) found 
individuals performing thrice-weekly moderate cycle ergometery training for up to 
35 minutes (n=25) had significantly higher (p< 0.05) natural killer cell activity 
compared to the control group (n=28) after 15 weeks.  Conversely, Nieman et al. 
(205) found no significant between-group differences when comparing a control 
group (n=8) to women undertaking thrice-weekly 60-minute resistance- and aerobic-
based exercise for eight weeks (n=8), but sample size was very small.  
 
The effect of exercise on the lymphatic system may vary depending on exercise 
mode prescribed.  Research in healthy subjects has demonstrated exercise in the form 
of dynamic muscle contractions increases lymph flow, both peripherally in lymphatic 
system collecting ducts (208) and in skeletal muscles (126; 127).  This may be due to 
the effects of contracted and stretched skeletal muscles on lymph production and 
transport.  As greater demand is placed on the musculoskeletal system, increases in 
blood flow and arterial pressure to the muscles contribute to greater lymph 
production (273).  Further, stretched muscle pulls on connective tissue and therefore 
the attached lymphatic vessels, allowing interstitial fluid to enter, while contracting 
muscle inhibits entry or escape of fluid and compresses the lymph vessels to help 
propel lymph proximally (180).  Muscular strength and endurance also improve with 
resistance-based exercise in healthy populations (167; 260), with the potential for 
similar improvements in individuals with breast cancer-related lymphoedema having 
important implications for decreasing stress on the affected limb during performance 
of daily activities (244) and helping condition the lymphatic system to handle 
increased loads.  Such evidence provides a foundation for prescription of resistance-
based exercise for individuals with breast cancer-related lymphoedema.   
 
Aerobic-based exercise may benefit breast cancer-related lymphoedema through its 
effects on the cardiovascular system.  Physiologically, inspiration assists in moving 
lymph by decreasing intrathoracic pressure and thereby reducing lymph transport 
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obstruction (292).  Accordingly, the increased respiration associated with exercise, 
particularly aerobic-based exercise, may therefore increase lymph flow and improve 
lymphoedema.  Deep diaphragmatic breathing has also been associated with 
improved lymph flow owing to its role in helping empty the thoracic duct, 
encouraging lymph transport (198), so incorporating this with exercise may further 
benefit breast cancer-related lymphoedema.  Greater activity of the cardiovascular 
system results in higher blood flow and capillary filtration, increasing interstitial 
fluid pressure, which may further aid lymph uptake and transport (172; 193).  
Aerobic-based exercise is also associated with weight management, and potential 
loss, helping counteract obesity (104; 249).  This has important implications for 
lymphoedema, as high BMI is a risk factor for lymphoedema (88), and obesity 
increases stress on physiological systems such as the lymphatic and immune system 
(263).  Given these factors, it is feasible aerobic-based exercise can play an important 
role in lymphoedema management.  
      
2.2.3 Exercise and risk of developing breast cancer-related lymphoedema 
Recent research suggests exercise appears physiologically safe for breast cancer 
survivors with and at risk of breast cancer-related lymphoedema.  Studies conducted 
in women at risk of breast cancer-related lymphoedema, which have contributed to 
the change in risk reduction advice from some lymphoedema organisations, have 
evaluated a range of intervention approaches and outcomes.  Study types include 
RCTs, pre-post interventions and case series, published between 2001 and 2012, with 
between 10 and 242 participants.  Study characteristics are summarised in Table 2.1.  
The inclusion criteria for studies that formed part of this review include: directly 
monitored breast cancer-related lymphoedema development as a primary or 
secondary outcome; included an exercise program not prescribed as a physiotherapy 
treatment.  Given these inclusion criteria, valuable physiotherapy-based studies were 
excluded that may be of interest for other researchers in this area but are not 
reviewed here (30; 33; 39; 79; 161; 277).   
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Table 2.1 Exercise interventions monitoring the development of breast cancer-related 
lymphoedema 
Study levela 
 
 
Level II (RCT), n=6(3; 9; 73; 160; 222; 243) 
Level III-1 (pseudo-RCT), n=1(236) 
Level IV (pre-/post-test case series/single-arm), n=7(57; 124; 171; 223; 237; 267; 281) 
Participant 
characteristics 
 
 
n=10 to 242; 13 studies only involved women with breast cancer, 1 study involved 
a mixed cohort(223) 
 
Still undergoing treatment (n=2)(73; 267), less than 3 months post-surgery (n=3)(9; 160; 
236) or post-treatment (range=1 month to 21 years; n=9)(3; 57; 124; 171; 222; 223; 237; 243; 281) 
Intervention 
duration 
 
Exercise mode 
 
 
Exercise 
prescription 
8 weeks to 12 months (median=6 months); 5 studies included post-intervention 
follow-up(9; 160; 236; 237; 281) 
 
Upper- or full-body RES only (n=6)(3; 160; 222; 236; 237; 281); combined RES and AER 
(n=3)(9; 222; 281) with dragon boating (n=3)(57; 124; 171); compared RES to AER 
(n=1)(73); Pilates (n=1)(267) 
 
Primarily moderate intensity and progressive, 2+ times/week; all with a gym-based 
supervised component 
Study quality 
 
 
 
 
 
 
 
Sample size 
calculations 
7 high-quality (e.g., Level II or III-1, blinded randomisation and assessments, 
intent-to-treat analysis)(3; 8; 73; 160; 222; 236; 243) 
 
3 moderate-quality (e.g., Level IV, multiple assessors or blinding to decrease 
bias)(223; 237; 267)  
 
4 low-quality (e.g., Level IV, no blinding, participants excluded from analyses)(57; 
124; 171; 281) 
 
3 studies powered to detect change in lymphoedema status between groups(3; 236; 243) 
Lymphoedema 
assessment 
 
 
Other 
outcomes 
Water displacement (n=7)(9; 57; 73; 171; 222; 236; 243); arm circumferences (n=5)(3; 124; 160; 
171; 281); BIS (n=1)(281); perometry (n=1)(267); clinical evaluation (n=1)(243) and/or self-
report (n=6)(3; 57; 223; 237; 243; 267) 
 
Strength (n=7)(3; 57; 73; 171; 222; 223; 243); ROM (n=4)(57; 160; 222; 267); physical functioning 
(n=6)(9; 57; 73; 222; 223; 281); anthropometric measurements (n=5)(3; 57; 73; 243; 281), QoL 
(n=8)(9; 57; 73; 222; 223; 236; 267; 281); other psychosocial constructs (e.g., depression, 
fatigue; n=3)(73; 267; 281) 
Lymphoedema-
related findings 
 
 
 
 
Other 
outcomes 
findings  
 
Overall level of evidence: good (grade B), numerous level II studies with low bias 
risk, most studies consistent in findings, moderate to substantial clinical impact  
 
Equivalence hypothesis supported: RES and/or AER not associated with increased 
rates of breast cancer-related lymphoedema compared to control or pre-post 
exercise, even in higher-risk participants (more nodes removed) 
 
Strength (n=7): good (grade B)(3; 57; 73; 171; 222; 223; 243) 
ROM (n=4): good (grade B)(57; 160; 222; 267) 
Physical functioning (n=6): good (grade B)(9; 57; 73; 222; 223; 281) 
Anthropometric measurements (n=5): satisfactory (grade C)(3; 57; 73; 243; 281) 
QoL (n=8): satisfactory (grade C)(9; 57; 73; 222; 223; 236; 267; 281)  
Psychosocial (e.g., depression, fatigue; n=3): satisfactory (grade C)(73; 267; 281) 
Limitations  Most did not meet or include sample size calculations 
Only half had usual care control group 
Variation in exercise prescription (e.g., mode, duration, location) 
Range in intervention adherence (47% to 100%) 
Limited consistency in lymphoedema assessment method 
Limited assessment of other physical and psychosocial outcomes 
agrading of studies using NHMRC criteria; a 
RCT=randomised controlled trial; RES=resistance-based exercise; AER=aerobic-based exercise; 
BIS=bioimpedance spectroscopy; ROM=range of motion; QoL=quality of life
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2.2.3.1 Populations studied 
Overall, 14 studies monitored development of breast cancer-related lymphoedema 
following an exercise intervention.  Of these, nine studies involved women who were 
post-treatment (surgery, chemotherapy and/or radiation therapy) (3; 57; 124; 171; 
222; 223; 237; 243; 281), and seven recruited participants that had undergone 
axillary node dissection (9; 124; 236; 281) and/or sentinel node biopsy (9; 160; 243).  
One study excluded participants that had a BMI >29 (‘obese’), basing this decision 
on obesity being a potential risk factor for lymphoedema development (236).  All but 
one study involved only breast cancer survivors, with Rajotte et al. (223) including 
111 participants with breast cancer out of 187 cancer patients.  Sample sizes ranged 
from 10 in a pilot study (281) to 242 in a three-arm RCT (73).   
 
2.2.3.2 Intervention 
Median intervention length was six months (9; 222; 236), with five studies including 
at least a three-week follow-up (range=three weeks to two years) (9; 160; 236; 237; 
281).  Exercise mode(s) investigated also varied.  Six studies investigated resistance-
based exercise only.  Another six studies included a combined upper- or full-body 
resistance- and aerobic-based exercise program (9; 222; 281), with three of these 
incorporating dragon boat training prior to (57) or as part of the intervention (57; 
124; 171).  The remaining two studies compared resistance- to aerobic-based 
exercise (73) or investigated a Pilates program (267).  Intensity was primarily 
moderate and progressed during the study, and most studies included a supervised 
component.  Exercise adherence ranged from moderate (63% adherence to 
resistance-based exercise and 47% adherence to aerobic-based exercise in a 
combined program) (222) to high (100%) in a combined-mode intervention (281).  
Similar results were found related to follow-up adherence, with studies reporting 
drop-out rates ranging from 8% (73) to 25% (225). 
 
2.2.3.3 Study quality 
Using criteria from the NHMRC (201), six of the studies were deemed level II 
studies (i.e., RCT), with the intervention group(s) compared to a usual care control 
group most commonly instructed to follow given medical advice and not 
purposefully change exercise levels (3; 9; 73; 160; 222; 236; 243).  One other study, 
a pseudo-randomised controlled trial (level III-1), compared an activities-restriction 
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group to a no restrictions plus exercise group (236).  The remaining seven studies 
were level IV, pre-post designs with a single cohort (57; 171; 223; 267; 281) or 
series of case reports (124; 237).  Only two interventions reported sample size 
calculations based on detecting a change in lymphoedema status between groups 
(236; 243), with the remaining studies being powered on another outcome variable or 
lacking sample size calculations.  
 
2.2.3.4 Outcome assessment 
Lymphoedema status was objectively and subjectively measured, most commonly 
using water displacement in isolation (9; 73; 222; 236) or in combination with 
circumference measures (171) or self-reported symptoms (57) and clinical evaluation 
(243).  Other assessment methods included subjective report (223) with 
circumference measurements (237) and symptoms (3), perometry with self-reported 
symptoms (267) or BIS with arm circumference measures (160; 281). 
 
Additional outcomes of interest assessed in multiple studies included strength, ROM, 
physical functioning, anthropometric measurements and QoL.  However, there was 
limited consistency in the methods used to measure these variables, and only a few 
studies assessed each outcome.   
 
2.2.3.5 Summary and limitations 
Current findings suggest exercise during or after breast cancer treatment is not 
associated with an increased risk of developing lymphoedema.  This was true even in 
higher-risk women who had more lymph nodes removed.  Evidence comes from 
seven high-quality studies, which employed a randomised, controlled design and had 
a low risk of bias.  Further support is added by two moderate-quality and four low-
quality single-arm trials.  Only one program, using Pilates (236), did not support the 
equivalence hypothesis that exercise does not increase lymphoedema rates, but this 
was only a moderate-quality, non-controlled intervention design.  Evidence of a 
satisfactory to good level also exists suggesting exercise in breast cancer survivors is 
associated with various physical and psychosocial benefits.  These include improving 
outcomes such as strength, physical functioning and QoL, although further 
confirming research is warranted.     
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Limitations still exist, however, in the research on women at risk of breast cancer-
related lymphoedema.  Longer follow-up beyond the exercise intervention is needed.  
Such research would improve understanding of whether women continue exercising 
after participation in an exercise study, whether exercise can be used to prevent 
progression of sub-clinical breast cancer-related lymphoedema and if those that stay 
active continue having a lower risk of developing lymphoedema.  If women do 
develop breast cancer-related lymphoedema, however, the goal shifts to 
lymphoedema maintenance, and potential reduction, rather than prevention.  The 
research on exercise and existing lymphoedema is summarised in the following 
section.   
 
2.2.4 Exercise for individuals with breast cancer-related lymphoedema 
Exercise may also aid with the management of lymphoedema.  Fifteen intervention 
studies have been undertaken involving women with breast cancer-related 
lymphoedema, between 2001 and 2014.  Sample size ranges from 8 to 141 
participants, with a mix of study designs.  Interventions have assessed the effect of 
various modes of exercise on lymphoedema status, as well as additional physical and 
psychosocial parameters, and are summarised below in Table 2.2. 
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Table 2.2 Exercise interventions for individuals with breast cancer-related 
lymphoedema  
Study levela 
 
 
Level II (RCT), n=10(3; 64; 130; 148; 149; 178; 184; 185; 244; 276) 
Level III-1 (pseudo-RCT), n=1(146) 
Level IV (pre/post-test case series/single-arm), n=4(40; 114; 124; 154) 
Participant 
characteristics 
 
n=8 to 141, all women with unilateral breast cancer-related lymphoedema 
 
Participants were post-treatment (range=1 month to 28 years)  
 
Lymphoedema most often ‘moderate’ and/or experienced >1 year 
Intervention 
duration 
 
Exercise mode 
 
Exercise 
prescription 
5 weeks to 12 months (median=12 weeks), with 4 studies including post-intervention follow-
up(40; 130; 184; 236) 
 
Upper- or full-body RES only(3; 64; 114; 146; 244); AER only (154); mixed-mode(124; 130; 185); 
rhythmic exercises and deep breathing(57; 148; 184); yoga(178); water-based exercise(149; 276) 
 
Primarily progressive to moderate intensity, 2+ times/week; most with a gym-based 
supervised component 
Study quality 
 
 
 
 
 
Sample size 
calculations 
11 high-quality (e.g., Level II or III-1, blinded randomisation and assessments, intent-to-treat 
analysis)(3; 64; 130; 146; 148; 149; 178; 184; 185; 244; 276) 
 
1 moderate-quality (e.g., Level IV, multiple assessors or blinding to decrease bias)(38)  
 
3 low-quality (e.g., Level IV, no blinding, participants excluded from analyses)(114; 124; 154) 
 
4 studies powered to detect change in lymphoedema status between groups(64; 130; 185; 244) 
Lymphoedema 
assessment 
 
 
 
 
Other outcomes 
Arm circumferences independently (n=2)(124; 146) or with other methods (n=5)(3; 64; 114; 184; 185); 
other methods included BIS (n=4)(64; 130; 149; 184), perometry (n=3)(130; 148; 149), water 
displacement (n=5)(114; 154; 185; 239; 276), tissue dielectric constant (n=1)(149), toniometry (n=1) 
(167), DXA (n=1)(64), clinical evaluation (n=1)(244) and/or self-report (n=3)(3; 64; 154); 4 studies 
reported exacerbations(64; 154; 244; 276) 
 
Strength (n=3)(3; 64; 244), aerobic fitness (n=1)(154), anthropometric measurements (n=4)(3; 148; 184; 
244), QoL (n=7)(40; 146; 148; 178; 184; 185; 276), ROM (n=3)(64; 148; 149), upper-body functioning (n=3)(64; 
148; 154), other psychosocial constructs (i.e., mood, fatigue, pain; n=2) (178; 184) 
Lymphoedema-
related findings 
 
 
 
 
Other outcomes 
findings  
 
Overall level of evidence: good (grade B), numerous level II studies with low bias risk, most 
studies consistent in findings, moderate to substantial clinical impact  
 
Equivalence hypothesis supported: RES and/or AER not associated with worsening of breast 
cancer-related lymphoedema compared to control or pre-post exercise 
 
Strength (n=3): good (grade B)(3; 64; 244) 
Aerobic fitness (n=1): satisfactory (grade C)(154) 
Anthropometric measurements (n=4): poor (grade D)(3; 148; 184; 244)  
QoL (n=7): satisfactory (grade C)(40; 146; 148; 178; 184; 185; 276)  
ROM (n=3): satisfactory (grade C)(64; 148; 149) 
Upper-body functioning (n=3): satisfactory (grade C)(64; 148; 154) 
Other psychosocial constructs (i.e., mood, fatigue, pain; n=2): satisfactory (grade D)(178; 184) 
Limitations  Small sample sizes, with few power calculations based on change in lymphoedema 
Narrow participant population (i.e., most with chronic, stable lymphoedema) 
Variation in exercise prescription (e.g., mode, duration, location) 
Range in intervention adherence (56% to 96%) 
Limited consistency in lymphoedema assessment method 
Limited assessment of other physical and psychosocial outcomes 
agrading of studies using NHMRC criteria  
RCT=randomised controlled trial; RES=resistance-based exercise; AER=aerobic-based exercise; 
BIS=bioimpedance spectroscopy; DXA=dual-energy X-ray absorptiometry; ROM=range of motion; 
QoL=quality of life
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2.2.4.1 Participants 
All 15 studies assessing the effects of exercise in individuals with breast cancer-
related lymphoedema involved participants that were post-treatment (1 month to 28 
years).  Four studies reported excluding women with Stage III lymphoedema (146; 
184; 185) and Stage II lymphoedema (167), and, overall, participants had most often 
experienced ‘moderate’ (10-30% interlimb difference) and/or longer-term breast 
cancer-related lymphoedema (>1 year).  Only those with unilateral breast cancer-
related lymphoedema were included in the 15 studies, and sample size ranged from 
eight participants in a case series report (38) to 141 in a RCT (244).   
 
2.2.4.2 Intervention 
Median intervention length was 12 weeks (130; 276), ranging in duration from five 
weeks (184) to 12 months (124; 244), with four studies including a one- to three-
month follow-up (40; 130; 184; 236).  There was variety in exercise modes evaluated 
in studies.  One study investigated aerobic-based exercise in those with breast 
cancer-related lymphoedema, using an unsupervised eight-week pole-walking 
program (154).  Sessions were undertaken three to five times a week, for 30-60 
minutes plus warm-up and cool-down, maintained at 70-80% of maximum heart rate 
using a heart rate monitor.  Four participants completed less than 24 exercise 
sessions (and thereby did not meet exercise amount guidelines) and were excluded 
from analyses, while an additional 23% of participants dropped out after inclusion.   
 
Five of the 15 studies investigated the effects of resistance-based exercise in those 
with breast cancer-related lymphoedema using full-body exercise (3; 64; 244) or 
upper-body only exercises (114; 146).  Three interventions began with low upper-
body weights and progressed as tolerated, with 8-15 repetitions and two to three sets 
(3; 244).  One of these studies reported weight used was based on repetition 
maximum (RM) results (50-60% 10RM) (114).  Another study compared low- to 
high-load resistance training groups, comparing 15-20 repetitions at 55-65% 1RM 
weight to six to ten repetitions at 75-85% 1RM weight for one to four sets as 
tolerated (64).  The final resistance-based exercise study remained at a low intensity 
with one set of ten repetitions, primarily using exercises for ROM over strength 
improvement (146).  Exercise was home-based and unsupervised in two studies (114; 
146), while the remaining three studies were gym-based and began as supervised 
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(64), with two progressing to unsupervised (3; 244).  Sessions ranged from two times 
per week for 60 (3; 64) or 90 minutes (244) to five times per week for an undisclosed 
duration (114), up to daily at three times per day (146).  Adherence rates were 
reported as 75% for a 12-month program (244) to 96% for a three-month program 
(64), and were not reported in one study (146).   
 
Three studies investigated combined resistance- and aerobic-based exercise, with one 
study using full-body resistance-based exercises (130) and two limited to upper-body 
exercises (124; 185).  Harris and colleagues (124) did not provide information on 
resistance-based exercise intensity.  The other studies gradually progressed from 
light to moderate/hard intensity by increasing weight and decreasing repetitions over 
12 weeks (130) or increased over eight weeks as tolerated from a ‘light’ weight at 
baseline using three sets of 10 repetitions (185).  Aerobic-based exercise was 
conducted using multiple types (e.g., walking, cycling) (124; 130) or restricted to 
arm ergometry (185).  One study monitored intensity using rating of perceived 
exertion (RPE) and progressed from low/moderate (RPE 3-5/10 scale) to 
moderate/high (RPE 4-7/10 scale) (130).  Another study increased intensity through 
time (from 5 to 20 minutes) and arm ergometry resistance (185).  The final study did 
not regulate intensity and reported this as a limitation, as it therefore ranged among 
participants (124).  Hayes and colleagues (123) gradually increased number of 
unsupervised sessions from one of three to three of four or more, and McKenzie and 
Kalda (185) only had supervised sessions, three times a week.  The final study did 
not include information on supervision (124).  Only one study reported adherence, 
finding 88% of participants attended 70% or more of supervised sessions but not 
providing data on unsupervised session adherence (130).        
 
The remaining six studies used group classes of rhythmic exercises and deep 
breathing/relaxation (40; 148; 184), yoga (167) or water-based exercise (149; 276), 
with four conducted at a low intensity (40; 148; 185; 276) and one at a moderate 
intensity (149).  Four programs were initially supervised one to two times a week, 
with participants also encouraged to continue the program (40; 184) or self-care of 
massage and compression (276) at home.  Two programs involved only an initial 
supervised session, with instructions for participants to undertake three 30-minute 
sessions for the eight weeks (149) or daily exercise for 10-15 minutes for the six 
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months (148).  None of these interventions used weights, instead using gravity and 
body weight (40; 184) or water resistance (149; 276).  Supervised sessions ranged 
from 30 (149) to 90 minutes (167).  Average exercise adherence rates (above 75%) 
were reported in three studies (40; 178; 276), and 91% of participants in a third study 
performed the exercise at least five of the seven targeted days (148).  One other study 
found exercise adherence declined from 55% following the 5-week intervention to 
38% at the three-month follow-up (184), while the remaining study found 27% of 
intervention group participants did not complete minimum exercise criteria (149).   
 
2.2.4.3 Study design 
Ten of the 15 studies were level II studies, RCTs, comparing an exercise intervention 
to a usual care control group instructed to maintain normal lymphoedema treatment 
and not purposefully change physical activity levels (3; 64; 130; 148; 149; 244; 276),  
One study did not provide information on the randomisation process (185) and 
another randomised participants prior to baseline testing (184).  An additional study 
(level III-1) was randomised, but participants were divided between an exercise-only 
and exercise plus compression treatment group with no control group or information 
on randomisation process (146).  The remaining studies were level IV pre-post 
single-group (114; 154) or case series reports (40; 124).  Additionally, only some 
participants in two studies had breast cancer-related lymphoedema at baseline, with 
13 of 45 in one study (3) and 13 of 20 participants in the other (124).  Nine of the ten 
randomised trials used an assessor blinded to group allocation (3; 64; 130; 146; 149; 
184; 185; 244; 276), and one of the case studies reported assessors were blinded to 
previous measurements (124).  Six of the reviewed studies completed sample size 
calculations based on expected change in lymphoedema status (64; 130; 185; 244), 
but two of these studies did not achieve adequate numbers (178; 184).  No studies 
were designed to allow separation of the effects of resistance-based exercise 
intervention components from aerobic-based exercise components.   
  
2.2.4.4 Lymphoedema assessment   
The majority of studies used arm circumference measurements to assess 
lymphoedema, either independently (40; 124; 146) or with BIS (64; 149; 184), water 
displacement (114; 185), DXA (64) or symptoms and self-reported clinical diagnosis 
(3).  However, one study only obtained contralateral arm circumferences after the 
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intervention (124).  Other assessment methods used were perometry (148) and BIS 
(130) with tissue dielectric constant (149), BIS with toniometry (167) and water 
displacement (236; 276) with symptoms (64; 154) and the Common Toxicity Criteria 
(244).  Additionally, four studies reported on lymphoedema exacerbations (64; 154; 
244; 276).  
 
2.2.4.5 Lymphoedema status 
Overall, there is good evidence (grade B) that exercise can help lymphoedema 
management.  None of the 15 studies included in the review observed a significant 
objective change in lymphoedema status following participation in the exercise 
program, despite the method of lymphoedema assessment.  The RCTs reported no 
significant differences for change in lymphoedema between a usual care control 
group and a group undertaking resistance-based exercise (3; 64; 244), resistance- and 
aerobic-based exercise (130; 185), yoga (167), water-based exercise (149; 276) or 
rhythmic exercise and deep breathing (148; 184).  Further, results from four of these 
studies were suggestive of a lymphoedema benefit following an exercise 
intervention.  Specifically, following water-based exercise, Tidhar and Katz-Leurer 
(276) found a statistically significant and clinically relevant decrease (defined as 
more than 40.4 mL) in lymphoedema, as assessed by water displacement, but this 
change was only short-term.  Another study found a similar significant decrease in 
lymphoedema, measured using water displacement, as well as a significant decrease 
in self-reported tightness ratings, after an eight-week pole-walking program (154).  
McClure and colleagues (184) found, after five weeks of a group exercise and 
relaxation class with three-month follow-up, there were trends towards improvement 
in lymphoedema measurements in the exercise group.  These three studies, however, 
were not powered to detect statistically significant changes in lymphoedema.  An 
RCT by Hayes and colleagues (130), with adequate sample size to detect clinically 
relevant changes in lymphoedema, found two of 16 participants in the 12-week 
resistance- and aerobic-based exercise intervention group (compared with zero 
participants in the control group) no longer had clinical signs of breast cancer-related 
lymphoedema upon study completion.   
 
Results were mixed for the remaining four studies.  In a pre-post home-based, mixed-
type exercise intervention, Gautam et al. (114) found a statistically significant 
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reduction in upper-limb circumference and volume measures.  Also, after a 
randomised study of six months of upper-body stretching and light resistance-based 
exercise performed with and without compression, Irdesel et al. (146) observed 
significant between-group differences for arm circumferences change, and wrist and 
distal circumference measures significantly decreased in the exercise with 
compression group.  However, neither of these two studies included a non-exercising 
control group, so improvements in lymphoedema cannot be definitively attributed to 
the intervention.  One case series report found no significant interlimb circumference 
differences after approximately 12 months of resistance- and aerobic-based exercise 
with dragon boat racing, but no baseline values were included for comparison (124).  
The other report found lymphoedema volume (circumference measures) was 
maintained or decreased for all eight participants after eight weeks of a group class 
of deep breathing, rhythmic exercise and self-massage, with change independent of 
lymphoedema severity or compression garment usage (38).  In studies containing 
both resistance- and aerobic-based exercise, it cannot be concluded if one mode is 
more effective for managing lymphoedema or both have equivalent effects.   
 
In the four studies monitoring lymphoedema exacerbations, three studies reported no 
objectively-measured (i.e., change in arm volume) exacerbation during eight weeks 
of pole-walking (n=20) (154) or three months of water-based exercise (n=48) (276).  
Additionally, no participants self-reported an exacerbation during three months of 
low- or high-load resistance-based exercise training (64).  The fourth study, a well-
designed large-scale RCT comparing 12 months of resistance-based exercise to usual 
care (n=141), found significantly more objectively-measured exacerbations in the 
usual care group (19 versus 9) requiring a greater number of treatment sessions (195 
versus 77) (244).   
 
Three RCTs subjectively measured lymphoedema using self-reported symptoms and 
observed either no difference among groups in three-month change of symptom 
severity (64), or that participants in the usual care control group reported a greater 
number and severity of symptoms than the resistance-based exercise group after six 
(3) and 12 months (244) of progressive low- to moderate-intensity training.  An 
eight-week pre-post study found a significant decrease in self-rated tightness, but not 
heaviness (154).  One other study found the exercise group reported a difference (not 
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negative or positive) in arm symptoms during the intervention.  The researchers 
undertook mid-study objective measures to assess if the change in symptoms was 
associated with a change in lymphoedema status, finding no worsening of 
lymphoedema, with potential improvement in some subjects (130).   
 
2.2.4.6 Other outcomes 
A variety of other physical and psychosocial parameters were assessed in the 
reviewed trials.  Four RCTs monitored anthropometric changes (weight and/or body 
composition) following exercise participation (3; 148; 184; 244), yielding poor 
evidence (grade D) of benefit.  Only one study found a significant improvement in 
weight for the exercise versus control group (p=0.04), but there were only 21 
participants and data were only presented on treatment group weight loss (3.5 ± 5.0 
lbs/1.6 ± 2.3 kg) (184).  Further, only one aerobic-based exercise intervention, an 
eight-week pole-walking pre-post intervention, assessed body mass index, finding no 
significant changes (154).  As aerobic-based exercise has been associated with 
positive anthropometric changes in breast cancer survivors without breast cancer-
related lymphoedema (73; 160), and increased weight is associated with increased 
lymphoedema risk (88), further research is warranted, ideally of a longer duration 
and assessing changes in body composition in addition to weight using gold standard 
techniques.   
 
Three studies reported on strength changes, finding good evidence (grade B) of an 
exercise benefit.  Upper- and lower-body strength, assessed by 1RM testing, 
increased in the resistance-based exercise groups (versus usual care control group) 
after three (64), six (3) and 12 months (244) of full-body exercise.  However, only 13 
of 45 participants had lymphoedema in one study and data were not separated based 
on lymphoedema status.  Therefore, whether strength changes were observed in those 
with breast cancer-related lymphoedema is unclear (3).  It is also feasible that 
strength improvements were partly due to a learning effect, whereby individual 
performance initially improves due to increased familiarisation with the activity, 
particularly in individuals who had never completed resistance-based exercise (7).     
 
There is only satisfactory evidence (grade C) that exercise in women with breast 
cancer-related lymphoedema improves aerobic fitness, as only one pre-post single-
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group study assessed this outcome.  Jönsson et al. (154) tested fitness with a cycle 
ergometer test, finding a significant improvement in steady-state heart rate after the 
eight-week pole-walking program.  This was a small single-group (n=20), walking-
based intervention.  As such, further research is warranted, particularly comparing 
cardiovascular fitness changes between an aerobic-based exercise group and a 
control and/or resistance-based exercise group, using a more transferable 
measurement (i.e., walking-based test for a walking-based intervention).   
 
Three studies assessed changes in shoulder ROM following a three-month low- 
versus high-load resistance-based RCT (64), a six-month daily home exercise RCT 
(148) or an eight-week water-based exercise program (149), yielding satisfactory 
evidence (grade C) of an exercise benefit.  One RCT found significant increase in 
shoulder flexion, compared to the control, in the low-load group (p<0.05) (64), while 
the water-based program found both flexion (p<0.001) and external rotation (p=0.07) 
increased in the intervention group, compared to the control, and over half of the 
exercise group experienced a clinically significant increase in at least one ROM area 
(149).  The remaining study found no significant improvement in ROM (148). 
 
Seven studies monitored QoL changes using a variety of questionnaires (e.g., SF-36, 
Lymphedema Quality of Life Tool [LYMQOL], Upper Limb Lymphoedema-27) 
(40; 64; 148; 178; 184; 185; 276), with all but one (148) finding an improvement in 
QoL following the prescribed exercise intervention.  However, many of these 
improvements were not significantly different from changes seen in the control 
group, or were only in certain domains rather than overall QoL.  As such, there is 
only satisfactory evidence (grade C) that exercise in women with breast cancer-
related lymphoedema significantly improves QoL.   
 
There is poor to satisfactory evidence (grade C/D) that exercise improves other 
psychosocial outcomes.  One study assessed mood (Beck Depression Inventory), 
observing a significant improvement in the exercise compared to control group after 
both the five-week intervention and at three-month follow-up (184).  Three studies 
assessed self-reported physical functioning using the Disability of the Arm, Shoulder 
and Hand (DASH) questionnaire (64; 154) or QuickDASH-9 (148).  Only one study 
found a significant improvement, following eight weeks of pole-walking (154), while 
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Cormie et al. reported non-significant improvements in the resistance-based exercise 
groups and a decrease in the control group (64).  Finally, Loudon and colleagues 
(167) found no signifcant improvements in pain or fatigue following eight weeks of 
yoga.   
 
Therefore, the focus to date has been on the effect of exercise on lymphoedema 
status.  There is significant scope for evaluating the effect on other outcomes likely 
to influence physical and psychosocial functioning, especially as preliminary 
evidence suggests such parameters may benefit from exercise.  
  
2.2.4.7 Summary and limitations 
As highlighted in the previous section, exercise does not appear to increase rates of 
breast cancer-related lymphoedema, even in women with more nodes removed (i.e., 
axillary dissection) and therefore at a higher risk of lymphoedema development (88).  
There is also consistent evidence that exercise is safe for women who already have 
breast cancer-related lymphoedema, with some research suggesting exercise may 
decrease lymphoedema.  Currently, ten studies have demonstrated resistance- and 
aerobic-based exercise are not associated with exacerbation of lymphoedema, 
particularly when initially supervised, gradually progressed and monitored for 
adverse effects.  Preliminary evidence from four studies, three being RCTs, also 
suggests exercise may improve objective and subjective lymphoedema status (154; 
184; 276).  One adequately powered trial reported two of 16 participants in the 
exercise intervention group (compared with no patients in the control group) no 
longer had clinical signs of breast cancer-related lymphoedema upon study 
completion (130).  Results from the reviewed studies suggest exercise also improves 
other lymphoedema- and general cancer-related side effects, but these parameters 
were only monitored in a few studies. 
 
What remains under-researched is whether lymphoedema response may be 
influenced by exercise parameters such as mode (9); that is, whether certain types of 
exercise (e.g., resistance- versus aerobic-based exercise), intensities or durations are 
optimal with respect to influence on lymphoedema.  Current research focused on 
resistance-based exercise as optimal to help maintain lymphoedema.  There is less 
evidence for the impact of aerobic-based exercise alone on lymphoedema.  As 
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different exercise modes may physiologically impact the lymphatic system and 
lymphoedema in different ways (Section 2.2.2), and have also been demonstrated to 
produce different physical and psychosocial benefits in the general cancer population 
(73; 253), a comparison is warranted.  Other subjective differences between modes, 
such as ease of access to and confidence in undertaking, warrant comparison of 
resistance- to aerobic-based exercise.  This will assist in maximising exercise 
prescription, as such factors need to be addressed when designing a program to 
ensure adherence, and thereby benefits.   
 
Additionally, there has been limited consistency across trials for methods used to 
assess breast cancer-related lymphoedema.  There is significant scope for evaluating 
the condition using objective and subjective measures, taking into account their 
sensitivity to lymphoedema stage (Section 1.2.2.1).  Further research is also 
warranted on how exercise in individuals with breast cancer-related lymphoedema 
may benefit other outcomes.   Both lymphoedema and breast cancer and its 
associated treatments have been associated with physical and psychosocial side 
effects, and preliminary findings suggest these may be counteracted with exercise.  
 
2.2.5 Self-efficacy 
One factor that needs to be considered when prescribing exercise is how feasible 
partaking in an exercise program is for an individual.  Factors such as time, 
accessibility and confidence may impact exercise adherence.  Despite growing 
evidence on the importance of engaging in exercise, many cancer survivors fall 
below the nationally recommended levels of weekly physical activity (55; 95; 125).  
While exercise interventions in individuals with and at risk of cancer-related 
lymphoedema (breast) have predominantly reported adherence rates of over 70%, 
many of these programs are supervised with continuous follow-up to encourage 
participation and do not track longer-term continued exercise participation.  Even if 
cancer survivors know that they are able to and should be physically active, this does 
not always easily translate to exercising.  While survivors may be interested in 
adopting healthy behaviours (82), the physical and psychosocial sequelae of cancer 
may be barriers to exercise, in conjunction with, and magnifying, general barriers 
such as time and motivation.  
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An individual’s ability to overcome such barriers and engage in exercise is self-
efficacy and can also be described as the confidence to deal with stressful or 
challenging situations (19).  Self-efficacy, defined by Albert Bandura as ‘the 
conviction that one can successfully execute the behaviour required to produce the 
outcome’ (20), is commonly assessed to help predict behaviour change.  It is 
behaviour-specific, whereby high self-efficacy in one situation does not readily 
transfer to other situations (252).  
 
In the health behaviour field, self-efficacy is primarily identified as a key construct in 
Social Cognitive Theory.  Outlined by Bandura (18), Social Cognitive Theory 
provides a framework to examine the relationships among behaviour, personal 
factors and environmental influences (233).  Also central to Social Cognitive Theory 
is the role of ‘outcome expectations’, an individual’s beliefs that “a given behaviour 
will lead to certain outcomes” (18).  Figure 2.1 presents the relation between self-
efficacy expectations and outcome expectations. 
 
 
 Efficacy expectations    Outcome expectations 
 
Figure 2.1 Efficacy and outcome expectations relationship in Social Cognitive 
Theory 
 
Based on this model, individuals may feel a behaviour will be highly beneficial and 
produce desirable outcomes, but they must first possess the efficacy, or confidence, 
to undertake the behaviour. 
 
2.2.5.1 Lymphoedema and exercise barriers self-efficacy 
Research on cancer survivors’ exercise behaviour has commonly assessed self-
efficacy as an outcome measure or an effect modifier (271), with a literature review 
by Keller and colleagues (157) including both types of studies.  Their review 
highlighted self-efficacy improved following exercise interventions (outcome 
measure), regardless of whether the intervention was designed to enhance self-
Person' Behaviour' Outcome'
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efficacy, and that self-efficacy influenced exercise participation.  Research in cancer 
survivors further supports these conclusions, whereby higher self-efficacy levels 
were associated with greater intervention effect (234).  Additionally, in both healthy 
(93; 181; 182; 262) and clinical populations (70; 199; 221; 233), self-efficacy has 
been positively associated with exercise intentions and adherence.  When self-
efficacy is evaluated in conjunction with outcome expectations, the other key 
construct in the Social Cognitive Theory, both factors have been associated with 
greater physical activity performance (21; 157; 231; 233). 
 
The concept of exercise barriers self-efficacy refers to how confident one is to 
overcome various barriers and engage in exercise (230).  Common general barriers 
identified by both healthy and clinical populations including time, motivation, social 
support and weather (35; 71; 136; 212; 230).  Higher physical activity levels are 
more often observed in individuals reporting greater self-efficacy to overcome such 
barriers (182; 233; 279).  However, cancer survivors also encounter unique barriers 
to exercise that may include physical and psychosocial treatment-related factors such 
as nausea, fatigue and uncertainty about what exercises are safe to do (69; 76; 212; 
238).  Further, barriers such as finding time or motivation may be even greater 
challenges to overcome as survivors must balance cancer-related medical 
appointments in addition to everyday family, occupational and social responsibilities 
(231).   
 
In cancer survivors with lymphoedema, general barriers are again heightened by the 
addition of lymphoedema treatment and management of general cancer treatment and 
everyday responsibilities.  Specific lymphoedema-related barriers may also exist, 
resulting from physical repercussions including swelling, pain or altered sensation in 
the affected area(s), as well as feelings of fear and uncertainty about making the 
lymphoedema worse (130; 175; 188; 220; 238).  As highlighted in Section 2.2.1, 
cancer survivors with and at risk of lymphoedema are advised to limit certain 
activities, which may include avoiding vigorous activity and heavy lifting, especially 
if they are deconditioned and not accustomed to such exertion (186).  However, some 
lymphoedema education organisations also encourage exercise and full use of the 
affected limb (43; 202).  This can create confusion about what is ‘safe’ and 
conversely translate to a significant barrier to exercise, due to fear and uncertainty of 
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developing or exacerbating lymphoedema (37; 174; 175).  The existence of both 
general and lymphoedema-specific barriers to exercise may contribute to the low 
exercise rates found in this population, with less than one-third of survivors with 
cancer-related lymphoedema meeting national activity recommendations (95; 128; 
217).  
 
Currently, no research has directly assessed barriers for individuals with cancer-
related lymphoedema or their self-efficacy for overcoming exercise barriers.  
Investigating these variables has important implications for potentially increasing 
exercise in this population, as both perceived barriers and exercise barriers self-
efficacy have been associated with exercise participation in cancer survivors (21; 69; 
70; 199; 220; 230; 232-234).  Once exercise barriers faced by those with cancer-
related lymphoedema have been identified, survivors’ confidence to overcome such 
barriers can be measured and assessed for association with exercise adherence and 
participation.  If related, clinicians and researchers will be better able to prescribe 
exercise and develop interventions that address these barriers and provide methods to 
overcome them, helping increase and maintain exercise participation.      
 
2.2.6 Direction for future study 
Evidence suggests exercise does not increase the risk of developing or exacerbating 
existing breast cancer-related lymphoedema, but having lymphoedema may make it 
more difficult to participate in exercise and decrease an individual’s exercise barriers 
self-efficacy.  Key directions for future study have been identified, which this 
research will address.  Specifically, the overall aims of the research were to assess 
potential barriers to exercise for those with cancer-related lymphoedema, and to 
undertake an exercise-based randomised trial that sought to understand the benefits 
of different exercise modes in those with breast cancer-related lymphoedema.  As 
such, the research objectives were to: 
1) identify and examine potential barriers to exercise for individuals with 
 cancer-related lymphoedema; and 
2) evaluate and compare the effects of resistance- and aerobic-based exercise on 
lymphoedema status, physical outcomes (strength, aerobic fitness, self-
reported upper-body functioning, body composition and bone density), 
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exercise barriers self-efficacy and QoL in individuals with breast cancer-
related lymphoedema 
 
This was done by conducting two studies, one for each overall objective.  However, 
these studies were connected in that: 
1) the exercise barriers self-efficacy scale developed in study one was used to 
measure self-efficacy (a secondary outcome) in study two; and 
2) the sample recruited for study two provided data required for testing validity 
and repeatability of the exercise barriers self-efficacy scale in study one. 
 
The relationship between these studies is outlined in Figure 2.2 below. 
**Blue arrows=study two time-point used to provide data for study one component 
    Red arrows=study two time-points when study one scale was used 
  
 
 
 
 
               
Figure 2.2 Flow of research'
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Chapter 3: Study one-Assessing exercise 
barriers self-efficacy in 
individuals with cancer-related 
lymphoedema 
Despite evidence on the benefits of exercise for improving cancer-related side 
effects, many survivors, including those with cancer-related lymphoedema, do not 
partake in nationally-recommended levels of activity (55; 95; 125).  This may in part 
be affected by exercise barriers self-efficacy levels, or confidence to overcome 
barriers and partake in exercise (230).  Common general exercise barriers identified 
by healthy and clinical populations include time, motivation, social support and 
weather (35; 71; 136; 212; 230).  However, cancer survivors also encounter unique 
barriers to exercise that arise as a consequence of their cancer and its treatment.  
These may include the presence of treatment-related side effects such as nausea or 
fatigue, reduced functional capacity or uncertainty about what exercise is safe (69; 
212; 238).  Lymphoedema-related barriers, such as the presence of swelling, pain and 
altered sensation in the affected body area, as well as feelings of fear and uncertainty 
about making the lymphoedema worse, may also exist (130; 175; 238).  However, 
there is currently no tool to directly assess exercise barriers self-efficacy in those 
with cancer-related lymphoedema.  Therefore, study one involved the development 
and validation of a lymphoedema-specific exercise barriers self-efficacy scale to 
examine potential barriers to exercise in individuals with cancer-related 
lymphoedema.  It also involved using this scale to evaluate exercise barriers self-
efficacy in this population, and to explore the relationship between exercise barriers 
self-efficacy and demographic, medical and behavioural characteristics.  The specific 
questions this research sought to address were: 
 
1) How can exercise barriers self-efficacy in individuals with cancer-related 
lymphoedema be assessed? 
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2) What is the level of exercise barriers self-efficacy in those with cancer-related 
lymphoedema? 
3) Is exercise barriers self-efficacy associated with physical activity levels 
(sedentary, insufficiently active, sufficiently active)? 
4) Is exercise barriers self-efficacy associated with demographic characteristics 
(age, gender, marital status, employment status, having children)? 
5) Is exercise barriers self-efficacy associated with medical characteristics 
(cancer type, treatment)? 
6) Is exercise barriers self-efficacy associated with lymphoedema-related 
characteristics (lymphoedema location, dominant versus non-dominant side, 
time since diagnosis, presence of symptoms)?  
 
To measure exercise barriers self-efficacy, this study involved the development of a 
scale, with participant feedback used to revise and finalise the scale.  This included 
validity and reliability testing.  Finally, the scale was used in a cross-sectional study 
involving people with cancer-related lymphoedema to measure exercise barriers self-
efficacy levels and assess the relationship between self-efficacy levels and 
participant characteristics.   
 
Ethical approval for study one was sought and obtained from the Research Ethics 
Unit at the Queensland University of Technology (Approval # 1100001471; 
Appendix 1).  Primary ethical considerations for this study included maintaining 
individual confidentiality and preventing the ability to track which individuals 
responded.  To address this, clinic staff not involved in the research project 
completed all mailings, and no identifying information was collected through the 
questionnaire.  Data security was also considered and maintained via storage of 
returned questionnaires in a locked filing cabinet and electronic entry of data only by 
the primary researcher on a password-protected computer.  Ethical approval for part 
of this study, validation of the final scale, was part of gaining approval for study two. 
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3.1 METHODS: OVERALL STUDY 
3.1.1 Participants and recruitment procedures 
Data for this study were collected from two convenience samples.  Sample one was 
used to develop an initial lymphoedema-specific exercise barriers self-efficacy scale 
and gain scale feedback.  Sample two was used to test the psychometric 
characteristic of the revised scale.  Finally, the two samples were combined to assess 
self-efficacy levels and related characteristics in those with cancer-related 
lymphoedema (Figure 3.1).   
 
 
Figure 3.1  Samples used in study one 
 
3.1.1.1 Sample one 
The initial sample included patients treated at a private physiotherapy practice that 
specialises in the treatment of lymphoedema, located in Brisbane, Australia.  
Eligibility criteria included: 
• secondary lymphoedema due to cancer treatment (including non-breast) 
• had received (within previous 18 months) or were currently receiving 
treatment for lymphoedema at the participating practice 
 
Eligible clinic patients were mailed a study information letter (Appendix 2) and 
questionnaire (Appendix 2) by clinic staff to ensure researcher blinding and 
individual confidentiality.  Invited individuals were informed that participation was 
voluntary and could not be tracked, and consent was implied by return of the 
questionnaire in the provided reply-paid envelope.  A follow-up letter (Appendix 2) 
Sample 1: 
scale 
development 
and feedback!
Sample 2: test 
pyschometric 
properties of  
revised scale!
Combined sample: 
measuring self-
efficacy and 
exploring associated  
characteristics!
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and additional copy of the questionnaire were sent out approximately one month 
after the initial mailing to maximise response rate.  This second mailing was only 
sent to participants who had not voluntarily provided contact details when 
responding to the initial mail-out.  Participant feedback on the initial scale was also 
collected from sample one, using participants returning the questionnaire and 
providing their contact details.  These participants were sent a form to provide 
feedback on the scale and a reply-paid envelope (Appendix 3). 
 
3.1.1.2 Sample two  
The second convenience sample included participants in study two of this research, 
the exercise trial (Chapter 4).  Recruitment information and eligibility criteria are 
outlined in sections 4.2.1 and 4.2.2.  Eligible participants were sent a survey 
collecting information on demographic, medical and lymphoedema-related 
characteristics and self-report outcome measures (including exercise barriers self-
efficacy), which was completed and returned at baseline, post-intervention and 12-
week follow-up assessments for the exercise trial.  Post-intervention data were used 
to test validity and repeatability of the revised self-efficacy scale developed in the 
first part of this study.  That is, at the post-intervention time-point, study two 
participants were asked to complete the exercise barriers self-efficacy scale twice, 
with a seven-day period between each assessment.  This was considered an 
appropriate time to test repeatability as it was expected self-efficacy would 
potentially change as a consequence of beginning the intervention, but was likely to 
remain relatively stable in the weeks immediately following the post-intervention 
assessment.  Baseline data contributed to the second part of this study, which used 
this scale to explore self-efficacy levels and associated characteristics.  No incentives 
or costs were incurred by either sample for participation.  
 
3.1.2 Participant characteristics 
Demographic, medical and lymphoedema-related characteristics measured by the 
questionnaire are listed and defined in Appendix 4.  Demographic characteristics 
included age, gender, marital and employment status, information on children and 
physical activity levels.  The Active Australia survey (Appendix 5) was used to 
collect information on physical activity levels, measuring number of physical activity 
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sessions per week, intensity of sessions and time spent in various activities.  Results 
allow classification of respondents as sedentary, insufficiently active or sufficiently 
active (based on number of sessions and minutes of activity).  More explanation on 
how this classification is determined is provided in Appendix 5.  Medical 
characteristics were related to cancer history (type of cancer, date of diagnosis, type 
of treatment).  In relation to lymphoedema, respondents were asked to provide 
information on lymphoedema location, diagnosis date, who diagnosed the condition 
and number and intensity of associated symptoms (e.g., pain, numbness, swelling).  
With the exception of age, all variables were categorised for descriptive and 
analytical purposes.  Age was reported as mean and 95% confidence intervals, while 
categorical variables were described using numbers and percentage values for each 
category. 
 
3.1.3 Data storage 
Hard copies of the returned surveys were kept in a locked filing cabinet.  All 
participants were given an identification number, and two separate Microsoft Excel 
spreadsheets were created, one with participant contact information when provided 
and the other with survey responses coded by ID number.  Electronic data were kept 
on a password-protected computer only accessible by the principal researcher.   
 
3.1.4 Data quality 
Responses to each item on the questionnaire were entered in a master Microsoft 
Excel spreadsheet and data were then imported into SPSS (Version 21.0).   A 
complete double entry verification process was conducted to ensure accurate 
transference of participant data.  An error log was generated, and all discrepancies 
were checked with the original corresponding questionnaire and corrected. 
 
3.1.5 Data cleaning 
Frequencies were run for all variables in the data set to check for any invalid values 
and potential outliers.  For each respondent, the general and lymphoedema-specific 
exercise barriers self-efficacy scales were examined for completion.  As is standard 
procedure for the general exercise barriers self-efficacy scale (232), if participants 
missed responding for individual items, and as long as less than 33% of items were 
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missing, the mean of remaining items was input to allow calculation of the total scale 
score.  When participants missed more than 33% of items, their data were excluded 
from analysis (n=3).  The procedure was applied to the general and lymphoedema-
specific exercise barriers self-efficacy scales.   
 
Categorical variables were collapsed into fewer categories when a category 
frequency was less than 10% and/or evidence (bivariate statistics undertaken as part 
of this work or theoretical evidence) indicated which categories were of interest with 
respect to the dependent outcome, exercise barriers self-efficacy (Appendix 4).  
Following recoding, crosstabs were run comparing recoded variables to the original 
variable to ensure correct coding and frequencies in each category. 
 
3.2 METHODS: SELF-EFFICACY SCALE DEVELOPMENT 
3.2.1 Scale development  
The lymphoedema-specific scale was designed in the same format as an existing 
validated nine-item exercise barriers self-efficacy scale (Appendix 6), created by 
Rogers and colleagues (230) to assess exercise barriers self-efficacy in cancer 
patients.  This scale asks respondents to rate their confidence to exercise when faced 
with situations such as “when I’m tired” and “when I don’t enjoy exercise.”  The 
scale has strong internal consistency (Cronbach’s alpha=0.96), test-retest reliability 
(r=0.89, p<0.001) and significant associations with physical activity levels of breast 
cancer patients (230).   
 
The new ten-item lymphoedema-specific scale contained common barriers to 
exercise for cancer patients with secondary lymphoedema.  To determine barriers to 
include on the scale, experts in the field of lymphoedema and cancer were consulted.  
An exercise physiologist, public health epidemiologist and psychologist assisted in 
generating a list of possible barriers to include on the scale.  A scale template with 
the generated barriers was then sent to a physiotherapist with specialist knowledge 
and skills in lymphoedema, as well as the author of the existing validated nine-item 
general exercise barriers self-efficacy scale, for feedback.  These specialists selected 
which barriers they perceived as most influential, as well as added other barriers to 
consider for inclusion. 
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Once a list of barriers was generated from expert opinion, published and unpublished 
literature was consulted to determine which barriers were most commonly reported 
in relation to exercise and lymphoedema (53; 54; 60; 115; 130; 169).  A study by 
Hayes and colleagues (130) highlighted the importance of including potential 
psychological barriers to exercise, as study participants often reported fear and 
uncertainty as limiting factors.  Additionally, qualitative data were consulted, 
collected by Meiklejohn and colleagues (189) from focus groups and telephone 
interviews (16 in focus groups of 2-4 participants, 13 completing telephone 
interviews) exploring how individuals with cancer-related lymphoedema construct 
their experience in daily life (189).  Participants in this work included men and 
women with lymphoedema following treatment for breast, gynaecological or ‘other’ 
cancers.  As part of this work, participants were questioned about potential barriers 
of participation in physical activity.  Issues highlighted included concern about their 
appearance, fear of doing too much and lymphoedema-related side effects all 
influencing activity levels, barriers that were then incorporated into the scale.  
Through use of expert opinion, review of literature and consideration of relevance for 
an exercise intervention program design, ten situations were identified that would 
potentially impact self-efficacy in those with cancer-related lymphoedema. 
 
The barrier identification process highlighted that individuals with cancer-related 
lymphoedema face both condition-related barriers as well general exercise barriers, 
such as lack of time and motivation.  As such, the new ten-item exercise barriers self-
efficacy scale was designed using Rogers’ pre-existing validated exercise barriers 
self-efficacy scale as a template, with the intention to use both scales to fully assess 
potential barriers.  By following the template of the general exercise barriers self-
efficacy scale (230), the lymphoedema-specific scale response options ranged from 
0% (not at all confident) to 100% (extremely confident), with 10% intervals.  As is 
standard procedure with the general exercise barriers self-efficacy scale, responses to 
items were then categorised as 0-20%=not at all confident; 20-40%=slightly 
confident; 40-60%=moderately confident; 60-80%=very confident; 80-
100%=extremely confident.  A copy of the original lymphoedema-specific exercise 
barriers self-efficacy scale is presented below (Figure 3.2).  
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Figure 3.2 Original lymphoedema-specific exercise barriers self-efficacy scale 
 
3.2.2 Scale revision  
The initial lymphoedema-specific scale was revised based on analysis of the scale 
(Section 3.2.3) and the participant feedback provided by a sub-group of sample one 
(n=21).  This revised scale was then included as an outcome measure in study two to 
assess exercise barriers self-efficacy.  Self-efficacy was measured by obtaining an 
average total score of the general and lymphoedema-specific items combined, as well 
as separate average scores for the general items and lymphoedema-specific items.  
 
3.2.3 Statistical analysis 
Total scale and individual item scores for the lymphoedema-specific exercise barriers 
self-efficacy scale were assessed for normality prior to further data analysis by 
Using the scale from 0-100%, indicate how confident you are that you could exercise in each 
of the following situations.  Even if you are not currently exercising, please read and 
respond to each question by circling one number for each situation. 
**Please note, “affected”=body segment(s) with lymphoedema 
Not at all 
Confident 
Slightly Confident Moderately Confident Very  
Confident 
Extremely  
Confident 
When I am worried about my 
appearance. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment feels heavy. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is painful. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is numb or tingling. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is swollen. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I fear making my 
lymphoedema worse. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am unsure what 
exercise advice to follow. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not certain if I am 
doing an exercise correctly. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am lifting/moving heavy 
objects a few times. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am lifting/moving light 
objects repetitively. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 
!
!
!
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running frequency distributions showing a normal curve to confirm the following 
criteria were met: 
• Mean within ± 10% of median 
• Mean ± 3 standard deviations approximates the observed minimum and 
maximum values 
• Skewness and kurtosis coefficients within ± 3 
• Roughly bell-shaped histogram 
 
Median and range were reported for total scale and individual item scales. 
 
A principal component analysis was conducted on the initial and revised scale to test 
factor structure, with direct oblimin rotation used if more than one factor was found.  
This rotation method was selected due to the small size of the data set and 
expectation that correlation would exist between factors, which this technique 
permits (101).  Other analyses conducted on the initial scale included calculating a 
Pearson correlation coefficient between scores on the ten-item lymphoedema-
specific scale and nine-item general scale by Rogers et al. (230) to test construct 
validity.  High correlations (>0.6) were expected, showing the scales measure a 
similar construct. 
 
Additional testing on the revised version of the scale assessed validity and reliability.  
Construct (discriminant) validity was assessed by calculating correlations between 
the final lymphoedema-specific scale and QoL (FACT-B+4) and upper-body 
function (DASH), and criterion validity was assessed by comparing self-efficacy 
scores and physical activity levels (one-way ANOVA).  Low correlations were 
expected between the scale and QoL and upper-body function, given the differences 
in these constructs.  However, higher self-efficacy levels were expected in 
participants reporting higher physical activity levels.  The internal consistency (i.e., 
Cronbach’s coefficient alpha) and test-retest reliability statistics (i.e., Pearson 
correlation coefficients and paired-sample t-tests) were also calculated.  Pearson 
correlation coefficients were used to determine how strongly test and retest scores 
correlated (i.e., how consistent participants were in responding), and paired-sample t-
tests were used to examine if changes in response were statistically significant from 
initial to repeat assessment for any item.  
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Significance level was two-tailed, p<0.05, and analyses were done using IBM SPSS 
statistics version 21.0 software.        
 
3.3 RESULTS: SELF-EFFICACY SCALE DEVELOPMENT 
3.3.1 Response rate and respondents 
3.3.1.1 Sample one response rate 
A total of 62 of 107 questionnaires were returned from the first mailing and 14 of 72 
from the second mailing, for a total of 76 responses (71%).  Three and two 
individuals did not provide responses for the general and lymphoedema-specific 
exercise barriers self-efficacy scale, respectively (Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Sample one response flow 
 
 
Initial!mailing!of!questionnaire!(n=107)!
 
62!respondents!from!initial!mailing!
Follow=up!mailing!of!questionnaire!(n=72)!
• 45!of!62!from!first!mailing!provided!contact!details!
and!were!excluded!from!follow=up!mailing!
 
14!respondents!from!follow=up!mailing!
76!total!respondents!(71%),!with!analyses!using!data!from!68!of!these!respondents!
• 2!did!not!provide!sufficient!lymphoedema=specific!exercise!barriers!self=efficacy!
data!to!compute!total!score!
• 3!did!not!provide!sufficient!general!exercise!barriers!self=efficacy!data!to!
compute!total!score!
• 3!respondents!also!participated!in!study!two!and!were!thereby!excluded!from!
sample!one!!!
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3.3.1.2 Sample two response rate  
Forty-one women were enrolled in study two, with 38 providing post-intervention 
data for analysis of the revised exercise barriers self-efficacy scale (Figure 3.4).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Sample two response flow 
 
3.3.1.3 Sample one and two respondent characteristics 
Respondents (N=106) were on average 58 (95% CI: 56 to 60) years old, with 95% 
female (Table 3.1).  Based on Active Australia guidelines for sufficient weekly 
physical activity (≥ 150 minutes and 5 sessions), 58% met national physical activity 
standards.  Most participants had multiple cancer treatments, with diagnoses of breast 
(78%), gynaecological (13%) or other (bowel, prostate, skin; 9%) cancer (Table 3.1).  
Cancer-related lymphoedema most commonly developed in the upper-body (e.g., 
arm, breast, trunk) (79%), with range in how long participants had experienced 
lymphoedema (Table 3.2).  Lymphoedema symptoms most frequently reported as 
moderate or higher were swelling (79%), aching (48%) and heaviness (46%) (Table 
3.2). 
 
 
 
 
 
 
Final!scale!completed!at!post=
intervention!by!participants!in!study!
two!(n=38)!
 
Test=retest!mailing!following!post=
intervention!assessment!(n=38)!
32!individuals!provided!test=
retest!data!(78%)!
!
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Table 3.1 Demographic and medical characteristics of combined sample (N=106) 
 
*n=104; asedentary (no physical activity), insufficient (< 150 min OR ≥ 150 min & < 5 sessions), 
sufficient (≥ 150 min and ≥ 5 sessions); bother=bowel, melanoma, prostate; cother treatments included 
Herceptin, immune modulators and not defined CI-confidence intervals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographic variables n (%) 
Age (years), mean (95% CI) 58.4 (56.4, 60.4) 
Gender  
  Male  
  Female  
 
5 (4.7) 
101 (95.3) 
Marital Status  
  Married/de facto 
  Single/widowed/divorced 
 
77 (72.6) 
29 (27.4) 
Employment status 
  Paid employment 
  Unemployed/retired  
 
66 (62.3) 
40 (37.7) 
Children in care* 
  No children 
  Children living at home 
  Children living out of home 
 
21 (20.2) 
36 (34.6) 
47 (45.2) 
Total physical activitya 
   Sedentary 
   Insufficient 
   Sufficient 
 
11 (10.4) 
34 (32.1) 
61 (57.5) 
Medical variables n (%) 
Cancer type  
  Breast  
  Gynaecological 
  Otherb 
 
83 (78.3) 
14 (13.2) 
9 (8.5) 
Surgery 105 (99.1) 
Chemotherapy and Radiation 
Therapy 
  Chemotherapy only 
  Radiation therapy only 
  Both 
  Neither 
 
12 (11.3) 
12 (11.3) 
76 (71.7) 
6 (5.7) 
Hormone therapy 52 (49.1) 
Other treatmentc 16 (15.1) 
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Table 3.2 Lymphoedema-related characteristics of combined sample (N=106) 
Lymphoedema-related variables n (%) 
Lymphoedema on dominant side*  47 (44.3) 
Lymphoedema location  
  Upper-body  
  Lower-body 
 
84 (79.2) 
22 (20.8) 
Who diagnosed lymphoedema** 
  Physiotherapist/occupational therapist/massage therapist 
  Oncologist/GP/Surgeon 
  Self 
 
44 (41.5) 
46 (43.4) 
12 (11.3) 
Time with lymphoedema 
  < 2 years 
  2-5 years 
  > 5 years 
 
42 (39.6) 
42 (39.6) 
22 (20.8) 
Lymphoedema-related symptomsa n (%) 
Swelling 84 (79.2) 
Heaviness  49 (46.2) 
Tightness  46 (43.4) 
Aching  51 (48.2) 
Tenderness  27 (25.5) 
Stiffness  33 (31.2) 
Weakness  34 (32.1) 
Numbness  33 (31.1) 
Tingling  19 (17.9) 
Pain  30 (28.3) 
Limited ROM 33 (31.1) 
*n=105; **n=102; apercentage of participants reporting ‘somewhat/moderately’ or ‘quite a lot/very 
much’; NA=not applicable 
 
 
3.3.2 Lymphoedema-specific exercise barriers self-efficacy scale 
3.3.2.1 Initial scale: using Sample one data  
Scale spread 
The distribution of total scale and individual items were approximately normal.  The 
total scale had a median score of 55% (11-100%), and individual item median values 
were between 50% (0-100%) and 75% (0-100%) (Table 3.3).    
 
Table 3.3 Initial lymphoedema-specific scale average scores (%; N=68) 
Scale item Median  Range  
Total scale 56 11-100 
When I am worried about my appearance 75 0-100 
When my affected body segment feels heavy 60 10-100 
When my affected body segment is swollen 60 0-100 
When my affected body segment is painful 50 0-100 
When my affected body segment is numb or tingling 52 0-100 
When I fear making my lymphoedema worse 50 0-100 
When I am not certain if I am doing an exercise correctly 60 0-100 
When I am unsure what exercise advise to follow 55 0-100 
When I am lifting/moving heavy objects a few times 55 0-100 
When I am lifting/moving light objects repetitively 60 0-100 
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Scale construct  
Results of the principal component analysis revealed scale items loaded on two 
significant factors, which accounted for 72.7% of the total variance.  Eight items 
loaded highly on the first factor (all > 0.67), and two items loaded highly on the 
second factor (> 0.90) (Table 3.4).  Given the small sample size, the Kaiser-Meyer-
Olkin (KMO) measure of sampling adequacy was calculated to determine if principal 
component analysis was appropriate.  Values can range from 0 to 1, with 0.5 
considered a minimum desirable value (101; 143).  Sampling adequacy for this study 
was confirmed by a value of 0.81 related to the total scale.  Bartlett’s test of 
sphericity was also run, testing the null hypothesis that the correlation matrix is an 
identity matrix, whereby acceptance of the null hypothesis indicates that the factor 
model used is not appropriate (283).  The resulting value, χ2 (45)=639.2, had a 
significance level of p<0.001, indicating principal component analysis was 
appropriate for this sample.  Individuals’ scores on the general and lymphoedema-
specific exercise barriers self-efficacy scales were highly correlated (Pearson’s 
r=0.72, p<0.01), indicating good construct validity (i.e., that the scales measure 
similar constructs).  Total scale internal consistency was assessed by calculating 
Cronbach’s alpha (alpha=0.93), with values closer to one indicating greater internal 
consistency. 
 
Table 3.4 Pattern matrix presenting loading values for initial scale items 
Scale Item  Factor 1 Factor 2 
When I am worried about my appearance 0.758  
When my affected body segment feels heavy 0.796  
When my affected body segment is painful 0.812  
When my affected body segment is numb or tingling 0.811  
When my affected body segment is swollen 0.671  
When I fear making my lymphoedema worse 0.797  
When I am unsure what exercise advise to follow 0.843  
When I am not certain if I am doing an exercise correctly 0.790  
When I am lifting/moving heavy objects a few times  0.904 
When I am lifting/moving light objects repetitively 0.928 
 
Scale feedback 
Forty-three respondents provided contact details and were therefore mailed a 
feedback questionnaire, with 21 responding (45%).  Feedback questions and 
corresponding responses indicated most individuals found the scale instructions easy 
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to follow, as determined by 80% ranking the instructions as a 4 or 5 (with 1=very 
unclear and 5=easy to understand).  Suggestions for improvement of instructions 
included clarifying the difference in “could” versus “would” and what respondents 
should do if a question does not apply.  Participants were asked to list what most 
commonly prevents them from exercising, and responses included lack of time 
and/or motivation, work and family commitments, heat exacerbating lymphoedema 
symptoms and embarrassment.  Suggestions for other barriers that cancer survivors 
may lack confidence to overcome included cost and location of exercise programs, 
pain, lack of confidence and limited advice following treatment.  Most respondents 
found all questions of the scale relevant to those with cancer-related lymphoedema, 
with a suggestion to clarify if the question on embarrassment about appearance was 
lymphoedema-related or general (i.e., obesity, unfit).  Additional suggestions for the 
scale included clarifying what was meant by exercise, and having respondents rate 
their degree of lymphoedema severity experienced.   
   
3.3.2.2 Revised scale 
Scale revision 
From the ten lymphoedema-specific items on the original scale, only five items were 
retained.  Three remained unchanged items: “when I fear making my lymphoedema 
worse,” “when I am not certain I am doing an exercise correctly,” and “when I am 
unsure what exercise advice to follow.”  The appearance barrier question was 
reworded to provide greater clarity that it was related to worry regarding swelling 
and/or compression garment use.  Four original items about side effects as a barrier 
(heaviness, swelling, numbness/tingling and pain) were collapsed into a single item.  
The two items loading on a separate factor in the original principal components 
analysis were removed (Table 3.4), also guided by participant feedback suggesting 
these items were only relevant in certain situations (i.e., during resistance-based 
exercise).  As initial scale analyses and feedback highlighted the existence of general 
exercise barriers as well, the revised scale was used in conjunction with the nine-item 
general barriers scale by Rogers et al (234).     
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Testing of revised scale: using Sample two data 
Scale spread  
The distribution of scores for total scale (nine general and five lymphoedema-
specific barriers items) was approximately normal.  The total scale had a median 
score of 57% (16-100%), and individual item median values were between 40% (0-
100%) and 80% (10-100%) (Table 3.5).    
 
Table 3.5 Final combined self-efficacy scale averages scores (%; N=38) 
Scale item Median  Range  
Total scale 57 16-100 
When I am worried about my appearance (e.g. due to swelling and/or 
compression garment)* 
80 
 
30-100 
When I am experiencing lymphoedema-related symptoms (e.g. pain, 
heaviness, numbness/ tingling, swelling)* 
80 10-100 
When I fear making my lymphoedema worse* 70 0-100 
When I am unsure what exercise advice to follow* 70 10-100 
When I am not certain if I am doing an exercise correctly* 60 10-100 
When I lack the discipline to exercise 60 0-100 
When I am nauseated 40 0-100 
When exercise is not a priority 50 0-100 
When the weather is bad 60 10-100 
When I am tired 50 0-100 
When I am not interested in exercising 50 0-100 
When I lack time 50 10-100 
When I do not enjoy exercising 70 10-100 
*lymphoedema-specific items 
Scale structure 
Results of the principal component analysis revealed items in the final scale loaded 
on two significant factors, which accounted for 76.6% of total variance. Eight of the 
nine items from Rogers and colleagues’ scale (234) loaded on the first factor (all> 
0.60), while the five lymphoedema-specific items, as well as one item from the nine-
item general barriers scale, loaded highly on the second factor (all> 0.64) (Table 3.6).  
However, structure matrix results revealed this single general barriers scale item also 
loaded highly on the first factor (loading=0.65) and, as such, was retained with its 
original scale.  Therefore, remaining validity and reliability testing was conducted on 
the five-item lymphoedema-specific sub-scale.   
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Table 3.6 Pattern matrix presenting loading values for combined self-efficacy scale 
Scale Item  Factor 1 Factor 2 
When exercise is not a priority 0.946  
When I lack time 0.936  
When I am tired 0.913  
When I am not interested in exercising 0.873  
When the weather is bad 0.849  
When I am nauseated 0.806  
When I lack the discipline to exercise 0.779  
When I do not enjoy exercising 0.602  
When I am experiencing lymphoedema-related symptoms (e.g., 
pain, heaviness, numbness/tingling, swelling)*  
0.965 
When I am worried about my appearance (e.g., due to swelling 
and/or compression garment)*  
0.941 
When I fear making my lymphoedema worse*  0.868 
When I am unsure what exercise advise to follow*  0.807 
When I am not certain if I am doing an exercise correctly*  0.746 
When I do not have someone to encourage me to exercise  0.637 
*lymphoedema-specific items 
 
Scale validity 
Construct (discriminant) and criterion validity testing were completed on the revised 
five-item lymphoedema-specific scale.  Results of construct validity testing showed 
self-efficacy score correlated minimally with QoL (FACT-B+4) or upper-body 
function (DASH) (Pearson’s r=0.31 and Pearson’s r= -0.34, respectively).  This 
suggests the self-efficacy scale is not measuring undesired concepts.  Criterion 
validity testing showed individuals classified as both insufficiently active (>0 min 
but <150 min OR ≥150 min and <5 sessions weekly) and sufficiently active (≥150 
min and ≥5 sessions weekly) had higher self-efficacy scores (mean [SD]: 62.1% 
[15.7%] and 56.7% [23.9%], respectively) than sedentary individuals (42.4 [30.4]), 
but this difference was not statistically significant.   
 
Scale reliability 
Thirty-two participants provided test-retest reliability data.  Total scale internal 
consistency was desirable (Cronbach’s alpha=0.93).  While Pearson correlation 
coefficient for overall scale reliability was average (r=0.68; p< 0.01), difference 
between test and retest mean self-efficacy level was only 0.79% (-5.28, 6.87).  
Results for each individual item are presented in Table 3.7.   
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Table 3.7 Pearson correlation coefficients for revised lymphoedema-specific scale 
test-retest reliability (N=32) 
Scale item Pearson correlation 
coefficient p value 
Total scale (n=32) 0.681 >0.01 
When I am worried about my appearance (e.g., due to swelling 
and/or compression garment). 0.576 >0.01 
When I am experiencing lymphoedema-related symptoms (e.g., 
pain, heaviness, numbness/ tingling, swelling) 0.440 0.01 
When I fear making my lymphoedema worse 0.602 >0.01 
When I am unsure what exercise advice to follow 0.654 >0.01 
When I am not certain if I am doing an exercise correctly 0.584 >0.01 
 
3.4 METHODS: SELF-EFFICACY AND ASSOCIATED 
CHARACTERISTICS, USING DATA FROM SAMPLES ONE AND 
TWO COMBINED 
Development of a scale to evaluate barriers to exercise in individuals with cancer-
related allowed measurement of exercise barriers self-efficacy levels in this 
population.  Additionally, it enabled assessment of whether certain demographic, 
medical or lymphoedema-related characteristics are associated with self-efficacy 
levels. 
  
3.4.1 Outcome variables 
Two scales were used to assess exercise barriers self-efficacy (Appendix 6).  These 
were the nine-item exercise barriers self-efficacy scale, developed by Rogers and 
colleagues (230), and the lymphoedema-specific exercise barriers self-efficacy scale 
(Appendix 6) designed in the first part of this study.  As data collected from sample 
one used the ten-item scale (original scale), results were adjusted (i.e., item scores 
combined/excluded) to provide individual item and total score for the final scale.  
Baseline data from sample two, women in the exercise trial (study two), were also 
used for analyses in this study.   
        
3.4.2 Statistical analysis 
Continuous variables (age and exercise barriers self-efficacy scores) were assessed 
for normality (as defined in Section 3.2.3).  Due to normality, continuous variables 
were described using mean and 95% confidence intervals, while proportions were 
used to describe categorical variables.  
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To examine barriers to exercise, mean total scores were calculated for the general 
and lymphoedema-specific exercise barriers self-efficacy scales.  Score ranges for 
total scale and for each item on the scale were also determined to assess the spread of 
responses.  Response proportions were calculated for each of the five scale categories 
(not at all confident, slightly confident, moderately confident, very confident and 
extremely confident).  These confidence levels were then re-categorised as ‘not at 
all-slightly confident’, ‘moderately confident’ and ‘very-extremely confident’ to 
allow further assessment of participant self-efficacy levels spread.            
 
3.4.3 Criteria used for determining significant associations 
Results of bivariate and multivariate analyses were assessed for both clinical and 
statistical significance.  For statistical significance, the traditional p < 0.05 (two-
tailed) level was used.  A priori clinical relevance was defined as a change/difference 
of 7% on the nine-item general barriers scale, as suggested by Rogers and colleagues 
(234).  This value was the observed percentage of exercise barriers self-efficacy 
score difference between a usual care and an intervention group after three months of 
a physical activity behaviour change intervention, corresponding with a significant 
difference between groups in physical activity participation.  As no current research 
exists on a clinically meaningful difference for the lymphoedema-specific scale, a 
pro-rata technique was used.  That is, as a seven-point clinical difference was used 
for the nine-item scale, our five-item lymphoedema-specific scale was calculated to 
need a difference of four points (i.e., 7/9=0.78; 0.78*5=3.9≈4).       
   
3.4.4  Bivariate analysis 
Bivariate analyses were performed to see if any independent variables were crudely 
associated with either general or lymphoedema-specific exercise barriers self-
efficacy levels.  As continuous dependent (exercise barriers self-efficacy scale 
scores) and independent (age) variables were normally distributed, parametric test 
statistics were used, specifically Pearson correlation coefficients.  The Student’s t-
test (dichotomous variables) or one-way ANOVA were used to evaluate crude 
associations between general and lymphoedema-specific exercise barriers self-
efficacy scores and categorical independent variables.  These variables included 
gender, marital status, employment status, children, physical activity levels, cancer 
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type, cancer treatment undertaken, time with and location of lymphoedema (upper- 
versus lower-body and dominant versus non-dominant side), and number and 
severity of lymphoedema-related symptoms.   
 
3.4.5 Multivariate analysis 
General linear modelling was used to quantify the relationship between the outcome 
variable, exercise barriers self-efficacy, and several explanatory variables.  A step-
wise process was used to determine variables relevant to include in the final model.  
Age was included in all models, with the remaining independent variables then 
categorised into different blocks (Table 3.8).  These blocks were used to run initial 
models separately against general and lymphoedema-specific exercise barriers self-
efficacy.  Output of the initial models was used to determine which variables to 
include for subsequent models, based on both statistical significance and clinical 
relevance.  When trends towards clinical relevance were observed, models were run 
both including and excluding the variable.  The same process was used to generate a 
separate final model for general and lymphoedema-specific exercise barriers self-
efficacy, allowing comparison of which variables were independently related to 
general and lymphoedema-specific exercise barriers self-efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 3: Study one 55 
Table 3.8 Initial general linear model blocks for general and lymphoedema-specific 
exercise barriers self-efficacy 
Block* Variables  
Block 1-Demographic characteristics Gender, marital status, employment status, children, 
physical activity levels 
Block 2-Medical characteristics 
   Block 2a 
    
   Block 2b 
  
   Block 2c 
 
Cancer type, chemotherapy, hormone therapy, other 
treatment 
Cancer type, radiation therapy, hormone therapy, other 
treatment 
Cancer type, chemotherapy and/or radiation therapy, 
hormone therapy, other treatment 
Block 3-Lymphoedema characteristics 
   Base variables (block 3a)  
 
   Block 3b 
   Block 3c 
   Block 3d 
   Block 3e 
   Block 3f 
   Block 3g 
   Block 3h 
   Block 3i 
   Block 3j 
   Block 3k 
   Block 3l 
   Block 3m 
 
Lymphoedema on dominant/non-dominant side, upper- or 
lower-body lymphoedema, time with lymphoedema 
Base variables + number of symptoms 
Base variables + severity of symptoms 
Base variables + swelling 
Base variables + heaviness 
Base variables + tightness 
Base variables + aching 
Base variables + tenderness 
Base variables + stiffness 
Base variables + numbness 
Base variables + tingling 
Base variables + pain 
Base variables + limited ROM 
*all blocks included age 
 
Results of each model were monitored for potential indication of collinearity 
between variables.  Variables suspected of collinearity were added into the model 
separately and then jointly, with mean exercise barriers self-efficacy values and p-
values assessed for unexpected changes when both variables were in the model.  If 
such changes were observed, a cross-tabulation was done to determine the degree of 
collinearity.  Mean exercise barriers self-efficacy and 95% confidence interval 
values, as well as number of respondents in each category, were used to determine 
when to consider collapsing variable categories.  Additionally, when confidence 
intervals were large and number of respondents in the related variable category was 
low, a variable was considered for exclusion from final models.     
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3.5 RESULTS: SELF-EFFICACY AND ASSOCIATED 
CHARACTERISTICS 
3.5.1 Respondent characteristics (combined samples) 
Respondents (N=109) were on average 58 (95% CI: 56, 60) years old, with 95% 
female (Table 3.9).  Based on Active Australia guidelines for sufficient weekly 
physical activity (≥ 150 minutes and 5 sessions), 44% participants were sedentary or 
insufficiently active, while 56% met national physical activity standards.  
Participants reported diagnoses of breast (79%), gynaecological (13%) or other 
(bowel, prostate, skin; 8%) cancer.  Cancer-related lymphoedema was present in the 
upper-body for 80% of respondents, and lymphoedema symptoms most frequently 
reported as moderate or worse were swelling (79%), aching (49%) and heaviness 
(47%) (Table 3.10).  
 
Table 3.9 Demographic and medical characteristics of respondents (N=109) 
 
*N=107; asedentary (no physical activity), insufficient (< 150 min OR ≥ 150 min & < 5 sessions), 
sufficient (≥ 150 min and ≥ 5 sessions); bother=bowel, melanoma, prostate; cother treatments included 
Herceptin, immune modulators and not defined; CI-confidence intervals 
Demographic variables n (%) 
Age (years), mean (95% CI) 58.1 (56.1, 60.1) 
Gender  
  Male  
  Female  
 
5 (4.6) 
104 (95.4) 
Marital Status  
  Married/de facto 
  Single/widowed/divorced 
 
80 (73.4) 
29 (26.6) 
Employment status 
  Paid employment 
  Unemployed/retired  
 
67 (61.4) 
42 (38.5) 
Children in care* 
  No children 
  Children living at home 
  Children living out of home 
 
22 (20.6) 
38 (35.5) 
47 (43.9) 
Total physical activitya 
   Sedentary 
   Insufficient 
   Sufficient 
 
11 (10.1) 
37 (33.9) 
61 (56.0) 
Medical variables  
Cancer type  
  Breast  
  Gynaecological 
  Otherb 
 
86 (78.9) 
14 (12.8) 
9 (8.3) 
Surgery 108 (99.1) 
Chemotherapy and Radiation Therapy 
  Chemotherapy only 
  Radiation therapy only 
  Both 
  Neither 
 
12 (11.0) 
12 (11.0) 
78 (71.6) 
7 (6.4) 
Hormone therapy  54 (49.5) 
Other treatmentc 16 (14.7) 
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Table 3.10 Lymphoedema-related characteristics of respondents (N=109) 
Lymphoedema-related variables n (%) 
Lymphoedema on dominant side* 50 (46.3) 
Lymphoedema location  
  Upper-body  
  Lower-body 
 
87 (79.8) 
22 (20.2) 
Who diagnosed lymphoedema** 
  Physiotherapist/occupational/massage therapist 
  Oncologist/GP/Surgeon 
  Self 
 
46 (43.8) 
47 (44.8) 
12 (11.4) 
Time with lymphoedema 
  < 2 years 
  2-5 years 
  > 5 years 
 
43 (39.4) 
43 (39.4) 
23 (21.1) 
Lymphoedema-related symptomsa  
Swelling  86 (78.9) 
Heaviness  51 (46.8) 
Tightness* 49 (45.3) 
Aching  53 (48.6) 
Tenderness  28 (25.7) 
Stiffness  35 (32.1) 
Weakness  37 (33.9) 
Numbness  35 (32.1) 
Tingling  20 (18.4) 
Pain  31 (27.5) 
Limited ROM 36 (33.0) 
*N=108; **N=105; apercentage of participants reporting ‘somewhat/moderately’ or ‘quite a lot/very 
much’; NA=not applicable; ROM=range of motion 
 
3.5.2 Exercise barriers self-efficacy levels 
On average, participants (N=109) were 48% (44, 52%) confident to exercise when 
encountering general problems, such as not having the motivation and lacking time.  
Respondents were 51% (47, 55%) confident to engage in exercise when faced with 
lymphoedema-specific barriers such as exacerbated symptoms and fear of worsening 
lymphoedema.  For general cancer-related barriers, scores were between 0% and 
90%, while for lymphoedema-specific situations, exercise barriers self-efficacy 
ranged from 8% to 100%.   
 
Over one in four participants (26 to 39%) reported being “not at all confident” or 
only “slightly confident” to exercise when faced with seven of the nine general 
exercise barriers, particularly “when I am nauseated” (39%), “when exercise is not a 
priority” (33%) and “when I lack time” (31%) (Table 3.11).  Additionally, only the 
minority (between 31 and 39%) expressed high levels of confidence to exercise when 
faced with eight of these situations.  One in two (51%) reported high confidence to 
overcome the barrier of “when I lack the discipline to exercise.” 
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Table 3.11 Frequencies for confidence categories for general exercise barriers self-
efficacy items (N=109) 
Scale item 
 
 
Not at all- 
slightly 
confident  
n (%) 
Moderately 
confident 
n (%) 
Very-
extremely 
confident 
n (%)  
When I lack the discipline to exercise 19 (17.4) 35 (32.1) 55 (50.5) 
When I am nauseated 43 (39.4) 32 (29.4) 34 (31.2) 
When exercise is not a priority 36 (33.0) 39 (35.8) 34 (31.2) 
When the weather is bad 32 (29.4) 34 (31.2) 43 (39.4) 
When I am tired 28 (25.7) 40 (36.7) 41 (37.6) 
When I am not interested in exercising 32 (29.4) 42 (38.5) 35 (32.1) 
When I lack time 34 (31.2) 32 (29.4) 43 (39.4) 
When I do not enjoy exercising 30 (27.5) 36 (33.0) 43 (39.4) 
When I do not have someone to encourage 
me to exercise 
26 (23.9) 41 (37.6) 42 (38.5) 
 
Almost one-third of participants (32 to 39%) expressed low confidence (“not at all” 
to “slightly confident”) to exercise when faced with four of the five lymphoedema-
specific situations (Table 3.12).  Appearance concerns were not a major barrier for 
the majority, with 58% of respondents reporting as “very” to “extremely confident” 
to exercise even when they were ‘worried about their appearance’.     
 
Table 3.12 Frequencies for confidence categories for lymphoedema-specific exercise 
barriers self-efficacy items (N=109) 
Scale item 
 
 
Not at all- 
slightly 
confident  
n (%) 
Moderately 
confident 
n (%) 
Very-
extremely 
confident 
n (%)  
When I am worried about my appearance (e.g., 
due to swelling and/or compression garment). 
15 (13.8) 31 (28.4) 63 (57.8) 
When I am experiencing lymphoedema-related 
symptoms (e.g., pain, heaviness, numbness/ 
tingling, swelling) 
35 (32.1) 40 (36.7) 34 (31.2) 
When I fear making my lymphoedema worse 43 (39.4) 35 (32.1) 31 (28.4) 
When I am unsure what exercise advice to follow 40 (36.7) 43 (39.4) 26 (23.9) 
When I am not certain if I am doing an exercise 
correctly 
43 (39.4) 41 (37.6) 25 (22.9) 
 
3.5.3 Characteristics associated with self-efficacy levels 
3.5.3.1 Bivariate analyses 
Results from the bivariate analysis exploring the crude relationship between 
demographic, medical and lymphoedema-related characteristics and general and 
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lymphoedema-specific exercise barriers self-efficacy are presented in Appendix 7, 
with findings briefly summarised below. 
 
Demographic and medical characteristics and exercise barriers self-efficacy  
General exercise barriers self-efficacy scores were clinically (7+ points) and 
statistically different between physical activity levels, with lower self-efficacy levels 
observed in sedentary individuals.  There were also clinically significant differences 
in self-efficacy related to gender, children and cancer type, with lowest self-efficacy 
reported by females, those with children living at home and individuals with breast 
or gynaecological cancer.  Lymphoedema-specific self-efficacy scores were also 
significantly lower in sedentary individuals and females, and individuals reporting 
gynaecological cancer.  Respondents not receiving chemotherapy or radiation, and/or 
receiving ‘other’ treatment had clinically relevant lower self-efficacy.         
 
Lymphoedema-related characteristics and exercise barriers self-efficacy 
General and lymphoedema-specific exercise barriers self-efficacy was clinically and 
statistically lower in individuals reporting a greater number of symptoms, as well as 
more severe symptoms.  Additional variables showed clinically significant 
differences in lymphoedema-specific exercise barriers self-efficacy score: location of 
and time with lymphoedema.  Self-efficacy was lower in individuals with 
lymphoedema for over five years, and respondents with lower-body lymphoedema.        
 
3.5.3.2 Multivariate results 
General linear models were used to assess independent relationships between general 
and lymphoedema-specific exercise barriers self-efficacy and demographic, medical 
and lymphoedema-related characteristics.  Analyses suggested collinearity between 
the severity and number of symptoms variables, whereby those reporting more 
severe symptoms also trended towards reporting a higher number of overall 
symptoms.  Therefore, these variables were included in separate models.  As with 
bivariate analyses, a clinically relevant difference in general exercise barriers self-
efficacy scores between variable categories was defined as a change of 7%, and in 
lymphoedema-specific self-efficacy scores as a change of 4% (234).  
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Final models 
Variables included in the final general exercise barriers self-efficacy model were age, 
gender, physical activity levels, time with lymphoedema and total number and 
severity of symptoms (these two variables included in separate models) (Table 3.13).     
The final lymphoedema-specific exercise barriers self-efficacy model included age, 
cancer type, physical activity levels and severity and number of symptoms (these two 
variables included in separate models) (Table 3.13).   
 
General exercise barriers self-efficacy explanatory variables 
A clinically relevant and statistically significant relationship between general 
exercise barriers self-efficacy and physical activity levels and number and severity of 
lymphoedema-related symptoms was identified (Table 3.13).   Specifically, lower 
self-efficacy was observed in individuals who were sedentary compared to 
insufficiently or sufficiently active, reported symptoms as moderate or severe 
compared to mild and reported five or more symptoms compared with one to four 
(p< 0.05).  Additionally, clinically relevant lower self-efficacy was observed in 
females compared to males and individuals with lymphoedema for over two years 
compared to those with lymphoedema for less than two years.  However, exercise 
barriers self-efficacy score differences for gender and time with lymphoedema were 
not supported statistically.  
 
Lymphoedema-specific exercise barriers self-efficacy explanatory variables 
Table 3.13 presents crude and adjusted associations for variables included in the final 
lymphoedema-specific exercise barriers self-efficacy model.  Clinically relevant 
lower self-efficacy was observed in individuals with gynaecological or other cancers 
compared to breast cancer, as well as sedentary respondents compared to 
insufficiently or sufficiently active individuals.  Exercise barriers self-efficacy levels 
were also clinically different for number and severity of lymphoedema-related 
symptoms, with trends the same as those found with general self-efficacy.  That is, 
lower scores were reported by individuals with moderate or severe symptoms, and 
with five or more symptoms.  Self-efficacy score differences related to cancer type, 
physical activity levels and number and severity of symptoms were not statistically 
significant.     
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Table 3.13 Variables independently associated with general and lymphoedema-specific exercise barriers self-efficacy 
 General Lymphoedema-specific 
Variables n Crude Adjusted n Bivariate Adjusted 
  x (95% CI) p-value EMM (95% CI) p-value  x (95% CI) p-value EMM (95% CI) p-value 
Age (years; Pearson r) 109 0.008  0.394  0.82 109 0.032 0.74  0.56 
Gender 
  Male 
  Female 
 
5 
104 
 
65.0 (31.8, 98.2) 
47.2 (43.2, 51.3) 
 
0.07 
 
61.1 (42.9, 79.2) 
48.2 (42.4, 53.9) 
 
0.19 
     
Physical activity levels1 
  Sedentary 
  Insufficient 
  Sufficient 
 
11 
37 
61 
 
31.4 (17.1, 45.7) 
49.8 (42.9, 56.8) 
50.0 (44.0, 52.1) 
 
0.02* 
 
42.0 (26.4, 57.5) 
62.0 (51.2, 72.9) 
59.7 (49.5, 69.9) 
 
0.01* 
 
 
 
11 
37 
61 
 
36.0 (20.9, 51.1) 
51.4 (44.5, 58.3) 
53.1 (47.1, 59.2) 
 
0.07 
 
34.4 (20.0, 48.8) 
50.6 (41.4, 59.9) 
51.4 (43.5, 59.3) 
 
0.08 
Time with lymphoedema 
  <2 years 
  >2 years 
 
43 
66 
 
51.0 (44.9, 57.1) 
46.1 (40.7, 51.6) 
 
0.25 
 
58.8 (47.7, 69.8) 
51.3 (41.0, 61.6) 
 
0.07 
     
Type of cancer 
  Breast 
  Gynaeacological 
  Other 
 
 
     
86 
14 
9 
 
52.7 (47.9, 57.5) 
40.0 (27.6, 52.4) 
49.7 (27.8, 71.6) 
 
0.16 
 
51.3 (44.8, 57.9) 
39.6 (27.0, 52.3) 
45.5 (30.3, 60.8) 
 
0.18 
Severity of symptomsa 
  Mild 
  Moderate 
  Severe 
 
14 
51 
44 
 
60.4 (48.2, 72.6) 
49.3 (44.1, 54.5) 
42.7 (35.8, 49.7) 
 
0.02* 
 
62.2 (49.1, 75.3) 
48.4 (37.1, 59.7) 
45.0 (33.6, 56.5) 
 
0.01* 
 
14 
51 
44 
 
60.4 (47.6, 73.1) 
49.7 (43.4, 56.0) 
49.1 (41.9, 56.3) 
 
0.25 
 
54.4 (40.5, 66.3) 
40.9 (31.8, 50.0) 
42.2 (33.3, 51.0) 
 
0.19 
Number of symptomsa 
  1-2 
  3-4 
  5+ 
 
17 
20 
72 
 
61.6 (52.1, 71.1) 
53.7 (45.3, 62.0) 
43.3 (38.3, 48.3) 
 
<0.01* 
 
65.0 (52.3, 77.6) 
54.7 (42.1, 67.3) 
45.3 (35.2, 55.5) 
 
<0.01* 
 
17 
20 
72 
 
58.6 (46.6, 70.7) 
57.0 (44.2, 69.8) 
47.2 (42.3, 52.2) 
 
0.07 
 
52.1 (40.2, 64.0) 
47.9 (35.7, 60.0) 
40.3 (32.3, 48.2) 
 
0.11 
*p<0.05 
a Models run separately for number and severity of symptoms variables, final data for general self-efficacy from number of symptoms model; final data for lymphoedema self-
efficacy from severity of symptoms model 
1sedentary (no physical activity), insufficient (< 150 min OR ≥ 150 min and < 5 sessions), sufficient (≥ 150 min and ≥ 5 sessions) 
CI=confidence intervals 
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3.6 DISCUSSION 
 
This study has provided evidence to support the validity and reliability of a sub-scale 
to assess confidence in ability to exercise in individuals with cancer-related 
lymphoedema when faced with barriers.  The final sub-scale now has five 
lymphoedema-specific barriers that correlated highly with the general self-efficacy 
scale, but form a distinct separate factor, indicating the importance of lymphoedema-
specific barriers to exercise.  The work has contributed to the completion of a 
manuscript currently in press, attached as Appendix 8. 
 
Development of this scale allowed assessment of exercise barriers self-efficacy in 
individuals with cancer-related lymphoedema.  Average exercise barriers self-
efficacy, out of 100%, was 48% for general barriers and 51% for lymphoedema-
specific barriers, reflecting that participants only had moderate confidence to engage 
in exercise when faced with potential barriers.  Additionally, when encountering the 
majority of these barriers, only one in three cancer survivors with lymphoedema 
reported they were very to extremely confident to engage in exercise.  Lower general 
and lymphoedema-specific exercise barriers self-efficacy was associated with 
reporting lower physical activity levels and experiencing a greater number of and 
more severe lymphoedema-related symptoms.  Additionally, females and individuals 
with lymphoedema for over two years (compared to males and those with cancer for 
two years or less) reported lower general exercise barriers self-efficacy, and 
individuals with gynaecological or other cancers (compared to breast cancer) 
reported lower lymphoedema-specific self-efficacy.  This study is the first to assess 
self-efficacy for lymphoedema-related exercise barriers, so direct comparisons to 
other research cannot be made.  Nonetheless, exercise barriers self-efficacy levels are 
similar to those found in studies involving women undergoing adjuvant treatment for 
breast cancer (218; 230), as well as post-treatment breast (55; 218; 233) and 
endometrial cancer survivors (21).     
 
Our finding of a relationship between lower self-efficacy and moderate or severe 
symptoms (p<0.05 for general barriers) and/or higher number of symptoms (p<0.05 
for general barriers) is novel, yet expected.  Multiple studies on individuals with 
cancer-related lymphoedema have reported the undesirable effects of symptoms on 
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everyday life and ability and confidence to perform daily physical activity (60; 115; 
159; 250).  The lower lymphoedema-specific self-efficacy levels observed in 
gynaecological and other cancer survivors, compared to breast, are also not 
completely unexpected.  Much of the research on exercise and lymphoedema comes 
from studies in women with upper-body, breast cancer-related lymphoedema (169).  
There is very limited research-supported advice for lymphoedema beyond breast 
cancer-related, which may contribute to the lower self-efficacy observed in other 
cancer groups.    
 
In agreement with previous research was the finding of a positive relationship 
between physical activity and self-efficacy levels, with studies reporting higher self-
efficacy is associated with higher physical activity levels (55; 218) and daily energy 
expenditure (233).  This association may work both ways, whereby confidence to 
exercise translates to higher physical activity and conversely higher physical activity 
participation results in greater ability and knowledge to overcome barriers (55).  
Time with lymphoedema was also associated with general self-efficacy, whereby 
longer-time lymphoedema corresponded with lower self-efficacy.  It is possible that 
this association may reflect the difference in traditional versus more recent 
lymphoedema management guidelines.  Lymphoedema education organisations are 
only recently starting to endorse rather than discourage exercise and full use of the 
affected limb (43; 202).  However, for individuals that have had lymphoedema 
longer-term and been previously advised against exercising, finding the motivation, 
discipline and time to exercise may be a challenge, reflected in a lower general self-
efficacy score.  Additionally, these individuals may have been older and 
experiencing other co-morbidities and age-related functional declines that could have 
contributed.  
  
As highlighted in Sections 2.2.3 and 2.2.4, emerging evidence supports rather than 
discourages cancer survivors both with and without lymphoedema to engage in 
exercise (43; 135; 202; 249).  However, this research underlines that those with 
cancer-related lymphoedema may require additional encouragement, support and 
guidance.  Overcoming barriers and engaging in exercise is not easy for some 
individuals, even when the evidence clearly shows safety, feasibility and benefit 
(82).  For individuals with cancer-related lymphoedema, both general and 
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lymphoedema-related barriers need to be considered.  By understanding what 
barriers are faced by those with cancer-related lymphoedema, healthcare 
professionals may be able to assist patients in finding solutions to overcome these 
barriers and increase their confidence to engage in, and maintain, exercise.   
 
Study limitations should be considered when interpreting these findings.  This was a 
cross-sectional study involving a convenience sample of people with cancer-related 
lymphoedema.  Respondents were primarily drawn from a physiotherapy practice 
specialising in lymphoedema treatment and with a strong emphasis on exercise.  This 
may be reflected in over half (64%) of participants meeting national physical activity 
guidelines, higher than that typically reported by cancer survivors (95; 125).  It 
seems plausible that the potential response bias from a convenience sample such as 
this would lead to overestimation of exercise barriers self-efficacy.  That is, it is 
likely these results reflect ‘best-case’ scenario of individuals that are motivated to 
seek further care, as well as financially able to.  As such, the results may not reflect 
the barriers faced by individuals without such motivation and/or financial ability.  
Further adding to the potential for an overestimation of barrier self-efficacy was that 
most respondents in this study either had, or were receiving, physiotherapy care for 
their lymphoedema, which may have decreased the number and severity of 
lymphoedema symptoms they experienced. Additionally, the majority (79%) 
reported lymphoedema following breast cancer, limiting the generalisability of these 
findings to other cancer-related lymphoedema groups.  Finally, while findings 
suggested an association between gender and general self-efficacy, we had a low 
number of male participants (n=5).  Given previous research in breast and prostate 
cancer survivors has reported similar self-efficacy levels between males and females 
(31; 216), this result warrants further investigation.    
 
Despite study limitations, the results clearly highlight the importance of recognising 
and understanding exercise barriers faced by those with cancer-related 
lymphoedema.  This is supported by the finding that, despite exposure to exercise 
and encouragement from healthcare professionals, respondents were still only 
moderately confident to overcome exercise barriers.  Using the new lymphoedema-
specific sub-scale along with the existing general barriers self-efficacy scale by 
Rogers and colleagues’ (230) will allow healthcare professionals and patients to 
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identify low self-efficacy for overcoming exercise barriers when cancer-related 
lymphedema is present.  Without support and advice to help this cohort become and 
stay active, it will be difficult for clinical recommendations from research trials to be 
translated into practice.  However, information is needed on ways to help this 
population overcome exercise barriers.  One way may be through inclusion of an 
Accredited Exercise Physiologist into standard lymphoedema care, delivering an 
initially-supervised exercise program and providing assessment and discussion of 
exercise barriers.  Information is required, however, on what type of exercise this 
program should consist of, and if one mode is best for improving self-efficacy levels.  
To address these gaps in the research, exercise barriers self-efficacy was included as 
a secondary outcome of interest in study two, which looked at the effects of a 
supervised exercise program, in the form of either resistance- or aerobic-based 
exercise, on cancer-related lymphoedema. 
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Chapter 4: Study two-Randomised trial 
comparing effects of resistance- 
and aerobic-based exercise 
4.1 BACKGROUND 
Building confidence to exercise in individuals with cancer-related lymphoedema 
partly relies on having knowledge on the safety and benefits of engaging in regular 
exercise. As highlighted in Section 2.2.4, research has demonstrated exercise is safe 
for individuals with cancer-related lymphoedema, although this research has focused 
on women with breast cancer-related lymphoedema.  Further study in this population 
is needed, however, to improve exercise prescription.  One key research gap is 
identifying which, if any, mode of exercise is most beneficial, and if this varies 
depending on an individual’s unique survivorship concerns.  While a combination of 
resistance- and aerobic-based exercise is the most commonly endorsed exercise 
prescription, limited research has compared these modes when used individually to 
see if one may be better at optimising specific outcomes.   
 
Only three studies were identified that directly compare resistance- to aerobic-based 
exercise in breast cancer survivors, with none of these studies focused on women 
with lymphoedema.  These studies provide preliminary support that both modes of 
exercise are beneficial (full summary table presented in Appendix 9), but may 
improve different areas.  Further research is warranted in women with breast cancer-
related lymphoedema given the difference in physiological benefits associated with 
each mode in the general population.  Resistance-based exercise is recommended to 
help improve muscular strength and endurance, increase lean muscle mass, improve 
bone health and help counteract age-related functional and physiological declines 
(167; 260; 270).  Conversely, aerobic-based exercise is prescribed to improve 
cardiopulmonary function, decrease body fat and weight, reduce risk of 
cardiovascular disease and improve metabolic function (104).  As cancer treatments 
commonly impact numerous body systems (e.g., cardiovascular, metabolic, 
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lymphatic), it is feasible that cancer survivors respond to exercise differently than a 
healthy population (153).  However, whether one mode of exercise is superior for 
inducing such physiological changes in cancer survivors, specifically those with 
breast cancer-related lymphoedema, is unknown.  
    
Exercise mode comparison is also needed given the physiological differences of each 
mode and their impact on the lymphatic system, outlined in Section 2.2.2.  Briefly, 
the musculoskeletal and cardiovascular systems are both closely linked with the 
lymphatic system.  Resistance-based exercise, by engaging the musculoskeletal 
system, helps lymph transport through a ‘muscle pump’ action.  Lengthening and 
contracting muscle pulls on connective tissue and therefore the attached lymphatic 
vessels, helping fill lymph vessels and propel fluid proximally (180).  This mode of 
exercise may also improve muscular strength and endurance, decreasing stress on the 
affected limb during performance of daily activities (244).   Conversely, aerobic-
based exercise, via the cardiovascular system, assists lymph movement through 
effects on breathing and blood flow.  Inspirations (292) , as well as deep 
diaphragmatic breathing (198), help reduce transport obstruction and propel lymph 
fluid. Increasing cardiovascular system activity through aerobic-based exercise, 
resulting in greater blood flow and capillary filtration and therefore higher interstitial 
fluid pressure, may further aid lymph uptake and transport (172; 193).  
 
In addition to physiological differences, there are participant-related factors 
associated with each exercise mode that may have important implications for 
program design.  Studies suggest that activities such as unsupervised aerobic-based 
exercise (especially walking) may be preferred by breast cancer survivors (151; 231), 
possibly due to greater accessibility and confidence associated with this mode.  It is 
likely women have better access to, and greater experience with, aerobic-based 
activities, which may in turn positively influence adherence to such exercise.  
Conversely, breast cancer survivors may not have as much previous exposure to 
resistance-based exercise and thereby be less aware of how to undertake such 
exercise, and its potential benefits.  However, it may be possible to influence 
exercise selection and adherence by providing survivors with information on what 
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mode is best for concerns such as lymphoedema and regaining physical functioning 
(72; 238).     
 
Currently, the highest-quality research (i.e., RCTs) comes from a trial using only 
resistance-based exercise (244).  This has contributed to the pattern of healthcare 
professionals and women with breast cancer-related lymphoedema perceiving that it 
is primarily resistance-based exercise that contributes to the benefits observed related 
to objective and subjective lymphoedema status, rather than, for example, another 
mode or exercise in general.  However, there is no clear study on the impact of 
aerobic-based exercise in isolation.  Therefore, comparing resistance- and aerobic-
based exercise will provide valuable information to support or dispute the idea that 
resistance-based exercise is optimal for women with breast cancer-related 
lymphoedema.  It will also demonstrate whether exercise principles such as 
specificity and the cross-over effect are relevant to this sub-group of survivors.  
Specificity refers to certain types of exercise impacting certain systems of the body 
(e.g., aerobic-based exercise such as jogging improves the cardiovascular system), 
while the cross-over effect refers to, for example, resistance-based exercise 
producing cardiovascular benefits and aerobic-based exercise producing 
musculoskeletal benefits (46).  Gaining a greater understanding of how each mode 
affects lymphoedema, as well as other areas such as fitness and QoL, can assist in 
improving exercise prescription, as well as provide individuals with clearer exercise 
advice and confidence in being active.   
 
As such, this component of the PhD program of research was a single-centred, 
randomised trial that evaluated a 12-week supervised exercise intervention, with a 
12-week unsupervised follow-up period, prescribing either resistance- or aerobic-
based exercise to individuals with breast cancer-related lymphoedema.  It used a 
two-group parallel design comparing the effect of participation in a resistance- 
versus aerobic-based exercise group with a 1:1 allocation.  It sought to address the 
following objectives and related hypotheses:   
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Primary objective: What is the effect of resistance- versus aerobic-based exercise on 
lymphoedema status? 
Null hypothesis: Resistance- and aerobic-based exercise will have no effect 
on lymphoedema status. 
Alternative hypothesis: Resistance-based exercise will benefit lymphoedema 
significantly more than aerobic-based exercise.   
 
Secondary objectives:   
What is the effect of resistance- versus aerobic-based exercise on physical outcomes 
(muscular strength and endurance, aerobic fitness, self-reported upper-body 
functioning, body composition, bone density), exercise barriers self-efficacy and 
QoL? 
Null hypothesis: Resistance- and aerobic-based exercise will have no effect 
on physical outcomes (muscular strength and endurance, aerobic fitness, self-
reported upper-body functioning, body composition, bone density), exercise 
barriers self-efficacy and QoL. 
Alternative hypothesis: Resistance-based exercise will lead to greater 
improvements in muscular strength and endurance, self-reported upper-body 
functioning, body composition and QoL.  Aerobic-based exercise will lead to 
greater improvements in aerobic fitness, bone density and exercise barriers 
self-efficacy. 
 
Ethical approval for this study was obtained from the Research Ethics Unit at the 
Queensland University of Technology, approval number 1300000103.  It was also 
reviewed and approved by the Metro South Human Research Ethics Committee (MS 
HREC), approval number HREC/13/QPAH/306 (Appendix 10). 
 
4.2 METHODS 
4.2.1 Participants 
Eligibility criteria included:  
• females aged 18 and over with a history of primary breast cancer and no 
metastatic cancer; 
 Chapter 4: Study one 71 
 
 
• in remission at the time of study enrolment; 
• have completed all planned cancer-related treatments (still eligible if on 
hormone therapy/aromatase inhibitors); 
• physically capable of participating in an exercise program, with no 
prohibiting medical conditions (such as unstable hypertension); 
• not pregnant or plan to become pregnant during the study duration; 
• have no plans for taking holidays that would interfere with data collection or 
intervention procedures (i.e., longer than two weeks or at assessment time-
points); 
• not undertaking more than 75 minutes of moderate resistance- and/or aerobic-
based exercise per week in the past three months (equivalent of ≤50% of 
intervention exercise prescription); 
• willing to be randomised and able to commit to the full study period. 
 
Participants needed to have unilateral upper-limb lymphoedema as defined using a 
previously-established classification (244): (1) a ≥10% interlimb discrepancy in 
volume or circumference at the point of greatest visible difference or swelling or 
obstruction of the anatomic architecture on close inspection or pitting oedema; or (2) 
a prior clinical diagnosis of lymphoedema and having had any prior intensive 
lymphoedema therapy on the affected arm; or (3) self-report a clinical diagnosis of 
lymphoedema that is later confirmed by a qualified clinician or study measurements 
(sum of circumferences on treated side >5% of the untreated side or BIS ratio of 
impedance exceeds three standard deviations of normative mean values- upper-limb: 
>1.134 when treated on dominant side, >1.106 when treated on non-dominant side) 
(285).  
 
Exclusions were made for those with lymphoedema restricted to the breast/trunk and 
unstable lymphoedema, defined as the participant: (1) needing intensive 
lymphoedema therapy within three months before study entry; or (2) experiencing a 
lymphoedema-related infection requiring use of antibiotics within three months prior 
to study entry; or (3) requiring a notable change in activities of daily living due to 
exacerbation of lymphoedema within three months before study entry (244). 
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4.2.2 Recruitment 
Potential participants were recruited through the distribution of a study information 
packet, which included a letter outlining the study, expression of interest form and 
consent form that could be returned to the investigator (Appendix 11).  Also included 
was a form allowing women to decline participation, but still provide basic 
demographic and medical details (Appendix 11).  Collection of such information 
provided valuable information on characteristics of individuals who chose to 
participate versus those who elected not to, which can be used to improve future 
research recruitment and translation of these interventions into clinical practice.  
Brisbane-based private physiotherapy practices with specialisation in lymphoedema 
treatment were asked to distribute packets to all potentially eligible participants 
currently or previously attending the clinic.  Packets were also distributed by 
occupational therapists at the Princess Alexandra Hospital, Brisbane, Australia, 
physiotherapists and occupational therapists at the Royal Brisbane and Women’s 
Hospital, Brisbane, Australia, via local lymphoedema groups and to a pre-existing 
database of women with lymphoedema interested in being informed of future 
research studies, held at the Queensland University of Technology.  Additionally, 
recruitment fliers with researcher contact details were posted in participating 
physiotherapy and hospital-based practices and printed in Queensland lymphoedema-
associated newsletters. 
 
Upon expression of interest, individuals were screened via telephone for eligibility 
using a standardised checklist and the Physical Activity Readiness Questionnaire 
(PAR-Q) (48).  The PAR-Q is a common tool used to assess participant safety and 
ability to partake in exercise.  Eligible participants who had not sent back a 
completed informed consent form were then read the form (which was also signed 
prior to initial assessment) and a baseline assessment was scheduled.  Contact details 
for the individual’s general practitioner were obtained to allow the researcher to gain 
medical consent.  Eligible participants were sent a survey collecting information on 
demographic, medical and lymphoedema-related characteristics and self-report 
outcome measures (subjective lymphoedema status, physical activity levels, self-
reported upper-body functioning, exercise barriers self-efficacy, QoL), to be 
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completed and returned at baseline assessment of objectively-measured outcomes 
(lymphoedema status, muscular strength and endurance, aerobic fitness, body 
composition, bone mineral density) (Appendix 12).  Attempts were also made to 
collect demographic, disease and lymphoedema-related information on those who 
expressed interest and were either deemed ineligible or later decided not to 
participate, using a self-report survey.  
 
4.2.3 Location and settings 
Baseline, post-intervention and 12-week follow-up assessments  (Figure 4.1) were 
conducted at Queensland University of Technology, Brisbane, Australia, at the 
Institute of Health and Biomedical Innovation health clinic facilities.  Supervised 
exercise sessions were conducted at the participant’s home or other selected 
convenient location (e.g., gym, local park, pool). 
Figure 4.1 Study two flow 
 
4.2.4 Interventions 
The exercise interventions that were used in this study model a program previously 
developed for use in a large-scale RCT involving women with breast cancer-related 
lymphoedema (244).  Modifications of the prescribed exercises were made and are 
reported in the results when a participant was physically unable to perform a given 
exercise, such as adapting a resistance-based exercise when a participant had 
restricted ROM.  Metabolic equivalents of task (METs), which is a unit indicative of 
energy expenditure, were used to quantify exercise amount.  METs per hour 
represent physical activity intensity (4).  As the mode used by the two intervention 
groups was different (resistance- versus aerobic-based), this was done to increase 
equivalence of exercise prescribed to participants.  Further detail of how METs was 
used is provided below for the two exercise groups. 
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Both exercise groups (resistance- and aerobic-based) incorporated standard 
components.  Participants in both groups were instructed to maintain their normal 
lymphoedema management (e.g., manual lymphatic drainage, compression garment) 
during the 24-week study timeframe.  Additionally, during the 12-week intervention 
women were asked weekly about their physical activity levels during the past seven 
days (e.g., house/yard work, job-related, general recreational activities).  At this time, 
participants were also asked about any changes in lymphoedema symptoms 
experienced and changes to lymphoedema treatment (both in relation to symptoms 
changes if relevant, and in general).  All supervised sessions were conducted as part 
of the research, guided by an Accredited Exercise Physiologist with specialist 
training in exercise for cancer patients. 
 
4.2.4.1 Resistance-based exercise 
The resistance-based exercise intervention was similar to that used by Schmitz and 
colleagues (223; 224), the Physical Activity and Lymphedema (PAL)  trial, an RCT 
assessing the effects of full-body progressive strength training in women with and at-
risk of lymphoedema.  Modifications from the PAL program included: 
• 50-minute supervised sessions (90 minutes in PAL) 
• Home-based option using free weights to increase accessibility of program 
(gym-based in PAL)   !
In the current intervention, all resistance-based exercise sessions began with a five-
minute cardiovascular warm-up period, followed by a full-body strength training 
program, including: chest fly, triceps kick-back, squat, curl-ups, bent-over row, 
bridging, wall push-up, bicep curls, calf raises, shoulder press, external rotation and 
forward lunge.  Weight-lifting exercises were introduced with little to no resistance 
initially and progressed as needed.  Modifications were made at the researcher’s 
discretion if pain, injury or altered ROM prevented proper technique of the given 
exercise.  The initial six exercises were introduced during week one, with one new 
exercise introduced weekly, for a total of 12 exercises by week seven.  All exercises 
were performed during the supervised sessions, with participants instructed to 
complete each exercise unsupervised once (weeks 1-4) or twice (weeks 5-12) each 
week.  No single exercise (e.g., bicep curl, squat) was to be undertaken more than 
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three times per week, and no exercise was to be performed on consecutive days.  All 
sessions concluded with a cool-down and full-body stretching incorporating all major 
muscle groups, holding each position for 20 seconds.   
 
Participants in the resistance-based exercise group were instructed to undertake 150 
minutes of supervised and unsupervised training each week (Table 4.1 and Table 
4.2).  Exercise prescription was progressive and based on METs, with intensity in 
each session monitored by using the revised Borg Rating of Perceived Exertion 
(RPE) scale (36) (Table 4.3).  Intensity was adjusted by gradually increasing weight 
lifted and through use of exercise pairing (i.e., two to three exercises conducted in 
succession with minimal rest).  For participants unable to maintain this intensity for 
the full supervised session duration, intervals were used and gradually lengthened to 
build exercise tolerance.  Instructions were given to undertake unsupervised exercise 
at the prescribed intensity, accumulating the prescribed minutes of exercise in as 
many sessions as needed, provided the same exercise wasn’t performed on 
consecutive days (Table 4.2).  All women were provided with hand-held weights and 
progressed as needed to enable completion of unsupervised sessions.   
 
Table 4.1 Resistance- and aerobic-based exercise schedule 
Intervention Weeks 1-4 Weeks 5-12 
  
 
 
 
Resistance  
 
 
Supervised 
-2x/week, 50 minutes/session of 
resistance-based exercise and 
flexibility 
-progressive increase of intensity 
using weight and repetitions 
-1x/week, 50 minutes/session of 
resistance-based exercise and 
flexibility 
-progressive increase of intensity 
using weight  
 
 
Unsupervised 
 
-50 minutes, recorded in log 
books checked at supervised 
session 
-continuous session or 
accumulated over week 
-100 minutes, recorded in log 
books checked at supervised 
session 
-no set number of sessions to 
achieve this in 
 
 
 
 
Aerobic 
 
 
 
Supervised 
-2x/week, 50 minutes/session of 
aerobic-based exercise and 
flexibility 
-combine aerobic intervals with 
rest periods as needed to achieve 
full time  
-1x/week, 50 minutes/session of 
aerobic-based exercise and 
flexibility 
-build to continuous aerobic 
exercise for duration of session 
 
 
Unsupervised 
 
-50 minutes, recorded in log 
books checked at supervised 
session 
-continuous session or 
accumulated over week 
-100 minutes, recorded in log 
books checked at supervised 
session 
-no set number of sessions to 
achieve this in 
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The exercises were initially performed using light weight (less than 1.5 kgs for free 
weights).  For weeks 1-4, participants performed two sets of 10-12 repetitions, with 
weight increased once the participant was able to complete the assigned number of 
sets and repetitions.  Weight increase was based on what was needed to maintain an 
RPE of 11-13 so as to achieve a MET level of 3-3.5.  For weeks 5-12, participants 
performed two sets of 8-10 repetitions, with weight increased once participants 
correctly and safely performed assigned sets and repetitions, so as to maintain an 
RPE of 12-14 and MET level of 5.  
 
Time and intensity of all unsupervised exercise was recorded by participants in an 
activity log, which was checked at each supervised session to assess adherence and 
monitor for any changing symptoms or other issues.   The researcher conducted all 
supervised sessions.  If participants developed an injury or experienced a 
change/development of lymphoedema symptoms during training, and if the exercise 
intervention was likely to have contributed to or exacerbated concerns, the 
intervention was modified accordingly.  Following recovery, the participant restarted 
the intervention component(s) at a lower weight and gradually progressed the 
amount lifted.  
 
4.2.4.2 Aerobic-based exercise 
All aerobic-based exercise sessions incorporated the same warm-up and cool-down 
undertaken by those in the resistance-based exercise group, with total duration of 
each supervised session 50 minutes.  Any form of aerobic-based exercise could be 
undertaken during these sessions, which was discussed and decided with the 
participant, depending on personal preference and ability and available resources.  
This may have included one or more of the following types: walking/jogging, 
swimming, cycling, rowing.  Nonetheless, the primary type chosen was walking 
(151; 231).   
 
During initial sessions, some participants were able to exercise continuously over the 
50 minutes, while others had to use intermittent bouts of aerobic-based exercise 
 Chapter 4: Study one 77 
 
 
interspersed with rest intervals and gradually build their exercise tolerance over the 
intervention.  Program structure, related to time, duration and intensity, was 
equivalent to that prescribed to the resistance-based exercise group (Table 4.1, Table 
4.2 and Table 4.3). As with the resistance-based exercise group, aerobic-based 
exercise group participants were instructed to record time and intensity of all 
unsupervised exercise in an activity log, which was checked and discussed at each 
supervised session to assess adherence and monitor for any changing symptoms or 
other issues.      
Table 4.2 Examples of methods to accrue 150 weekly minutes of exercise 
Week of 
intervention 
Supervised session 
time 
 Unsupervised session times 
(examples) 
Total weekly 
activity 
Weeks 1-4 
100 minutes  
(2x 50-minute 
sessions) 
 
+ 
1x 50-minute session 
OR 
2x 25-minute sessions 
 
=150 minutes 
Weeks 5-12 50 minutes (1 session) 
 
+ 
2x 50-minute sessions 
OR 
4x 25-minute sessions 
 
=150 minutes 
 
Table 4.3 Prescribed exercise intensity 
Intervention time Prescribed METs (aerobic/resistance 
equivalent) 
RPE 
Weeks 1-6 3-3.5 (“brisk pace”/”light workout”) 11-13 (light-moderate) 
Weeks 7-12 5 (“very brisk pace”/”moderate effort”) 12-14 (moderate-hard) 
METs=metabolic equivalents of task; RPE=rating of perceived exertion 
 
4.2.5 Intervention adherence 
Strategies were used to maximise intervention adherence.  During initial sessions, 
participants were given advice on how to minimise common barriers, such as 
identification of potential sheltered locations where exercise might be feasible during 
poor weather.  Participants were given activity logs in which to record their weekly, 
unsupervised exercise, including time, type and RPE during the session.  They were 
also asked to record relevant information for exercise sessions (e.g., modifications, 
pain/discomfort, barriers encountered).  At each one-on-one supervised session 
during the 12-week intervention period, this log was reviewed with the participant to 
assess adherence and address any concerns or queries that arose.  The researcher and 
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participant also scheduled days and times during the week when the unsupervised 
exercise would be undertaken, with identification of an additional ‘back-up’ time 
period if barriers arose during any of the selected times.  When needed, each 
supervised session included a discussion of personal barriers and strategies to 
overcome them, as is traditionally done by exercise physiologists. 
 
Additionally, each week, the researcher collected information on weekly physical 
activity levels (excluding the intervention), experience of lymphoedema-related 
symptoms (with follow-up information on treatment, duration and possible cause for 
any changed symptoms) and lymphoedema treatment undertaken.  If a participant 
was unable to attend a supervised session during the relevant week, an additional 
session was added if possible the following week.  However, this was only done 
twice for each participant, if needed, to ensure consistency throughout the program 
and to allow a more accurate measurement of overall adherence.  All reasons for 
missed/rescheduled sessions were recorded and discussed in the results. 
   
Verbal praise was used when participants completed expected unsupervised exercise, 
and they were given positive encouragement and advice when unsuccessful in 
meeting the weekly goal.  While 100% weekly adherence was emphasised, 
individuals were reminded that an overall adherence of 1800 total minutes over the 
12 weeks was the ultimate aim, and if there were weeks they could not obtain 150 
minutes of exercise, they were encouraged to make up the missed time the following 
week, within reason.  
 
4.2.6 Outcomes 
Objective outcome measures were taken at baseline, post-intervention and 12-week 
follow-up assessment, with self-report outcome measures (lymphoedema status, 
physical activity levels, self-reported upper-body functioning, exercise barriers self-
efficacy, QoL) also assessed at these three time-points using self-report 
questionnaires.  Prior to all outcomes measurements, participant heart rate and blood 
pressure were taken manually to ensure safety of completing exercise-related 
assessments. 
 Chapter 4: Study one 79 
 
 
 
4.2.6.1 Primary outcome: lymphoedema status 
Lymphoedema status was assessed using two objective measures, specifically BIS 
and circumference measurements, and a subjective participant-completed survey.  
Prior to testing, participants were provided with instructions about controlling fluid 
intake and vigorous activity participation, and individuals that wore compression 
garments were instructed to remove the garment one hour prior to measurement.  
When possible, these measurements were taken at the same time of day for all three 
assessments. 
 
Bioimpedance Spectroscopy 
Multifrequency BIS (SFB7; ImpediMed, Brisbane, Australia) was used to measure 
the impedance of extracellular fluid in the participant’s arms.  The manufacturer’s 
software was used to generate impedance scores for both the affected and unaffected 
limb, and a ratio of these values was calculated.  Lymphoedema is considered 
clinically evident when this impedance ratio of R0 values exceeds three standard 
deviations of normative mean values (unilateral; upper-limb: >1.134 when treated on 
dominant side, >1.106 when treated on non-dominant side) (282).  Previous work has 
demonstrated BIS is a reliable method to assess lymphoedema, particularly early-
stage lymphoedema when it is characterised by an increase in extracellular fluid 
(289). 
 
To obtain impedance measurements, participants were instructed to lay supine with a 
towel between the legs, to prevent the thighs from touching.  Colour-coded 
electrodes were then placed on the individual’s feet and wrists, as per manufacturer 
instructions (66).  Impedance values were generated by the machine passing a small 
electrical current through the body, with current direction dictated by location of the 
electrodes, allowing for assessment of each limb in solidarity.       
 
Circumference measurements 
Circumference measures were obtained for the arms based on the Australasian 
Lymphoedema Association’s (ALA) national standards (13), with modification made 
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to distance between measurements (5 cm rather than standard 10 cm).  Values were 
used to determine interlimb percentage difference.  The participant was seated and 
the affected arm pronated and abducted 90 degrees at the shoulder.  If this angle 
could not be achieved, the obtained angle was measured and used for all subsequent 
testing on both arms.  The individual’s arm was positioned on a scaled measuring 
board (Jobst; North Carolina, USA) and locations were recorded for the tip of the 
third finger, the mid-point of the ulnar and radial metacarpo-phalangeal joints and 
the mid-point of the ulnar styloid process.  A set-square was then used to mark 5-cm 
increments, using the styloid mark as 0 cm, up to the participant’s axillary fold.  
Circumference measures were recorded for the metacarpo-phalangeals and each 5-
cm increment, with a full, blinded re-measure (i.e., the original measurements values 
were recorded separately) repeated after all values had been obtained and an average 
taken between the two values.  This was used to maximise intra-rater reliability.  The 
procedure was repeated on the opposite arm.   
 
Self-reported assessment 
The validated Norman lymphoedema survey was used to obtain a subjective measure 
of upper-limb lymphoedema, specifically information on the presence and severity of 
various common symptoms over the past three months.  This scale has been shown 
to have a specificity of 0.90 (out of 1) and sensitivity values of 0.86 to 0.92 for 
ability to diagnose lymphoedema when compared to a lymphoedema-specialist 
physiotherapist (207).  Participants are asked to what severity and frequency, if any, 
they experience common lymphoedema symptoms.  These include 14 symptoms 
related to upper-limb lymphoedema, such as swelling, pain and difficulty writing.  
Severity is reported on a scale from 0 (no symptom) to 4 (very severe) and an 
average is obtained for the 14 symptoms.  A clinically significant change is defined 
as one for shift in overall number or severity (224).  
  
Lymphoedema flare-up monitoring 
Care was taken to monitor participants for potential flare-up of their lymphoedema.  
Individuals in both groups were reminded to monitor lymphoedema and were asked 
weekly about changes in symptoms.  Participants were instructed that if they had any 
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concern about changing symptoms at any stage of the intervention, they could 
request an objective evaluation.  When measurements from this objective assessment 
were worse than those from baseline, the participant was sent to the physiotherapist 
who referred them to the study for further evaluation.  For participants not recruited 
from a physiotherapy practice, they were referred to their normal lymphoedema-
related healthcare professional (physiotherapy or other).  A worsening from baseline 
was defined as: 1) a 5% increase in difference between the affected and unaffected 
arm; or 2) 10% increase in BIS impedance ratio between limbs. 
 
Participants who reported changing symptoms but had no objective sign of flare-up 
were encouraged to monitor their lymphoedema over the following weeks and, if 
concern still existed, another objective evaluation was conducted and appropriate 
action taken.  Any participants requesting two or more objective evaluations within a 
month were referred to their treating physiotherapist or other healthcare professional 
irrespective of whether there was an objective change.  All objective evaluations 
were recorded, along with reason for conducting, outcome and if further referral and 
treatment was undertaken.         
 
4.2.6.2 Secondary outcomes 
Clinically-assessed outcomes 
Muscular fitness 
Lower-body muscular endurance was assessed using a squat test.  This test requires 
participants to complete as many body-weight squats (i.e., no additional weight held) 
as possible, lowering to the edge of a chair to achieve 90 degrees, until fatigue or 
when correct form can no longer be maintained.  The number of correctly-performed 
squats was then recorded.  No clinically significant change could be found for this 
test, and therefore a change of ≥1/2 standard deviation of baseline scores was a priori 
deemed clinically relevant (134).  This was used for any outcome with no defined 
clinically relevant change. 
 
Upper-body muscular strength was assessed in three ways: a 4-6 RM bench press, a 
shoulder and arm dynamometer and a handgrip dynamometer.  The 4-6RM test was 
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performed with the participant lying supine, using an initial 10-kg bar with 2.5 or 5 
kg weight progression based on participant ease of performance.  The full testing 
protocol has been outlined in previous research (166).  
Upper-body isometric pushing and pulling strength was assessed using a shoulder 
and arm dynamometer (TTM, Tokyo, 100kg).  The participant stood erect, elbow 
bent to 90 degrees, grasping the device in both hands.  A maximal pushing motion 
was made during an exhale, avoiding any extraneous body movement.  A 30-second 
rest was given before the participant repeated the test.  Following another 30-second 
rest, this procedure was repeated for two trials with a pulling motion.  The highest 
score for push and pull was recorded.  While normative values exist for this test, no 
clinically meaningful difference value could be found.         
 
Handgrip strength was assessed using a dynamometer (Smedley’s, TTM, Tokyo, 
100kg) and recorded as amount of force applied in kilograms.  A standard testing 
protocol was followed (49), with two trials conducted with each hand and highest 
score recorded.  This test correlates with overall upper-body strength (22; 156), and 
better performance is associated with better functioning and lower mortality, 
although this has primarily been tested in the elderly population (34; 224; 239).  A 
change of 6.5kg is considered clinically relevant (162). 
 
Aerobic fitness 
Aerobic fitness was assessed using the 6-Minute Walk Test, based on guidelines of 
the American Thoracic Society (7).  This submaximal test measures functional 
exercise capacity and is suggested to provide an indication of functional ability 
during daily activities.  Research has demonstrated the test has strong reliability, with 
intraclass correlation coefficient values from 0.91 to 0.92 (122), and is responsive to 
change following a rehabilitation program (29).  Clinically meaningful differences in 
score are defined as 25 meters (141).  
 
Body composition and bone density 
Height and weight were measured using a mechanical flat scale (Seca; California, 
USA) and a wall-mounted standiometer, and these values were used to determine a 
 Chapter 4: Study one 83 
 
 
participant’s body mass index.  Dual-energy X-ray absorptiometry (DXA) was used 
to measure body composition (fat and lean mass) and bone mineral content.  The 
same DXA scanner (Lunar Prodigy Advance, GE Healthcare, Wisconsin, USA) and 
analysis software (enCORETM 2011 Version 13.6; GE Healthcare, Wisconsin, USA) 
was used for all testing.  A total body scanning mode was used, with notes made on 
positioning to minimise error during subsequent follow-up testing, and effort was 
made to conduct post-intervention and 12-week follow-up assessments at the same 
time of day.  Participants were fully informed of the minimal radiation received 
during the scan, and pre-screening was done to ensure participants had no 
contraindications for undergoing scanning.  For participants that exceeded the width 
of the scanning area (n=13), two partial scans were conducted and results combined 
to obtain full-body measurements (275).  As most women in this study did not have 
osteoporosis (n=1 with osteoporosis) at baseline and were post-menopausal, bone 
density was reported using t-score, with a value of -1.0 to -2.5 indicating osteopenia 
and -2.5 or lower indicating osteoporosis (211).  Clinically relevant changes were 
defined as 2% for body fat, 5% for lean body mass and 0.5 units for t-score (81; 
152).   
 
Self-reported outcomes 
Upper-body function 
Self-reported functioning was assessed using the Disabilities of the Arm, Shoulder 
and Hand (DASH) questionnaire, a validated tool that measures the impact of upper-
limb limitations on daily life (24).  The scale uses a 5-point Likert scale to assess the 
level of disability related to each item, with a higher score indicating greater 
disability (total score=0-100 each section).  A clinically relevant difference is defined 
as a 10-point change in overall score (264).   
 
Exercise barriers self-efficacy 
Self-efficacy to overcome general and lymphoedema-specific potential barriers to 
exercise was assessed using a 14-item scale, developed in study one (Section 3.3.2).  
A change of ten points is considered clinically meaningful (230).  
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 Quality of life 
Quality of life was measured using the Functional Assessment of Cancer Therapy-
Breast+4 (FACT-B+4).  This scale, designed specifically for breast cancer patients, 
assesses five well-being domains: emotional, functional, physical, social and 
additional concerns.  Four additional items were added to the original FACT-B to 
make an ‘arm subscale’, forming the FACT-B+4 (92).  Each item is answered using 
a five-point Likert scale, rating how applicable each statement has been over the past 
seven days (0=‘not at all’ to 4=‘very much’).  Better QoL is reflected by a higher 
overall score, and each sub-scale can be used independently (37).  The scale has been 
shown to have sufficient test-retest reliability (0.97) and good internal consistency 
(alpha coefficient=0.62 to 0.88) (68).  A seven-point change in overall score is 
defined as clinically meaningful, and two points on each sub-scale (52; 97; 183). 
 
Physical activity levels 
The Active Australia survey was used to assess weekly physical activity participation 
(15), and has previously been described in Section 3.1.2 and Appendix 6.   
Additionally, two strength training-related questions were included, modelled off 
questions on the Community Healthy Activities Model Program for Seniors 
(CHAMPS) survey (269).  Participants were asked about number of sessions and 
total time spent in the past week doing light and doing moderate to heavy strength 
training.  It was decided not to use the full CHAMPS survey due to the extensive 
amount of information participants are asked to recall, and given the strong 
reliability and validity of the Active Australia.  Additionally, the Active Australia 
was deemed most appropriate for this population as the research was being 
conducted in a group of Australian participants, whereas CHAMPS was developed in 
the United States.    
    
4.2.6.3 Participant Safety 
 Participants were given guidelines on when not to exercise (Appendix 13) and 
instructed to monitor and immediately report any changes in lymphoedema-related 
symptoms so that appropriate follow-up could be undertaken, as outlined previously 
(Section 4.2.6.1).  Those with a compression garment were allowed to choose 
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whether they wore the garment during exercise participation and were encouraged to 
follow their normal wearing routine at all other times, as well as to ensure the 
garment was properly cleaned and replaced as needed.  Care was also taken to 
monitor for any changes in skin condition or skin damage (e.g., burns, cuts).  For 
individuals exercising outside, guidance was provided about sun and heat exposure.  
At each supervised session, participants were asked if they had experienced any 
adverse events (were given examples of what these include, e.g., muscle or joint 
pain, increased fatigue).  All adverse events were documented by the researcher in 
weekly session notes.  When relevant, adverse events were reported to the 
participant’s general practitioner or other appropriate medical professional to allow 
for treatment and determination of the safety and feasibility of continuing study 
involvement.   
 
4.2.7 Sample Size 
Sample size calculations were based on a primary alternative hypothesis: greater 
benefits in lymphoedema will be observed in those in the resistance-based exercise 
group compared to the aerobic-based exercise group by the 12-week follow-up.  In 
order for this alternative hypothesis to be accepted, a clinically meaningful difference 
needed to be defined and results needed to surpass this selected threshold.  
Therefore, a clinically relevant between-group difference was defined as ≥ 0.2 units 
impedance ratio for BIS or a change of ≥ 5% interlimb difference for circumference 
measurements, based on recommendation from previous research and the National 
Lymphedema Network (132; 202).   
 
Sample size calculations were based on findings from previous research studies in 
women with breast cancer-related lymphoedema (Table 4.4).  Data were extracted 
from exercise interventions, as well as studies comparing lymphoedema 
measurements to controls without lymphoedema (for BIS only).  As minimal data 
were available related to circumference measure (most studies convert this to a 
volume, whereby interlimb percentage difference was used in this study), ≥ 5% for 
interlimb size difference was set as a clinically meaningful change as recommended 
in previous research (131; 202).  Also taken into account for determining sample size 
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were considerations for scope of a PhD, particularly recruitment feasibility and time 
requirements.   
 
Sample size calculations were based on 80% power, allowing for a combined 20% 
attrition and non-compliance rate, based on a two-sided test with significance level 
of 0.05.  Additionally, past research suggests a standard deviation of 0.2 is expected 
for BIS scores. For interlimb circumference percentage differences, the two studies 
that included data on this outcome reported standard deviations between 7.5 and 7.9.  
However, these studies also included individuals with Stage 0 and/or 3 
lymphoedema, which may have contributed to the larger standard deviation.  As 
such, for this study, we used a standard deviation of 5 in power calculations as we 
expected a smaller spread and no individuals with stage 3 lymphoedema.  Using 
these parameters, a sample size of 38 was needed to detect clinically relevant 
difference in BIS and circumference change.   
 
Sample size calculations were also done for each objective and self-reported 
secondary outcome, when data were available.  These tables are presented in 
Appendix 14.  Results indicated that a sample size between 40 and 48 participants 
would allow detection of a clinically significant change in handgrip strength (≥ 6.5 
kg) at 80% power.  No relevant previous studies were found using the push and pull 
measurements, squat test or full self-efficacy scale given it was devised as part of 
this study.  
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Table 4.4 Details on studies used in sample size calculation based on lymphoedema status 
Study Study information Lymphoedema group 
mean (SD)a 
No lymphoedema group 
mean (SD) 
BIS (impedance ratio) data    
Hayes et al., 2009 (130) N=32 (16 per group) 
All women had lymphoedema, enrolled in exercise intervention 
1.13 (0.19) NA 
Cormie et al., 2013 (64)  N=62 (19 in control) 
All women had lymphoedema, enrolled in exercise intervention 
1.21 (0.32) NA 
Turner et al., 2004 (281) N=10 
Women at risk of lymphoedema, enrolled in exercise intervention 
NA 1.03 (0.07) 
Ward et al., 2009 (288) N=66 
45 women had lymphoedema, 21 were controls with no history of 
breast cancer  
1.27 (0.25) 1.02 (0.05) 
Ward et al., 2009 (287) N=46 
23 women had lymphoedema, 13 were controls with no history of 
breast cancer  
1.33 (0.28) 1.01 (0.05) 
Smoot et al., 2011 (261) N=141 
70 women had lymphoedema, 71 were breast cancer survivors 
with no lymphoedema 
1.11 (0.15) 0.99 (0.04) 
Ridner et al., 2009 (229) N=233 
97 women had lymphoedema, 75 were breast cancer survivors 
with no lymphoedema, 60 were healthy controls 
Dominant arm: 1.17 (0.20) 
Non-dominant: 1.19 (0.24) 
Dominant: 1.02 (0.04) 
Non-dominant: 0.98 (0.04) 
Cornish et al., 2001 (67) N=102 
Data used from 22 women with lymphoedema and 60 healthy 
controls 
1.20 (0.09) 0.96 (0.03) 
Arm circumference data-interlimb percentage difference   
Cormie et al., 2013 (64)  N=62 (19 in control) 
All women had lymphoedema, enrolled in exercise intervention 
n=5 in study with Stage 3 lymphoedema 
13.5 (7.9)% NA 
 
Unpublished data from PAL 
trial 
Schmitz et al., 2009 (247) 
N=141 (70 in control group) 
n=41 in study with Stage 3 lymphoedema 
 
7.2 (7.5)% 
 
NA 
 
adata extracted from control group when all participants in study had lymphoedema; SD=standard deviation; BIS=bioimpedance spectroscopy; NA=not applicable 
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4.2.8 Randomisation 
Randomisation was conducted using a stratified, blocked approach, with participants 
allocated to the resistance- or aerobic-based exercise group after their initial 
assessment.  Stratification was based on stage of lymphoedema (Stage 0/1 or Stage 
2/3), as research has suggested stage of lymphoedema can impact the efficiency of 
objective measure to assess the condition (132) and potentially the responsiveness of 
the tissue to the intervention (145).  Blocking allowed for a 1:1 ratio of assignment to 
resistance- and aerobic-based exercise and occurred in blocks of two.   
 
Microsoft Excel was used to complete randomisation, with the process completed 
separately for each stratification group.  Both possible blocking combinations (i.e., 
AB or BA) were entered into a column, and a random number was then generated to 
correspond to each option.  These numbers were placed into descending order to 
obtain randomisation order.  Two piles of sealed, non-translucent envelopes were 
labelled corresponding to these number tables and distributed at the end of baseline 
assessment, depending on which group a participant was stratified into.  All 
participant enrolment, randomisation sequence generation and group allocation was 
completed by the researcher. 
 
4.2.9 Blinding 
Given the nature of the intervention, blinding to intervention group was not possible.  
Additionally, all baseline, post-intervention and 12-week follow-up assessments 
were completed by the researcher, allowing for consistency in data acquisition but no 
blinding to treatment allocation during assessment.         
 
4.2.10 Statistical analysis 
Continuous variables were assessed for normality (as defined in Section 3.2.3).  
These variables were described using mean and 95% confidence intervals, and 
categorical variables described using proportions and n-values.  Independent-samples 
t-tests and chi-square tests were used to compare groups at baseline for any 
significant differences in clinical measures or participant-reported characteristics.  Of 
note, since this analysis was not adequately powered, clinically relevant differences 
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between groups were deemed important, irrespective of statistical significance.  
Additionally, characteristics of study participants were compared to characteristics of 
those who declined participation but provided basic baseline data.   
 
Trial outcome data were analysed on an intention-to-treat basis, regardless of 
intervention compliance.  Analyses used baseline, post-intervention and 12-week 
follow-up data, with any mid-study measurements of lymphoedema only used to 
monitor the condition for participant safety and reassurance.  All results were 
assessed for both clinically important and statistically significant changes over time 
and/or differences between groups.  Initial analysis of outcomes was done by plotting 
each participant’s data using line graphs to examine trends and identify potential 
outliers.  To incorporate the longitudinal nature of the data, generalised estimating 
equation (GEE) models with an independent working correlation structure were used 
to analyse the data (134).  This method accounts for possible correlations among the 
repeated measurements taken on an individual and ensures individuals with 
incomplete data records were incorporated where possible, thereby minimising 
missing data.  Additionally, GEE models incorporate baseline data.  Consistent with 
the intention and design of the study, a preliminary GEE model was applied for each 
of the primary and secondary dependent variables, with time (baseline, post-
intervention, 12-week follow-up) and intervention group (resistance- versus aerobic-
based exercise) as main effects, and the interaction of time by group.  Between-group 
analyses included comparing change from baseline to post-intervention, baseline to 
12-week follow-up and post-intervention to 12-week follow-up in the resistance- 
versus aerobic-based exercise groups.  Within-group analyses assessed if the change 
from baseline to post-intervention, baseline to 12-week follow-up or post-
intervention to 12-week follow-up was statistically significant.  If groups were 
unbalanced at baseline for demographic, medical or lymphoedema-related 
characteristics, each relevant variable was included in an additional model to test for 
potential confounding.   
 
Exploratory analyses were conducted to examine if baseline exercise barriers self-
efficacy was a potential effect modifier on primary and secondary outcomes.   
Participants were categorised as having ‘low self-efficacy’ (0%-34%), ‘moderate 
 90 Chapter 4: Study two 
self-efficacy’ (35%-64%) or ‘high self-efficacy’ (65%-100%) based on confidence 
categories on the total self-efficacy scale (general with lymphoedema-specific sub-
scale), whereby 0-34%=not at all-slightly confident, 35-64%=moderately confident 
and 65-100%=very-extremely confident.  Potential effect modification by baseline 
self-efficacy was not expected to differ based on exercise group, with analyses done 
on all participants as a single group.  Box plots were generated to assess the effect of 
self-efficacy category on intervention (baseline to post-intervention) and follow-up 
change (post-intervention to 12-week follow-up) in outcomes. 
 
Clinically relevant changes in outcome were determined a priori (Table 4.5), with 
values identified previously by others, or pre-defined by the researcher when 
unavailable.  Statistical significance level was set at p< 0.05, and analyses were done 
using Microsoft Excel and IBM SPSS statistics version 21.0 software.      
 
Table 4.5 Clinically meaningful change values for primary and secondary outcomes 
Variable Clinically meaningful change 
BIS (impedance ratio) 0.2 units(116) 
Arm circumferences (interlimb % difference) 5 units(116; 184) 
Symptom severity (Norman survey) 1 unit(224) 
Number of symptoms (Norman survey) 1 unit(224) 
Self-efficacy  
   General barriers component 
   Lymphoedema-specific barriers component 
10 points(Section 3.4.3) 
7 points(234) 
4 points(Section 3.4.3) 
Aerobic fitness (6MWT, m) 25 m(141) 
Lower-body endurance (squat test)* 9 squats 
Upper-body strength (4-6RM, kg) 4 kg(56; 73) 
Push/pull strength (kg) 5 kg(118) 
Handgrip strength (kg) 6.5 kg(162) 
Bone density (DXA, t-score)* 0.5 units  
Body fat (DXA, %) 2%(81; 152) 
Lean body mass (DXA, %) 5%(152) 
QoL (FACT-B+4) 
   Physical well-being 
   Social well-being 
   Emotional well-being 
   Functional well-being 
   Breast cancer sub-scale 
7 points(97) 
2 points(49) 
2 points(49) 
2 points(52; 183) 
2 points(49) 
2 points(97) 
Upper-body functioning (DASH) 10 points(264) 
*when no pre-defined clinically meaningful difference could be found, change of ≥ ½ standard 
deviation was used(134) 
BIS=bioimpedance spectroscopy; DXA=dual-energy X-ray absorptiometry; 6MWT=6-minute walk 
test; RM=repetition maximum; FACT-B+4=Functional Assessment of Cancer Therapy-Breast+4; 
DASH=Disabilities of the Arm, Shoulder and Hand; kg=kilograms; m=meters 
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4.3 RESULTS 
4.3.1 Participant flow 
Potential participants were approached through multiple sources: private 
physiotherapy practices (n=71), hospitals (n=21), database from previous studies 
(n=77), Queensland Lymphoedema Association (n=34), National Breast Cancer 
Foundation (n=unknown) and other (n=15).  Of those contacted, 103 were assessed 
for eligibility, with 45 subsequently enrolled, and 41 completing baseline assessment 
and randomly allocated to the intervention.  Following baseline assessment, women 
were randomised to the resistance- (n=20) or aerobic- (n=21) based exercise group.  
Two women in the aerobic-based exercise group withdrew from the intervention 
following randomisation, with their data included in intention-to-treat analyses.  Two 
participants in the aerobic-based exercise group did not complete post-intervention 
assessments (n=1) or 12-week follow-up objective assessments (n=1) due to family 
issues.  An additional participant in the aerobic-based exercise group withdrew prior 
to post-intervention assessment and was not contactable, and was therefore only 
included in baseline analyses.  All 20 participants in the resistance-based exercise 
group completed the intervention and follow-up assessments (Figure 4.2).  
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Figure 4.2 Participant flow through intervention and data collection sessions 
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4.3.2 Comparison of participants and non-participants 
Table 4.6 summarises demographic and medical characteristics of study participants 
(N=41) compared to eligible individuals who did not consent to participate (N=31).  
Compared with eligible but non-consenting women, study participants were younger, 
less likely to have a partner, less likely to have private health insurance and were 
fewer months post-breast cancer (p< 0.05).         
 
Table 4.6 Demographic and medical characteristics of participants versus non-
participants 
 
Variable 
Participants (N=41) 
n (%) 
Non-participants (N=31) 
n (%) 
 
p-value 
Age, years-mean (95% CI) 56.0 (52.8, 59.2) 64.6 (60.1, 69.2) 0.45 
Living arrangementa 
  Couple living with children 
  Couple living with no children 
  Single living with children 
  Single living with friend/relative     
  Living alone 
 
13 (31.7) 
12 (29.3) 
8 (19.5) 
2 (4.9) 
6 (14.6) 
 
7 (23.3) 
17 (56.7) 
1 (3.3) 
2 (6.7) 
3 (10.0) 
 
0.11 
Educationa 
  High school only 
  Undergraduate degree 
  Post-graduate 
  Further study (other) 
 
13 (31.7) 
11 (26.8) 
7 (17.1) 
10 (24.4) 
 
12 (40.0) 
10 (33.3) 
2 (6.7) 
6 (20.0) 
 
0.53 
Health insurancea 
  No private insurance 
  Private-hospital coverage 
  Private-extras coverage 
  Private-hospital and extras  
 
13 (31.7) 
3 (7.3) 
1 (2.4) 
24 (58.5) 
 
5 (16.7) 
1 (3.3) 
0 (0.0) 
24 (80.0) 
 
0.27 
Months post-BC, mean (95% CI) 56 (43, 70) 85 (63, 108) 0.04* 
Surgery-completed 
Chemotherapy-completed 
41 (100.0) 
38 (92.7) 
31 (100.0) 
23 (74.2) 
NA 
0.08 
Radiation therapy-completed 36 (87.8) 24 (77.4) 0.24 
Hormone therapy-completed 
  Undergoing  
6 (14.6) 
18 (43.9) 
10 (32.3) 
10 (32.3) 
0.20 
Herceptin-completed 10 (24.4) 8 (25.8) 0.89 
*p<0.05; an=30 non-participants; BC=breast cancer; CI=confidence intervals; NA=not applicable 
 
Multiple differences existed between groups for lymphoedema-related 
characteristics.  Compared to the non-consenting group, participants had 
lymphoedema for a shorter duration (p< 0.01) and more commonly reported it as 
stable and persistent (p< 0.01) (Table 4.7).  Additionally, they were more likely to 
report trunk lymphoedema (p< 0.05), with between-group differences in who 
diagnosed lymphoedema (p< 0.01) and the additional treatments for lymphoedema. 
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Table 4.7 Lymphoedema characteristics of participants versus non-participants 
 
Variable 
Participants (N=41) 
n (%) 
Non-participants (N=31) 
n (%) 
 
p-value 
Time with lymphoedema 
  Months, mean (95% CI) 
 
39 (28, 51) 
 
74 (50, 98) 
 
0.01* 
Lymphoedema on dominant side 17 (41.5) 9 (29.0) 0.28 
Hand lymphoedemaa 16 (39.0) 7 (22.6) 0.14 
Arm lymphoedemaa 39 (95.1) 29 (93.5) 0.77 
Breast lymphoedemaa 9 (22.0) 7 (22.6) 0.95 
Trunk lymphoedemaa 12 (29.3) 3 (9.7) 0.04* 
Lymphoedema presentationb 
   Single episode    
   Recurrent/fluctuates 
   Stable and persistent 
 
0 (0.0) 
15 (36.6) 
26 (63.4) 
 
8 (26.7) 
12 (40.0) 
10 (33.3) 
 
>0.01* 
Who diagnosedc  
  Physiotherapist 
  Oncologist/surgeon/GP 
  Self 
 
20 (48.8) 
16 (39.0) 
5 (12.2) 
 
17 (60.7) 
7 (25.0) 
4 (14.3) 
 
>0.01* 
Routine treatmenta 
  CDT 
  MLD (healthcare) 
  MLD (self-administered) 
  Compression bandages 
  Compression garment 
  Laser therapy 
  Pneumatic pump 
  Other 
 
3 (7.3) 
20 (48.8) 
35 (85.4) 
9 (22.0) 
35 (85.4) 
3 (7.3) 
10 (24.4) 
8 (19.5) 
 
4 (12.9) 
10 (32.3) 
21 (67.7) 
8 (25.8) 
16 (51.6) 
2 (6.5) 
1 (3.2) 
6 (19.4) 
 
0.43 
0.16 
0.08 
0.70 
>0.01* 
0.89 
0.01* 
0.99 
*p<0.05; apercentage responding ‘yes’; bn=30 for non-participants; cn=28 for non-participants; 
CI=confidence intervals; CDT=complex decongestive therapy; MLD=manual lymphatic drainage 
 
Table 4.8 presents frequency of symptoms reported.  Compared with non-
participants, participants were more likely to report experiencing each symptom, 
with differences supported statistically (p< 0.05). 
 
Table 4.8 Lymphoedema-related symptoms in participants versus non-participants  
Variable Participants (N=41) 
n (%) 
Non-participants (N=31) 
n (%) 
 
p-value 
Swelling 41 (100.0) 24 (77.4) >0.01* 
Heaviness  36 (87.8) 16 (51.6) >0.01* 
Tightnessa 32 (78.0) 16 (51.6) 0.01* 
Aching  32 (78.0) 13 (41.9) >0.01* 
Tenderness  26 (63.4) 10 (32.3) 0.01* 
Stiffness  28 (68.3) 7 (22.6) >0.01* 
Weakness  31 (75.6) 13 (41.9) >0.01* 
Numbness  27 (65.9) 12 (38.9) 0.02* 
Tingling  27 (65.9) 10 (32.3) 0.01* 
Pain 27 (65.9) 8 (25.8) >0.01* 
Limited ROM 27 (65.9) 8 (25.8) >0.01* 
*p<0.05; an=40 for participant group; ROM=range of motion 
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4.3.3  Baseline participant characteristics 
Respondents (n=41) were on average 56 (95% CI: 53 to 59) years old, with half 
sedentary or insufficiently active (Table 4.9).  There were clinically relevant 
differences in baseline physical activity levels between groups, whereby 40% of 
participants in the resistance-based exercise group reported sufficient activity levels, 
compared to 57% in the aerobic-based exercise group.  Randomisation, with 
stratification for lymphoedema stage, was successful for all other characteristics. 
 
Table 4.9 Baseline demographic characteristics 
Variable Overall (N=41) RES (N=20) 
n (%) 
AER (N=21) 
n (%)  
Age, years-mean (95% CI) 56.0 (52.8, 59.2) 58.5 (54.2, 62.8) 53.7 (48.9, 58.5) 
Living arrangement 
  Couple living with children 
  Couple living with no children 
  Single living with children 
  Single living with friend/relative     
  Living alone 
 
13 (31.7) 
12 (29.3) 
8 (19.5) 
2 (4.9) 
6 (14.6) 
 
5 (25.0) 
6 (30.0) 
5 (25.0) 
1 (5.0) 
3 (15.0) 
 
8 (38.1) 
6 (28.6) 
3 (14.3) 
1 (4.8) 
3 (14.3) 
Employment status 
  Not working 
  Paid employment 
 
17 (41.5) 
24 (58.5) 
 
9 (45.0) 
11 (55.0) 
 
8 (38.1) 
13 (61.9) 
Education 
  High school only 
  Undergraduate degree 
  Post-graduate 
  Further study (other) 
 
13 (31.7) 
11 (26.8) 
7 (17.1) 
10 (24.4) 
 
6 (30.0) 
6 (30.0) 
2 (10.0) 
6 (30.0) 
 
7 (33.3) 
5 (23.8) 
5 (23.8) 
4 (19.0) 
Health insurance 
  No private insurance 
  Private-hospital coverage 
  Private-extras coverage 
  Private-hospital and extras  
 
13 (31.7) 
3 (7.3) 
1 (2.4) 
24 (58.5) 
 
7 (35.0) 
1 (5.0) 
0 (0.0) 
12 (60.0) 
 
6 (28.6) 
2 (9.5) 
1 (4.8) 
12 (57.1) 
Total physical activitya 
  Sedentary 
  Insufficient 
  Sufficient 
 
5 (12.2) 
16 (39.0) 
20 (48.8) 
 
3 (15.0) 
9 (45.0) 
8 (40.0) 
 
2 (9.5) 
7 (33.3) 
12 (57.1) 
Self-efficacy (0-100%) 
  Mean (95% CI) 
 
50.7 (44.1, 57.3) 
 
51.7 (42.6, 62.3) 
 
48.9 (39.2, 58.6) 
asedentary (no physical activity), insufficient (<150 min OR ≥ 150 min & <5 sessions), sufficient 
(≥150 min and ≥ 5 sessions) 
RES=resistance-based exercise group; AER=aerobic-based exercise group; CI=confidence intervals 
 
 
On average, participants were overweight (BMI> 25), and almost 5 years (56 [43, 
70] months) post-breast cancer diagnosis (Table 4.10).  The presence of at least one 
co-morbidity (e.g., diabetes, heart conditions, respiratory conditions) was reported by 
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90% of participants, with most common conditions including high blood pressure 
(32%), high cholesterol (37%) and depression (34%).  Stratified randomisation, 
based on lymphoedema stage, was successful for medical characteristics. 
 
Table 4.10 Baseline physiological and medical characteristics 
Variable 
 
Overall (N=41) 
n (%) 
RES (N=20) 
n (%) 
AER (N=21) 
n (%) 
Resting HR (beats per min) 
   mean (95% CI) 
 
73 (69, 76) 
 
70 (65, 75) 
 
75 (69, 80) 
Systolic BP (mmHg) 
  mean (95% CI) 
 
125 (121, 129) 
 
125 (119, 131) 
 
125 (119, 131)c 
Diastolic BP (mmHg) 
  mean (95% CI) 
 
77 (75, 80) 
 
78 (74, 82) 
 
76 (72, 81)c 
Weight (kg) 
  mean (95% CI) 
 
77 (71.3, 82.4) 
 
78.3 (68.9, 87.7) 
 
75.5 (68.6, 82.4) 
Body mass index (kg/m2) 
  mean (95% CI) 
 
29 (27, 32) 
 
30 (26, 33) 
 
29 (26, 32) 
Months post-BC diagnosis 
  mean (95% CI) 
 
56 (43, 70) 
 
57 (38, 76) 
 
56 (35, 77) 
Surgery-completed 
Chemotherapy-completed 
41 (100.0) 
38 (92.7) 
20 (100.0) 
19 (95.0) 
21 (100.0) 
19 (90.5) 
Radiation therapy-completed 36 (87.8) 18 (90.0) 18 (85.7) 
Hormone therapy-completed 
  Undergoing  
6 (14.6) 
18 (43.9) 
4 (20.0) 
9 (45.0) 
2 (9.5) 
9 (42.9) 
Herceptin-completed 10 (24.4) 5 (25.0) 5 (23.8) 
Co-morbiditiesd 
  0 
  1-3 
  >3 
 
4 (9.8) 
27 (65.9) 
10 (24.4) 
 
1 (5.0) 
14 (70.0) 
5 (25.0) 
 
3 (14.3) 
13 (61.9) 
5 (23.8) 
an=39; bn=40; cn=20; dco-morbidities=heart attack, angina, other heart problems, high blood pressure, 
high cholesterol, stroke, diabetes, asthma, chronic bronchitis, emphysema, stomach or duodenal 
ulcers, migraines, osteoporosis, rheumatoid arthritis, depression, cancer besides breast and other 
medical conditions 
RES=resistance-based exercise group; AER=aerobic-based exercise group; CI=confidence intervals; 
HR=heart rate; BP=blood pressure; BC=breast cancer; mmHG=millimetres of mercury; m=meters; 
kg=kilograms 
 
Lymphoedema stage was balanced between groups (overall=54% with Stage 1 and 
46% with Stage 2) (Table 4.11).  The majority of participants used self-administered 
manual lymphatic drainage and compression garments (85%) as regular 
lymphoedema treatment, with ‘other’ treatments including physiotherapist-prescribed 
exercise and elevation.  There were clinically relevant between-group differences 
with respect to lymphoedema presentation.  One in four women in the resistance-
based exercise group reported recurrent/fluctuating lymphoedema, compared to one 
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in two in the aerobic-based exercise group.  Randomisation was successful for other 
lymphoedema-related characteristics.  
 
Table 4.11 Baseline lymphoedema-related characteristics 
Variable 
 
Overall (N=41) 
n (%) 
RES (N=20) 
n (%) 
AER (N=21) 
n (%) 
Stage of lymphoedema 
  1 
  2 
 
22 (53.7) 
19 (46.3) 
 
11 (55.0) 
9 (45.0) 
 
11 (52.4) 
10 (47.6) 
Time with lymphoedema 
  Months, mean (95% CI) 
 
39 (28, 51) 
 
41 (25, 58) 
 
38 (20, 55) 
Time with lymphoedema 
  < 2 years 
  2-5 years 
  > 5 years 
 
11 (26.8) 
5 (12.2) 
25 (61.0) 
 
3 (15.0) 
4 (20.0) 
13 (65.0) 
 
8 (38.1) 
1 (4.8) 
12 (57.1) 
Lymph node removal 
  Sentinal node biopsy only 
  All nodes removed 
  Only some nodes removed 
  No lymph nodes removed 
 
18 (43.9) 
19 (46.3) 
2 (4.9) 
2 (4.9) 
 
8 (40.0) 
11 (55.0) 
0 (0.0) 
1 (5.0) 
 
10 (47.6) 
8 (38.1) 
2 (9.5) 
1 (4.8) 
Lymphoedema on dominant side  
  Dominant  
 
17 (41.5) 
 
8 (40.0) 
 
9 (42.9) 
Hand lymphoedemaa  16 (39.0) 8 (40.0) 8 (38.1) 
Arm lymphoedemaa 39 (95.1) 19 (95.0) 20 (95.2) 
Breast lymphoedemaa 9 (22.0) 3 (15.0) 6 (28.6) 
Trunk lymphoedemaa 12 (29.3) 8 (40.0) 4 (19.0) 
Lymphoedema presentation 
   Recurrent/fluctuatesb 
 
15 (36.6) 
 
5 (25.0) 
 
10 (47.6) 
Who diagnosed  
   Physiotherapist 
   Oncologist/surgeon/GP 
   Self 
 
20 (48.8) 
16 (39.0) 
5 (12.2) 
 
7 (35.0) 
9 (45.0) 
4 (20.0) 
 
13 (61.9) 
7 (33.3) 
1 (4.8) 
Routine treatmenta 
  CDT 
  MLD (healthcare) 
  MLD (self-administered) 
  Compression bandages 
  Compression garment 
  Laser therapy 
  Pneumatic pump 
  Other 
 
3 (7.3) 
20 (48.8) 
35 (85.4) 
9 (22.0) 
35 (85.4) 
3 (7.3) 
10 (24.4) 
8 (19.5) 
 
2 (10.0) 
11 (55.0) 
18 (90.0) 
3 (15.0) 
17 (85.0) 
2 (10.0) 
7 (35.0) 
3 (15.0) 
 
1 (4.8) 
9 (42.9) 
17 (81.0) 
6 (28.6) 
18 (85.7) 
1 (4.8) 
3 (14.3) 
5 (23.8) 
apercentage given for those responding ‘yes’; bremaining participants ‘stable and persistent’ 
RES=resistance-based exercise group; AER=aerobic-based exercise group; CI=confidence intervals; 
GP=general practitioner; CDT=complex decongestive therapy; MLD-manual lymphatic drainage 
 
Swelling, heaviness and tightness were reported as ‘somewhat/moderate’ or ‘quite a 
lot/very much’ by 80%, 56% and 50% of participants, respectively (Table 4.12).  
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Further, at least one-fifth of women reported experiencing these symptoms ‘quite a 
lot/very much’.  Clinically notable differences between groups existed for severity of 
aching and pain experienced.  For aching, 45% of those in the resistance-based 
exercise group reported somewhat/moderate aching, compared with 24% in the 
aerobic-based exercise group.  Ten percent of participants in the resistance-based 
exercise group reported somewhat to moderate pain, compared to 29% in the 
aerobic-based exercise group.   
 
Table 4.12 Baseline lymphoedema-related symptoms 
Symptom* 
  
Overall (N=41) 
n (%) 
RES (N=20) 
n (%) 
AER (N=21) 
n (%) 
Swelling 33 (80.4) 16 (80.0) 17 (80.9) 
Heaviness 23 (56.1) 11 (55.0) 12 (57.2) 
Tightnessa 20 (50.0) 10 (50.0) 10 (50.0) 
Aching  22 (53.6) 12 (60.0) 10 (47.6) 
Tenderness  13 (31.7) 6 (30.0) 7 (33.3) 
Stiffness  12 (29.2) 6 (30.0) 6 (28.5) 
Weakness  18 (43.9) 10 (50.0) 8 (38.1) 
Numbness  6 (14.6) 8 (40.0) 8 (38.1) 
Tingling 10 (24.4) 4 (20.0) 6 (28.5) 
Pain  15 (36.6) 5 (25.0) 10 (47.6) 
Limited ROM 14 (34.1) 6 (30.0) 8 (38.1) 
*percentage reporting symptom as somewhat/moderate or quite a lot/very much; an=40 and 20 
(overall and AER, respectively) 
RES=resistance-based exercise group; AER=aerobic-based exercise group; NA=not applicable  
 
4.3.4 Program adherence 
Three participants in the aerobic-based exercise group dropped out after baseline 
testing and randomisation, with two of these women completing other data collection 
assessments and therefore included in intention-to-treat analyses.  Adherence data is 
presented for the remaining 38 women.  Women were expected to participate in 16 
supervised exercise sessions, with groups matched for median number of sessions 
completed (Table 4.13).  Overall, 35 women (92%) completed 75% or more of 
supervised exercise sessions.  The remaining three participants had rates of 50% 
(resistance-based exercise group), 56% and 69% (aerobic-based exercise group), 
with lower adherence to these participants attributable to non-study related injury, 
family illness requiring travel and work commitments.    
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From baseline to post-intervention assessment, and from post-intervention 
assessment to 12-week follow-up assessment, participants in both groups were 
expected to do 150 minutes of weekly exercise (1800 minutes total).  Table 4.13 
presents the median minutes of exercise undertaken in each part of the study.  
Median adherence was similar between groups between baseline and post-
intervention, and post-intervention to 12-week follow-up.  However, minimum 
exercise minutes for the resistance-based exercise group (0 minutes) highlight at least 
one participant stopped exercising during the follow-up, while all participants in the 
aerobic-based exercise group continued some amount of exercise.     
 
Table 4.13 Adherence to participating in the supervised exercise sessions and to total 
exercise dose prescribed during the 12-week intervention, and exercise dose 
undertaken during the 12-week follow-up period 
Variable Overall (n=38) 
median (min, max) 
RES (n=20) 
median (min, max) 
AER (n=18) 
median (min, max) 
Supervised (#)a 16 (8, 16) 16 (8, 16) 16 (9, 16) 
T1-T2 (minutes)b 1725 (1200, 1800) 1700 (1200, 1800) 1750 (1200, 1800) 
T2-T3 (minutes)b 1800 (0, 1800) 1800 (0, 1800) 1800 (600, 1800) 
aout of 16 sessions; bout of 1800 minutes  
RES=resistance-based exercise group; AER=aerobic-based exercise group; CI=confidence intervals; 
T1=baseline; T2=post-intervention; T3=12-week follow-up    
 
4.3.5 Lymphoedema status 
4.3.5.1 Bivariate analysis 
Individual primary outcome data (i.e., lymphoedema status variables) were plotted to 
visualise potential group trends, as well as to identify potential outliers.  For BIS 
impedance ratios (Figure 4.3), 100% and 95% of participants in the resistance- and 
aerobic-based exercise groups, respectively, changed by less than 0.2 units.  Figure 
4.4 shows interlimb percentage circumference difference changed by less than 5% 
for 95% and 90% of resistance- and aerobic-based exercise participants, respectively.  
 
One aerobic-based exercise group participant (ID 35) was identified as an outlier 
based on BIS data, showing a clinically relevant change (>0.2 units) from post-
intervention to 12-week follow-up.  Three additional women were outliers based on 
circumferences (resistance-based exercise group=ID 2; aerobic-based exercise 
group=IDs 22 and 31), showing a clinically relevant change (>5 units).  Results for 
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participants ID 2, 31 and 35 suggested worsening lymphoedema by 12-week follow-
up.  Of note, those with worsening lymphoedema had the lowest levels of 
intervention adherence.  One woman completed baseline assessment and then had 
0% adherence to the intervention (personal issues).  Another individual experienced 
a golf-related injury (not attributable to program-related fatigue or other effect) in 
week six that significantly decreased her exercise levels, whereas prior to injury she 
had 100% adherence.  The final participant reported a flare-up in her lupus during the 
follow-up period that resulted in reduced exercise intensity.  She still performed over 
75% of the required amount of exercise, but only a total dose around 50-60% given 
some of this was performed at low intensity (compared to the moderate- to vigorous-
intensity prescribed). Conversely, participant ID 22 had an improvement in 
lymphoedema at post-intervention and 12-week follow-up.  However, at around the 
time of study enrolment, this participant also reported starting new medications 
(never provided name) to treat general oedema, which was present prior to breast 
cancer.  As she observed swelling decreases in other areas such as her legs, it is 
possible the medication contributed to improvements observed.  However, it is 
clearly not possible to determine the contribution of the exercise intervention versus 
medication change to her significant improvement in lymphoedema.   
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Figure 4.3 Individual participant BIS scores at baseline, post-intervention and 12-week follow-up 
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Figure 4.4 Individual participant circumference differences at baseline, post-intervention and 12-week follow-up
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4.3.5.2 Generalised estimating equation models 
Overall, the interaction effect between time and group was not statistically 
significant for lymphoedema status or associated symptoms, demonstrating no 
significant difference between modes of exercise or over time in effect on 
lymphoedema (Table 4.14).  That is, there were no group differences or changes over 
time in lymphoedema or lymphoedema-associated symptoms.  Aerobic-based 
exercise group participants reported a clinically meaningful decline in symptom 
number from baseline to post-intervention (-1.5 [-2.6, -0.4]) that was maintained 
during the 12-week follow-up.  Participants in the resistance-based exercise group 
also declined in number of symptoms by post-intervention, but magnitude of change 
was not clinically meaningful (-0.6 [-1.4, 0.2]).  There was a trend for symptom 
severity declines in both groups by post-intervention. 
 
As intention-to-treat analysis was used, data for the aerobic-based exercise group 
included two individuals that dropped out after randomisation but completed post-
intervention and/or 12-week follow-up assessments.  It also included one resistance-
based exercise group participant who only completed 50% of the intervention.  When 
models were re-run excluding these individuals, findings remained unchanged (data 
not shown).  
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Table 4.14 Lymphoedema status at baseline, post-intervention and 12-week follow-up 
 Baseline (T1) Post-intervention 
(T2) 
12-week follow-up 
(T3) 
p-value ΔT2-T1 scores ΔT3-T1 scores 
Variable mean  
(95% CI) 
mean  
(95%CI) 
mean  
(95% CI) 
Time x group  
interaction 
mean Δ (95% CI) mean Δ (95% CI) 
BIS (ratio) 
   RES    
   AER 
 
1.20 (1.10, 1.29) 
1.17 (1.09, 1.26) 
 
1.20 (1.11, 1.30) 
1.18 (1.10, 1.26) 
 
1.21 (1.11, 1.31) 
1.19 (1.10, 1.28) 
 
0.91 
 
0.01 (-0.02, 0.03) 
0.01 (-0.02, 0.03) 
 
0.01 (-0.02, 0.04) 
0.02 (-0.02, 0.06) 
Interlimb difference (%) 
   RES 
   AER    
 
5.7 (3.0, 8.4) 
5.1 (2.3, 7.9) 
 
6.2 (3.6, 8.8) 
5.4 (2.7, 8.0) 
 
6.5 (3.8, 9.2) 
5.1 (2.1, 8.1) 
 
0.48 
 
0.4 (-0.3, 1.2) 
0.3 (-0.4, 1.0) 
 
0.8 (0.0, 1.5) 
0.0 (-1.0, 1.0) 
Total symptoms 
   RES 
   AER    
 
4.5 (3.2, 5.8) 
6.0 (4.7, 7.4) 
 
3.9 (2.8, 5.0) 
4.6 (3.2, 5.9) 
 
4.0 (2.8, 5.2) 
4.6 (3.2, 6.0) 
 
0.38 
 
-0.6 (-1.4, 0.2) 
-1.5 (-2.6, -0.4) 
 
-0.6 (-1.7, 0.6) 
-1.5 (-2.6, -0.3) 
Symptom severity 
   RES 
   AER    
 
0.7 (0.4, 0.9) 
0.8 (0.5, 1.1) 
 
0.5 (0.3, 0.6) 
0.5 (0.3, 0.7) 
 
0.5 (0.3, 0.7) 
0.7 (0.4, 1.0) 
 
0.56 
 
-0.2 (-0.3, 0.0) 
-0.3 (-0.6, 0.0) 
 
-0.1 (-0.3, 0.0) 
-0.1 (-0.4, 0.1) 
RES=resistance-based exercise group; AER=aerobic-based exercise group; CI=confidence intervals; BIS=bioimpedance spectroscopy 
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4.3.6 Secondary outcomes: exercise barriers self-efficacy 
Although no statistically significant time by group interactions were found, results 
show improvements in self-efficacy following participation in either resistance- or 
aerobic-based exercise (Table 4.15).  The magnitude of improvement in general and 
lymphoedema-specific exercise barriers self-efficacy reached clinically relevant 
thresholds (≥ 7 and 4 points, respectively).  Findings from repeat analysis with 
exclusion of those who participated in 50% or less of the intervention (n=3) were 
similar (data not shown).  
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Table 4.15 Exercise barriers self-efficacy at baseline, post-intervention and 12-week follow-up  
 Baseline (T1) Post-intervention 
(T2) 
12-week follow-up 
(T3) 
p-value ΔT2-T1 scores ΔT3-T1 scores 
Variable mean (95% CI) mean (95% CI) mean (95% CI) Time x group 
interaction 
mean Δ (95% CI) mean Δ (95% CI) 
Self-efficacy-Total 
     RES 
     AER 
 
48.9 (40.0, 57.8) 
51.8 (42.4, 61.1) 
 
57.4 (48.7, 66.2) 
61.5 (52.2, 70.7) 
 
54.2 (48.9, 64.6) 
61.2 (52.5, 69.8) 
 
0.82 
 
8.6 (-2.3, 19.4) 
9.7 (-1.7, 21.2) 
 
5.4 (-3.8, 14.5) 
9.4 (-2.1, 21.0) 
  General  
     RES 
     AER 
  Lymphoedema-specific 
     RES 
     AER 
 
45.1 (35.0, 55.1) 
48.2 (37.6, 58.8) 
 
55.8 (45.9, 65.7) 
58.1 (48.7, 67.5) 
 
53.7 (43.8, 63.6) 
57.4 (47.5, 67.3) 
 
64.2 (54.7, 73.7) 
68.8 (58.5, 79.2) 
 
48.9 (36.2, 61.7) 
55.9 (46.1, 65.7) 
 
65.2 (55.2, 75.1) 
70.7 (62.1, 79.3) 
 
0.87 
 
 
0.92 
 
8.6 (-3.8, 21.0) 
9.1 (-3.1, 21.4) 
 
8.4 (-1.6, 18.4) 
10.7 (-0.8, 22.3) 
 
3.9 (-6.4, 14.2) 
7.7 (-5.1, 20.4) 
 
9.4 (-1.3, 20.1) 
12.6 (1.9, 23.3) 
RES=resistance-based exercise group; AER=aerobic-based exercise group; CI=confidence intervals 
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4.3.6.1 Exploratory analyses 
Lymphoedema-related outcomes 
Self-efficacy was also assessed as being a potential effect modifier to the primary 
outcome, lymphoedema, by using box plots to explore associations between baseline 
self-efficacy level and lymphoedema-related outcomes.  As can be seen in Figure 
4.5, there was no evidence that baseline exercise barriers self-efficacy modified 
response to the intervention. Change in lymphoedema during the exercise 
intervention and 12-week follow-up, as assessed by circumferences (Figure 4.5 and 
Figure 4.6), BIS or number or severity of symptoms (data not shown), was similar 
irrespective of baseline self-efficacy level. 
 
 
 
Figure 4.5 Change in interlimb arm circumference during the intervention based on 
baseline self-efficacy 
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Figure 4.6 Change in interlimb arm circumference during the 12-week follow-up 
based on baseline self-efficacy 
 
Baseline exercise barriers self-efficacy and program adherence 
Results related to exercise adherence, presented in Section 4.3.4, were stratified by 
baseline self-efficacy level (‘low’, ‘moderate’ and ‘high’).  Findings suggest that 
self-efficacy level was not related to adherence to supervised exercise (Figure 4.7), 
total exercise dose over the intervention period (Figure 4.8) or total exercise dose 
over the 12-week follow-up period (Figure 4.9).    
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Figure 4.7 Association between baseline exercise barriers self-efficacy (SE) and 
adherence to supervised exercise 
 
 
 
 
 
Figure 4.8 Association between baseline exercise barriers self-efficacy (SE) and 
adherence to total exercise dose over intervention period  
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Figure 4.9 Association between baseline exercise barriers self-efficacy (SE) and 
adherence to total exercise dose over 12-week follow-up period  
 
 
4.3.7 Secondary outcomes: objective-muscular strength and endurance, aerobic 
fitness, body composition and bone density 
There was a statistically significant time by group effect for upper-body strength.  
While both groups showed improvements in upper-body strength over time, 
improvements were greater in the resistance-based exercise group compared with the 
aerobic-based exercise group (5.1 [3.8, 6.4] kg vs 1.7 [0.9, 2.5] kg, respectively; p< 
0.01) (Table 4.16).  No other statistically significant time by group interactions were 
identified for other objectively-assessed secondary outcomes.  However, clinically 
meaningful increases were observed in both groups in lower-body endurance (> 9 
squats) between baseline and post-intervention (resistance-based exercise group: 9.4 
[1.7, 17.0]; aerobic-based exercise group: 9.4 [0.3, 18.4]), as well as between 
baseline and 12-week follow-up for the resistance-based exercise group (12.4 [3.4, 
21.4]).  Both groups also showed a clinically meaningful improvement in aerobic 
fitness (> 25 m in 6MWT) between baseline and 12-week follow-up (resistance-
based exercise group: 34.6 [10.4, 58.8] m; aerobic-based exercise group: 26.9 [3.1, 
50.7] m).  When analyses were re-run excluding those who partook in 50% or less of 
the intervention, findings remained unchanged (data not shown). 
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Table 4.16 Secondary objective outcomes at baseline, post-intervention and 12-week follow-up 
 Baseline (T1) Post-intervention 
(T2) 
12-week follow-up 
(T3) 
p-value ΔT2-T1 scores ΔT3-T1 scores 
Variable mean (95% CI) mean (95%CI) mean (95% CI) Time x group 
interaction 
mean Δ (95% CI) mean Δ (95% CI) 
Aerobic fitness (6MWT, m) 
   RES 
   AER 
 
528.3 (489.4, 567.2) 
554.4 (514.6, 594.1) 
 
542.8 (504.3, 581.2) 
569.1 (527.5, 610.7) 
 
562.9 (529.4, 596.4) 
581.3 (540.1, 622.5) 
 
0.82 
 
14.4 (13.2, 42.0) 
14.7 (-8.1, 37.6) 
 
34.6 (10.4, 58.8) 
26.9 (3.1, 50.7) 
Lower-body endurance (# of squats) 
   RES 
   AER 
 
23.7 (18.0, 29.3) 
33.6 (24.0, 43.3) 
 
33.1 (24.4, 41.7) 
43.0 (27.4, 58.6) 
 
36.1 (26.2, 45.9) 
42.5 (23.8, 61.2) 
 
0.75 
 
9.4 (1.7, 17.0) 
9.4 (0.3, 18.4) 
 
12.4 (3.4, 21.4) 
8.9 (-3.5, 21.2) 
Upper-body strength (4-6RM, kg) 
   RES 
   AER 
 
16.3 (14.9, 17.7) 
17.3 (15.5, 19.0) 
 
20.6 (19.1, 22.0) 
18.5 (17.0, 20.0) 
 
21.4 (19.9, 22.9) 
18.9 (17.5, 20.4) 
 
>0.01* 
 
4.2 (3.2, 5.2) 
1.2 (-0.1, 2.5) 
 
5.1 (3.8, 6.4) 
1.7 (0.9, 2.5) 
Push strength (kg) 
   RES 
   AER 
 
14.7 (11.9, 17.5) 
15.9 (12.5, 19.3) 
 
17.3 (14.5, 20.0) 
17.1 (14.5, 19.7) 
 
19.2 (16.6, 21.7) 
19.2 (16.3, 22.0) 
 
0.57 
 
2.6 (0.8, 4.3) 
1.2 (-0.9, 3.3) 
 
4.5 (2.6, 6.3) 
3.3 (0.9, 5.7) 
Pull strength (kg) 
   RES 
   AER 
 
12.1 (10.3, 13.9) 
12.3 (9.8, 14.8) 
 
13.7 (11.6, 15.7) 
13.5 (11.2, 15.8) 
 
15.1 (13.1, 17.1) 
13.4 (11.8, 14.9) 
 
0.21 
 
1.6 (-0.1, 3.2) 
1.2 (-0.7, 3.1) 
 
3.0 (1.4, 4.6) 
1.1 (-0.9, 3.0) 
Right grip strength (kg) 
   RES 
   AER 
 
19.2 (17.0, 21.3) 
17.0 (15.3, 18.8) 
 
18.7 (16.5, 21.0) 
17.6 (15.8, 19.4) 
 
20.1 (18.3, 21.8) 
17.8 (16.0, 19.5) 
 
0.46 
 
-0.5 (-2.8, 1.9) 
0.5 (-1.0, 2.0) 
 
0.9 (-1.2, 2.9) 
0.7 (-0.7, 2.1) 
Left grip strength (kg) 
   RES 
   AER 
 
16.0 (14.6, 17.5) 
17.1 (15.2, 19.0) 
 
16.6 (15.0, 18.3) 
17.1 (14.7, 19.4) 
 
17.9 (16.0, 19.8) 
17.8 (15.7, 20.0) 
 
0.48 
 
0.6 (-0.9, 2.1) 
-0.1 (-1.6, 1.4) 
 
1.9 (0.3, 3.5) 
0.7 (-0.6, 2.0) 
Bone mineral density (t-score) 
   RES 
   AER 
 
0.2 (-0.3, 0.8) 
0.4 (0.0, 0.8) 
 
0.2 (-0.3, 0.8) 
0.4 (0.0, 0.8) 
 
0.1 (-0.4, 0.6) 
0.2 (-0.2, 0.6) 
 
0.71 
 
 
0.0 (-0.1, 0.1) 
0.0 (-0.1, 0.1) 
 
-0.1 (-0.2, 0.0) 
-0.2 (-0.5, 0.0) 
Body fat (%) 
   RES 
   AER 
 
45.0 (40.2, 49.9) 
44.9 (42.0, 47.8) 
 
45.5 (41.1, 50.0) 
45.4 (42.7, 48.2) 
 
45.2 (40.9, 49.6) 
45.5 (42.8, 48.1) 
 
0.94 
 
0.5 (-0.1, 1.1) 
0.5 (-0.5, 1.6) 
 
0.2 (-1.2, 1.7) 
0.6 (-0.7, 1.9) 
Lean body mass (kg) 
   RES 
   AER 
 
40.6 (38.4, 42.9) 
39.8 (37.6, 42.1) 
 
40.9 (38.5, 43.3) 
40.4 (38.1, 42.7) 
 
40.2 (37.9, 42.5) 
39.5 (37.4, 41.5) 
 
0.69 
 
0.3 (-0.2, 0.7) 
0.6 (0.3, 1.1) 
 
-0.4 (-1.3, 0.4) 
-0.4 (-1.3, 0.6) 
*p<0.05; RES=resistance-based exercise group; AER=aerobic-based exercise group; CI=confidence intervals; 6MWT=6-minute walk test; RM=repetition maximum; kg=kilograms; m=meters 
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4.3.8 Secondary outcomes: self-report-upper-body functioning and quality of 
life 
No statistically significant interactions between time and group were observed for 
secondary self-reported outcomes including upper-body functioning and QoL (Table 
4.17).  Results showed clinically meaningful improvements in both groups in overall 
QoL from baseline to post-intervention (10.0 [6.2, 13.9] and 13.2 [6.7, 19.7], 
respectively) and baseline to 12-week follow-up (14.6 [9.6, 19.7] and 14.0 [7.3, 
20.6], respectively).  Clinically meaningful within-group improvements were also 
observed on multiple FACT-B+4 sub-scales, with physical well-being improving in 
the resistance- and aerobic-based exercise groups, and the breast cancer sub-scale 
improving in the aerobic-based exercise group.  Findings from repeat analysis with 
exclusion of individuals completing 50% or less of the intervention (n=3) indicated 
the resistance-based exercise group had a clinically meaningful improvement in 
functional well-being from baseline to 12-week follow-up (2.1 [0.6, 3.5]).   No other 
changes in findings were observed (data not shown). 
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Table 4.17 Secondary self-report outcomes at baseline, post-intervention and 12-week follow-up 
 Baseline (T1) Post-intervention 
(T2) 
12-week follow-up 
(T3) 
p-value ΔT2-T1 scores ΔT3-T1 scores 
Variable mean (95% CI) mean (95% CI) mean (95% CI) Time x group 
interaction 
mean Δ (95% CI) mean Δ (95% CI) 
Upper-body function 
(DASH) 
     RES 
     AER 
 
18.8 (12.4, 25.1) 
17.8 (10.7, 24.9) 
 
15.6 (8.3, 22.9) 
12.3 (6.8, 17.8) 
 
15.2 (8.9, 21.5) 
14.8 (8.1, 21.6) 
 
0.50 
 
-3.2 (-6.7, 0.3) 
-5.5 (-11.1, 0.2) 
 
-3.6 (-6.9, -0.2) 
-3.0 (-8.6, 2.7) 
QoL (FACT-B+4)-Total 
     RES 
     AER 
  Physical well-being  
     RES 
     AER 
  Social well-being  
     RES 
     AER 
  Emotional well-being  
     RES 
     AER 
  Functional well-being  
     RES 
     AER 
  Breast cancer sub-scale 
     RES 
     AER 
 
97.2 (88.8, 105.6) 
104.4 (96.5, 112.3) 
 
15.5 (13.9, 17.0) 
15.7 (14.0, 17.3) 
 
20.7 (18.2, 23.2) 
21.6 (19.8, 23.4) 
 
18.9 (17.2, 20.6) 
19.0 (17.5, 20.4) 
 
19.6 (16.9, 22.2) 
22.4 (20.4, 24.4) 
 
22.2 (19.1, 25.2) 
25.1 (21.9, 28.3) 
 
107.2 (97.9, 116.5) 
117.6 (108.9, 126.2) 
 
23.8 (22.2, 25.4) 
24.1 (22.3, 25.8) 
 
20.2 (17.3, 23.1) 
21.6 (19.3, 24.0) 
 
20.7 (19.5, 22.0) 
20.4 (19.0, 21.7) 
 
19.8 (17.0, 22.7) 
23.8 (22.0, 25.6) 
 
22.6 (19.3, 25.9) 
27.7 (24.7, 30.7) 
 
111.8 (102.6, 121.1) 
118.4 (108.4, 128.3) 
 
23.5 (21.7, 25.3) 
23.6 (21.1, 26.1) 
 
21.7 (19.0, 24.4) 
23.2 (21.6, 24.8) 
 
20.6 (19.2, 21.9) 
20.6 (19.0, 22.1) 
 
21.5 (18.9, 24.0) 
23.2 (21.0, 25.4) 
 
24.6 (21.3, 27.9) 
28.5 (25.6, 31.3) 
 
0.54 
 
 
0.98 
 
 
0.88 
 
 
0.78 
 
 
0.17 
 
 
0.36 
 
10.0 (6.2, 13.9) 
13.2 (6.7, 19.7) 
 
8.3 (7.1, 9.5) 
8.4 (6.7, 10.1) 
 
-0.5 (-3.1, 2.1) 
0.1 (-1.8, 1.9) 
 
1.8 (0.8, 2.9) 
1.4 (0.1, 2.8) 
 
0.3 (-1.4, 2.0) 
1.4 (-0.6, 3.4) 
 
0.4 (-1.3, 2.2) 
2.6 (0.0, 5.3) 
 
14.6 (9.6, 19.7) 
14.0 (7.3, 20.6) 
 
8.1 (6.3, 9.8) 
8.0 (5.7, 10.2) 
 
1.0 (-1.0, 3.0) 
1.6 (0.2, 3.1) 
 
1.7 (0.3, 3.0) 
1.6 (0.0, 3.2) 
 
1.9 (0.5, 3.3) 
0.8 (-0.6, 2.2) 
 
2.5 (0.9, 4.0) 
3.4 (0.2, 6.5) 
RES=resistance-based exercise group; AER=aerobic-based exercise group; CI=confidence intervals; DASH=Disabilities of the Arm, Shoulder and Hand; QoL=quality of life; 
FACT-B+4=Functional Assessment of Cancer Therapy-Breast+4 
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4.3.9 Adverse events 
Increased swelling, heaviness and/or aching were reported by the majority of 
participants at some point during the 12-week intervention (72%), which they 
attributed to hot, humid weather (majority of study conducted during late 
spring/summer).  While most women did not alter their lymphoedema treatment, 
some reported an increase in self-delivered manual lymphatic drainage (n=2), greater 
compression garment use (n=4) or less compression garment use (n=2).  Three 
women reported increased swelling and/or aching attributed to non-exercise related 
stress and fatigue, with no change in lymphoedema treatment.  Two women reported 
increased swelling following flights, increasing garment use (n=2) and self-massage 
(n=1) as a result.  No increase of lymphoedema-related symptoms were directly 
attributed to exercise participation by the participants.  Only one participant was 
clinically evaluated for lymphoedema exacerbation, which she requested in week two 
of the resistance-based exercise program.  Comparison of baseline and evaluation 
results found no significant increase (affected arm circumference: 230.6 cm versus 
232.1 cm, respectively; interlimb circumference difference: 19.0 cm versus 20.4 cm, 
respectively).   
    
Four women experienced injuries during their program participation, but none, 
according to the participants, were directly caused by the exercise program.  One 
participant herniated her back while golfing and had to stop the intervention to 
receive physiotherapy treatment (she still completed all assessments), while another 
participant broke a rib falling over her dog and had to reduce/modify her resistance-
based exercise until healed.  The remaining two injuries were flare-ups of pre-
existing arm pain attributed to scarring and radiation (which had both been 
intermittently occurring prior to exercise participation).  One case was diagnosed, 
after the intervention, as metastatic cancer. 
 
4.4 DISCUSSION 
This study was designed to test the primary hypothesis that resistance-based exercise 
is more beneficial for breast cancer-related lymphoedema than aerobic-based 
exercise.  However, results demonstrated that there were no significant changes in 
objective lymphoedema status (when assessed using either BIS or circumference 
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measurements) following participation in resistance- or aerobic-based exercise.  
Findings did suggest aerobic-based exercise may decrease the number of 
lymphoedema-related symptoms more than resistance-based exercise. As 
hypothesised, resistance-based exercise was associated with greater improvements in 
upper-body strength.  Findings showed both modes equivalently increased muscular 
endurance, aerobic fitness, exercise barriers self-efficacy and QoL, but neither mode 
led to changes in body composition, bone mineral density or self-reported upper-
body functioning.  Improvements were primarily gained by the post-intervention 
time-point, and then maintained during the 12-week unsupervised follow-up period.   
 
4.4.1 Comparison to similar studies 
This research was novel in its comparison of exercise mode in women with breast 
cancer-related lymphoedema.  Three previous studies have compared mode in breast 
cancer survivors, but did not include women with lymphoedema.  Similar to our 
findings, results of these previous studies suggest both resistance- (299) and aerobic-
based exercise (253) may produce clinically meaningful improvements in aerobic 
fitness.  These studies also support our results suggesting strength improves more 
with resistance-based exercise, although also to some extent with participation in 
aerobic-based exercise (253).  Also similar to our findings, Schwartz et al. (253) 
found both exercise modes help maintain, but do not improve, bone density.    
 
Previous work by Courneya et al. (73) found no clinically significant increase in QoL 
following participation in resistance- or aerobic-based exercise during chemotherapy.  
In contrast, findings from this study showed that QoL improvements were observed 
in both exercise groups.  Key differences in study design, specifically timing of the 
intervention (i.e., during versus after chemotherapy, respectively), could explain the 
differences in these findings.  Quality of life initially declines following a breast 
cancer diagnosis and during treatment, but tends to improve for the majority of 
women within the year following treatment and then level off at around 12 months 
post-diagnosis (89; 251; 258).  The Courneya and colleagues (73) study showed that 
QoL was maintained in the exercise group, with the intervention conducted during 
treatment; as such, expected QoL declines were prevented.  In this study, 
participation in either exercise group led to improvements in QoL, with the 
intervention conducted during a relatively stable period of survivorship where QoL 
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was not expected to significantly change.  Therefore, both resistance- and aerobic-
based exercise, irrespective of time undertaken (i.e., during or after treatment) seem 
beneficial with respect to QoL.  
 
4.4.2 Assessment of lymphoedema status 
Previous studies have provided evidence for the safety of progressive exercise for 
women with breast cancer-related lymphoedema (Section 2.2.4 and Table 2.2).  
Some research even suggested that exercising may lead to improvements in objective 
and subjective measures of lymphoedema.  While numerous studies have assessed a 
resistance-based (3; 64; 114; 146; 244), an aerobic-based (154) or a combined 
resistance- and aerobic-based exercise program (124; 130; 185),  this is the first study 
in this population to directly compare exercise modes.    
 
4.4.2.1 Change in objective measurements of lymphoedema  
Contrary to what was hypothesised, participation in resistance-based exercise was 
not found to improve objective measures of lymphoedema (as assessed by BIS or 
circumferences) more than participation in aerobic-based exercise.  Instead, there 
were no significant changes in lymphoedema following participation in either 
exercise mode.  Since BIS measures extracellular fluid, it is an optimal technique for 
the assessment of early-stage lymphoedema, characterised by increases in 
extracellular fluid (285).  Circumferences measures limb size, and reflects and 
appropriate method of assessing lymphoedema characterised by increases in 
extracellular fluid and/or deposition of fatty tissue (44; 116).  Thus, the findings from 
this study are relevant to women with early- and later-stage lymphoedema, and 
contribute to the growing body of evidence that demonstrates exercise (resistance-
based, aerobic-based or mixed type) is safe.  That is, lymphoedema is not 
exacerbated by exercise, and prevention of progression may occur via exercise 
participation (Section 2.2.4.5).   
 
Analysis of individual results adds to a more detailed understanding of the 
relationship between exercise and lymphoedema.  Three women showed a worsening 
of their lymphoedema by the 12-week follow-up.  As outlined in Section 4.3.5.1, 
these three individuals also reported low exercise participation before and during the 
time their lymphoedema worsened.  This suggests that lack of exercise participation, 
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rather than exercise, may have contributed to the changes in their lymphoedema 
status, thereby adding to the notion that exercise is safe.  However, this is based on a 
very small group of women who did not exercise as much as others, and a larger 
sample than available here would provide more evidence to support or dispute this 
observation.  A larger sample would allow grouping of participants based on 
adherence level (e.g., <50% or ≥50%) and exploration of what the minimal amount 
of exercise is that is needed to manage (keep at least stable) lymphoedema.  
Additionally, a longer or more targeted intervention could be used, particularly one 
that increases (or re-introduces) supervised exercise to individuals that decline in 
exercise participation.  Interventions could also provide participants with access to 
exercise facilities, and/or a group program, to address adherence issues.  Such 
research would further contribute to the knowledge on the relationship between 
exercise participation and lymphoedema, looking at whether lymphoedema does 
worsen once exercise participation declines and, if so, how long of renewed exercise 
is needed to counteract this worsening.    
 
4.4.2.2 Change in self-reported lymphoedema symptoms 
Findings from this trial suggest participation in aerobic-based exercise led to 
clinically meaningful reductions in number of symptoms (trends for decine in the 
resistance-based group) and that participating in either resistance- or aerobic-based 
exercise may lead to reductions in symptom severity.  While these findings were not 
supported statistically, they are consistent with those observed in the fully-powered 
PAL trial.  In PAL, women reported a significant reduction in number of symptoms 
following a 12-month resistance-based only exercise intervention, compared to usual 
care (224).  Based on our results, however, declines in lymphoedema-associated 
symptoms (either number or severity) can occur within 12 weeks of commencing 
regular resistance- or aerobic-based exercise.  This is clearly relevant to those with 
lymphoedema, as past research suggests changes in symptoms may be equally 
important to individuals as changes in objective measurments (e.g., BIS, 
circumferences) (103; 195).  
 
4.4.3 Changes in secondary objective outcomes: muscular strength and 
endurance, aerobic fitness, body composition and bone density 
Exercise interventions in this and previous studies improved objectively-measured 
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study outcomes including strength, endurance and aerobic fitness (Section 2.1.1) (56; 
106; 165; 245; 249; 265; 268).  In healthy populations and breast cancer survivors 
without lymphoedema, muscular strength and endurance improvements are 
associated with working the musculoskeletal system (resistance-based exercise 
targets the musculoskeletal system) (167; 260), and aerobic fitness improvements 
result from training the cardiovascular system (aerobic-based exercise targets the 
cardiovascular system) (104).  However, the present study adds to the evidence 
supporting these physical improvements from each exercise mode in women who 
have breast cancer-related lymphoedema (Section 2.2.4.6).  As lymphoedema results 
from improper functioning of the lymphatic system, which works closely with the 
musculoskeletal and cardiovascular systems (Section 4.1), it is feasible that women 
with breast cancer-related lymphoedema may respond to exercise differently than 
survivors without lymphoedema.  Therefore, muscular strength, endurance and 
aerobic fitness were included as secondary outcomes, with the hypothesis that 
participation in the exercise intervention would be associated with improvements in 
these areas.  Group differences related to changes in outcomes were expected, but not 
confirmed, with these expectations building on the results of previous research in 
breast cancer survivors and the exercise principle of specificity (Section 4.1).  More 
specifically, participation in the resistance-based exercise group was hypothesised to 
improve muscular strength and endurance more than participating in the aerobic-
based exercise intervention, while greater aerobic fitness improvements were 
predicted in those participating in the aerobic-based exercise group compared with 
those in the resistance-based exercise group.   
 
Expected changes in other outcomes, specifically body composition and bone 
mineral density, were based on factors including study duration and participant 
population.  Unfavourable body composition changes are most often observed in 
women with breast cancer during- and within the initial months post-treatment and 
associated with lower activity levels and certain treatments (e.g., chemotherapy, 
hormone replacement therapy) (83; 85).  Composition changes during and shortly 
after finishing treatment typically occur in the form of sarcopenic obesity, whereby 
fat mass increases while lean body mass is maintained or declines (74; 77).  Once 
developed, these changes, with higher body fat and lower lean tissue mass, 
commonly remain or progress (23; 81).  While significant reductions in body fat are 
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typically difficult to elicit in 24 weeks (the duration of our study) without moderately 
high-intensity training combined with dietary changes, meaningful improvements in 
lean body mass are commonly achieved in this duration when resistance-based 
exercise is incorporated into a program (23; 84; 295).  Therefore, it was hypothesised 
that body composition improvements would be greater in the resistance-based 
exercise group, compared to the aerobic-based exercise group.  Changes were 
primarily expected in lean body mass, rather than body fat, with past research 
demonstrating resistance-based exercise is more beneficial for this type of 
composition change (167; 260; 270).  Conversely, bone mineral density was 
expected to benefit more (i.e., be preserved versus lost) from aerobic- compared to 
resistance-based exercise.  Weight-bearing aerobic-based activities such as 
walking/jogging are helpful in maintaining and improving bone health (253), which 
were used from the start of the intervention.  Benefits from resistance-based exercise 
are more likely with moderately high-intensity training, which was only incorporated 
after at least six weeks (or more depending on individual progression) of the 
intervention.  As such, this short duration of higher-intensity training was not 
expected to be sufficient to affect bone density based on previous research (155; 
168).     
 
Exercise specificity (Section 4.1) was observed with respect to the strength outcome; 
that is, our hypothesis was supported: individuals in the resistance-based exercise 
group showed greater strength improvements compared with those in the aerobic-
based exercise group.  These findings support previous research, which has 
consistently found strength improvements in women with breast cancer-related 
lymphoedema following participation in resistance-based exercise.  Cormie et al. 
(64) compared usual care to high- or low-load strength training (n=62), finding that 
participation in three months of low-load training (i.e., 55-65% of 1RM, 15-20 
repetitions) was sufficient to produce clinically relevant and statistically significant 
improvements (p< 0.01).  Strength increases in their study (high-load=5.6 kg; low-
load=5.8 kg) and our resistance-based exercise group (5.1 kg) were similar.  
Significant increases in strength have also been observed by Ahmed and colleagues 
(3) in women with or at risk of breast cancer-related lymphoedema following six 
months of moderate-intensity, progressive resistance-based exercise, as well as by 
Schmitz and colleagues in women with breast cancer-related lymphoedema after 12 
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months (244) of resistance-based exercise.  The latter studies did not include an 
aerobic-based exercise group to allow comparison in the changes we observed in our 
aerobic-based exercise group.  The finding that strength remained stable in the 
aerobic-based exercise group, however, suggests participation in either resistance- or 
aerobic-based exercise is sufficient to counteract the strength loss commonly seen 
following breast cancer (133), and in particular in those with breast cancer-related 
lymphoedema (261).     
 
Findings did not support the hypotheses that participation in resistance-based 
exercise would benefit muscular endurance more than aerobic-based exercise, and 
participation in aerobic-based exercise would improve aerobic fitness more than 
resistance-based exercise.  Instead, the exercise principle of overload, rather than 
specificity, was observed for the muscular endurance and aerobic fitness outcomes.  
This principle refers to ensuring an exercise training program is greater than what the 
individual is currently doing in order to elicit benefits (46).  Participation in both 
exercise groups increased the exercise individuals were doing and thereby 
overloaded the physiological systems (i.e., musculoskeletal and cardiovascular 
systems).  Resistance-based exercise increases leg musculature strength, while 
aerobic-based exercise improves leg musculature endurance, particularly in 
deconditioned individuals.  As such, this likely contributed to benefits observed in 
both groups for these outcomes.    
 
Contrary to the hypothesis that resistance-based exercise would be most beneficial 
for body composition, neither resistance- nor aerobic-based exercise was found to 
change body composition at post-intervention or 12-week follow-up.  Previous 
studies in survivors with lymphoedema have not assessed body composition changes; 
instead, they only monitored weight or BMI changes, which do not always reflect 
change in body fat and lean body mass (3; 148; 184; 244).  Given total exercise dose 
was the same in both groups, between-group differences in weight change were not 
expected.  The lack of change in either group may be a reflection of the high baseline 
physical activity levels observed in participants, whereby a higher intensity of 
exercise than applied in this intervention would have been needed to elicit changes.  
While this study did not show beneficial changes in body composition, there is a 
body of research that supports the importance of exercise in the prevention of 
  
Chapter 4: Study two 121 
 
 
adverse, age-related accelerated changes in body composition that have been 
observed in women post-breast cancer (81; 83; 242).  Preventing adverse changes in 
body composition is important given the physical and psychosocial impacts of 
increased body fat (e.g., diabetes, hypertension and hyperlipidaemia risk, body image 
concerns, increased recurrence risk) (80; 83; 110).  This justifies the need to further 
explore the effect of exercise on body composition changes in women with breast 
cancer-related lymphoedema over a longer time period, as well as in women who 
more recently completed adjuvant treatment, in future studies.  Further study could 
also look to include the influence of diet in conjunction with exercise on body 
composition changes, as previous research in women with breast cancer highlights 
treatment-related adverse body composition changes are partly influenced by lack of 
balance between energy expenditure (i.e., physical activity) and energy intake (i.e., 
diet) (81). 
 
As summarised in a systematic review of exercise interventions that included 
measures of bone mass in pre- and post-menopausal women, bone maintenance 
through exercise participation is likely in the short-term, particularly in the lumbar 
spine, with significant accrual of bone mass only likely over a year or more of 
maintained exercise (155).  Since the majority of participants were post-menopausal 
(16), and older women as well as breast cancer survivors face an increased risk of 
poor bone health and osteoporosis due to aging and treatment-related effects (225; 
256), it was feasible that this sample could have experienced bone density declines in 
the absence of participating in the exercise intervention.  Instead, maintenance of 
bone density was observed.  Therefore, the finding that participation in either 
resistance- or aerobic-based exercise can maintain bone mineral density, even when 
conducted at a moderate intensity, is promising for counteracting the adverse effects 
of age-related changes, as well as cancer treatment-related effects. 
  
4.4.4 Changes in secondary self-reported outcomes: exercise barriers self-
efficacy, upper-body functioning and quality of life 
Improvements were expected in exercise barriers self-efficacy, given the intervention 
was initially supervised and involved individualised discussion of exercise barriers 
and ways to minimise them.  Additionally, improvements in self-efficacy were 
expected to be greater in the aerobic-based exercise group given participant-related 
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factors such as ease of access and likelihood of pervious exposure (151; 231).  Self-
reported upper-body functioning was also expected to increase, although primarily in 
the resistance-based exercise group.  This was a consequence of expected 
objectively-measured improvements in muscular strength and endurance, which 
previous studies have shown are associated with self-reported upper-body function 
(133).  Quality of life was expected to benefit more from participation in resistance-
based exercise than aerobic-based exercise.  This hypothesis resulted from past 
research demonstrating associations between increased QoL and improvements in 
muscular strength and body composition, both expected to benefit from resistance-
based exercise (73). 
 
Contrary to our hypothesis that aerobic-based exercise would improve exercise 
barriers self-efficacy more than resistance-based exercise, results showed 
participation in either exercise mode produced clinically meaningful improvements.  
The improvements observed were related to both the general and lymphoedema-
specific barriers.  As the lymphoedema-specific sub-scale was developed as part of 
this PhD (Chapter 3), findings from other studies are not available for direct 
comparison.  One previous study by Rogers et al (234) in post-treatment breast 
cancer survivors evaluated the effect of a three-month physical activity intervention 
on general exercise barriers self-efficacy.  The program was designed to reduce 
exercise barriers and increase physical activity levels (combined discussion group, 
counselling and exercise).  The researchers found no significant improvement in self-
efficacy in the intervention group post-program (mean change=0.5% [-11.4, 12.4]).  
Baseline general exercise barriers self-efficacy scores were similar between 
participants in their study (usual care group=42.7%, intervention group=46.8%) and 
our study (resistance-based exercise group=45.1%, aerobic-based exercise 
group=48.2%).  Given these similarities in barriers experienced, our finding that 
significant improvements were achieved by post-intervention in both exercise groups 
may in part be attributable to 12 weeks of the intervention being supervised, 
compared to only the first six weeks in Rogers and colleagues’ study (234).  As self-
efficacy levels in our study were maintained or further improved during the 
unsupervised 12-week follow-up, it suggests that an initially longer than 6-week 
supervised exercise program may be needed to build confidence to exercise.  This 
has important implications in the healthcare system, as resources (e.g., financial, 
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staffing) may not be available to continue long-term supervision.  However, little 
research exists on the cost effectiveness of exercise programs, an area requiring 
further investigation (248). 
 
In contrast to our objective upper-body functioning findings, there was no clinically 
meaningful change observed in self-reported upper-body functioning (DASH 
questionnaire) following participation in the resistance- or aerobic-based exercise 
intervention.  This was contrary to the hypothesis that resistance-based exercise 
would improve upper-body functioning more than aerobic-based exercise.  Our 
findings may be in part due to participants perceiving relatively high upper-body 
functioning at baseline (restriction in functioning at baseline=18.8 and 17.8 out of 
100).  These levels are comparable to baseline values observed in other exercise 
interventions involving women with breast cancer-related lymphoedema, which have 
ranged from 16.0 (154) to 19.5 (64).  Similar to our research, these studies showed 
only very small improvements in upper-body functioning following participation in 
either an eight-week pole-walking program (154) or three months of high- and low-
load resistance exercise (64).  As the DASH was originally designed to measure 
disability in patients with orthopaedic-related upper-body impairments (120), it may 
not be sensitive enough to detect clinically significant change (i.e., 10 points) in 
individuals with high baseline functioning.  Given this, and the discrepancy with the 
objectively measured functioning, selection of a different tool or intervening 
specifically with women with lower upper-body functioning is recommended for 
future work.    
 
Contrary to the hypothesis that resistance-based exercise would produce the greatest 
improvements in QoL, both the resistance- and aerobic-based exercise groups 
reported clinically relevant improvements in overall QoL (FACT-B+4; ≥ 7) between 
pre- and post-intervention.  Changes in the physical well-being domain drove QoL 
improvements in both groups, suggesting QoL benefits from exercise may be 
especially related to improvements in physical issues such as lack of energy and side 
effects (e.g., feel ill, nausea).  It should be highlighted that the items related to the 
physical well-being domain of QoL differ from most items on the DASH (i.e., 
majority of questions about ability to perform specific tasks such as opening a jar or 
washing your back).  As such, it is therefore plausible for physical well-being to 
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improve even when self-reported upper-body functioning does not.  Previous 
research has also demonstrated QoL improvements are most commonly driven by 
changes in physical well-being.  Four of the seven previous studies assessing this 
outcome in women with lymphoedema reported significant improvements in the 
physical functioning component following participation in an exercise intervention 
(SF-36 survey used) (64; 114; 184; 185).  The QoL improvements are encouraging 
for the role of resistance- and aerobic-based exercise in counteracting QoL declines 
that have been found in survivors reporting comorbidities, such as lymphoedema 
(163; 258). 
 
Improvements in objectively-measured outcomes including strength and fitness are 
desirable, as they translate to important factors such as decreased stress on the 
affected limb during performance of daily activities (244) and helping condition the 
lymphatic system to handle increased loads (241).  However, improvements in self-
reported areas including self-efficacy and overall QoL are of equal importance, as 
they reflect participant-perceived changes in areas that are often not measureable 
objectively (e.g., reduction of fatigue, symptoms, fear about exercising) (123; 200).  
Findings from this study show positive effect of both exercise modes on self-reported 
wellness, further highlighting the importance of exercise for women with breast 
cancer-related lymphoedema.            
 
4.4.5 Program adherence 
Intervention adherence was high, with 92% of participants attending 75% or more of 
supervised sessions.  These rates are similar or higher to those found in other 
exercise interventions involving women with breast cancer-related lymphoedema, 
which have reported adherence rates from 75% (244) to 96% (64).  Despite high 
adherence by most participants, three individuals, all in the aerobic-based exercise 
group, had 0% adherence, with one of these individuals not participating in 
subsequent data collection sessions.  Since all three withdrawals were aerobic-based 
exercise group participants, with no withdrawals from the resistance-based exercise 
group, it seems plausible that group allocation may have influenced withdrawal.  Of 
note, baseline sample characteristics highlighted that this was a relatively active 
group at baseline, particularly the aerobic-based exercise group (57% of aerobic-
based exercise participants were sufficiently active at baseline, compared to 40% of 
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resistance-based exercise group participants), and that based on results of the Active 
Australia and CHAMPS survey, the type of exercise most were already doing was 
aerobic-based.  Therefore, being randomised to the aerobic-based exercise group 
may have meant for these women doing more of the same form of exercise.  This, in 
addition to participation in data collection sessions, may have led to less incentive to 
participate, reflected in more aerobic-based exercise participants with 0% adherence 
or withdrawing. 
    
Adherence during the 12-week follow-up, the unsupervised, self-guided component 
of the study, was more variable than adherence during the 12-week supervised 
intervention.  During the follow-up period, six participants (four resistance- and two 
aerobic-based exercise group) reported adherence rates below 50%.  That is, women 
only completed between 0 and 600 minutes of the total 1800 minutes across the 
entire 12-week follow-up period.  Reasons for decreased adherence are similar to 
those observed in other research (9; 130) and included work and/or family 
commitments, lacking self-motivation and personal or family health issues.  During 
the supervised exercise intervention, multiple strategies were used to maximise 
exercise adherence during the unsupervised phase, as discussed in Section 4.2.5.   
However, the above findings suggest, at least for some participants, these strategies 
were not sufficient in helping maintain regular exercise.  Research from Rogers and 
colleagues (233) measured correlates of self-reported physical activity in breast 
cancer survivors.  They found key factors related to higher physical activity levels 
included having an exercise partner and/or breast cancer exercise role model (i.e., 
knowing another survivor that exercises) and more strongly valuing the positive 
effects of exercise (e.g., its usefulness in reducing depression).  This research, in 
addition to findings from the current study, highlights that some individuals may 
need a continuation of assistance and encouragement from a trainer, another survivor 
or scheduled sessions, or more gradual decline in supervision (e.g., drop to once 
every fortnight then once everyone month), to become regular exercisers.  
 
4.4.6 Adverse events 
Adverse events that occurred during the intervention period included increased 
lymphoedema-related symptoms and musculoskeletal injury/flare-ups, similar to 
those found in previous studies (73; 130; 244).  As indicated earlier, none of these 
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were considered a consequence of participating in the intervention.  Given the 
absence of a control group however, it is not possible to state this with certainty.  
Nonetheless, regular supervised sessions included a thorough assessment of 
symptom change (when relevant), reassessment of lymphoedema when considered 
necessary (one individual with subsequent assessment showing declines in 
lymphoedema status), and tracking of weekly activity and response to activity.  
Collection of such information provides confidence that neither resistance- nor 
aerobic-based exercise produced lymphoedema-related or other adverse events in this 
cohort.       
 
4.4.7 Study limitations and strengths 
Interpretation of findings from this study must take into consideration several 
limitations.  The main limitation of this work was the absence of a control group.  
This decision was made given the time and financial restrictions of a PhD, as well as 
past research already providing evidence on the natural history of lymphoedema 
(128; 246) and safety of exercise (Section 2.2.4).  Even with this reasoning, however, 
limitations remain as a result of no control group.  The majority of women completed 
baseline assessment at the start of summer and then participated in the 12-week 
exercise intervention as temperatures increased.  Many women find lymphoedema is 
at its worst and/or worsens in the summer heat (266).  This potential natural 
worsening has not been quantified, however, which inclusion of a control group 
would have allowed.  If a worsening was demonstrated (that is, control had 
worsening lymphoedema while the exercise groups had stable lymphoedema), more 
emphasis could be placed on the importance of exercise with respect to prevention of 
lymphoedema fluctuation or progression.  Women self-reported that while 
participating in the exercise intervention, their lymphoedema was not ‘playing up’ or 
worsening as much as it typically did in summer.  As such, it is possible that greater 
lymphoedema benefits would have been observed if assessments and the intervention 
were conducted in cooler, less humid weather, with this warranting further study.  A 
control group would also have allowed assessment of potential bias due to 
concomitant lymphoedema treatment.  As it was deemed unethical to have 
participants cease other lymphoedema treatment during the study (e.g., MLD, 
compression, laser therapy), a control group would have provided information on 
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whether participation in exercise contributes to decreased need for other 
lymphoedema treatment.  
   
As mentioned earlier, average baseline physical activity levels of participants were 
high, with half of the women (49%) meeting national recommendations of 150 
minutes of weekly exercise.  This participation bias could have potentially limited 
the ability to see changes in outcomes through participation in the exercise 
interventions.  Nonetheless, findings still showed statistically significant and 
clinically relevant improvements in fitness and self-reported outcomes, and no 
worsening of lymphoedema.  This highlights that exercise benefits may be greater in 
more sedentary women with breast cancer-related lymphoedema, a group that could 
be targeted in future research.  It would also be beneficial for future research to 
collect information on participants’ past exercise history, helping better individualise 
prescription as well as better assess the likelihood of results being impacted from 
factors such as a learning effect and muscle memory. 
  
Another potential implication of high baseline physical activity is the risk of 
contamination, whereby the resistance-based exercise group might have performed 
some aerobic-based exercise, and the aerobic-based exercise group may have 
undertaken resistance-based exercise.  We elected to encourage women to maintain 
their normal activity throughout the intervention period, which for some may have 
already included resistance- or aerobic-based exercise.  While this meant that some 
women were potentially performing more exercise than others, the eligibility criteria 
required participants to be undertaking less than half of the prescribed exercise (i.e., 
less than 75 minutes of weekly moderate exercise).  Therefore, all participants were 
still undertaking a level of exercise sufficient to induce the exercise principle of 
overload (Section 4.4.3).  Use of the Active Australia, in addition to resistance-based 
exercise questions from the CHAMPS survey, allowed estimation of potential group 
contamination.  Two aerobic-based exercise group participants and eight resistance-
based exercise group participants reported performing the other mode of exercise 
regularly (at least 30 minutes most weeks) during the intervention.  This was done in 
addition to the 150 weekly minutes of their assigned exercise mode.  Such findings 
highlight one of the challenges that exist in conducting an exercise intervention in an 
active sample.  
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Adherence information was based on self-report data rather than objective 
measurement (e.g., through the use of accelerometers and heart rate monitors).  This 
could lead to over-reporting of total minutes of activity undertaken, as well as over-
reporting of the intensity of that activity, during the unsupervised sessions.  
However, inclusion of at least one supervised session each week during the 12-week 
intervention, whereby the investigator ensured participants were correctly reporting 
intensity, minimised the chance of over-reporting.  Further, excellent rapport was 
developed between investigator and participant.  This established a trusting 
relationship, where regular conversation helped ensure participants were aware of the 
importance of accurate reporting and were supported in doing so with activity logs 
that were discussed weekly.  As such, this assisted in minimising the likelihood of 
purposeful (but not unconscious) over-reporting.  It could, however, have increased 
the participants’ tendency to report in a socially desirable way. 
 
Another study limitation was the lack of blinding during randomisation, assessments 
and supervised exercise.  Due to the nature of the intervention, it was not possible to 
blind participants.  The assessments, randomisation and supervised exercise, 
conversely, could have been conducted by independent, blinded health professionals.  
However, as this was a PhD study, with limited resources and funding, the researcher 
completed randomisation, assessments and exercise sessions.  Randomisation was 
done using a computer-generated sequence and sealed envelopes to ensure the 
researcher had no control over group assignment.  While risk of bias in data 
collection exists, there are notable strengths to using a single researcher to conduct 
assessments and exercise sessions.  Uniformity in assessments eliminates potential 
for poor inter-rater reliability.  To reduce the risk of research bias, a standardised 
protocol was followed and the researcher was blinded to previous assessment results 
at each follow-up, whereby data collected during the previous assessment(s) were 
kept in a locked filing cabinet and not brought to the subsequent assessment.  Also, 
having the same person conduct all supervised exercise sessions ensured the same 
level and type of support was provided to each participant.  That is, the psychosocial 
(i.e., psychological factors and social interaction) aspect of meeting with a healthcare 
professional regularly was the same in both groups.  This controlled factor 
contributes to the ability of this study to demonstrate that group differences in 
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outcomes were attributable to exercise mode (as opposed to how much 
encouragement participants received at each exercise session).   
 
A final study limitation is that improvements in fitness may have been influenced by 
the learning effect, whereby results during 12-week and follow-up assessments were 
higher partly due to participants having already been exposed to and familiarised 
with the test (7).  Additionally, tests used to measure self-reported upper-body 
functioning and fitness may have limited sensitivity compared to other assessment 
options.  Limitations of the DASH and potential sensitivity issues have been 
discussed in Section 4.4.4.  This study used the 6MWT to measure aerobic fitness.  
Given the relatively high levels of baseline physical activity reported by participants, 
a VO2max or sub-VO2max test may have been more suitable to measure aerobic fitness 
as it provides a measure of aerobic capacity as opposed to change in distance walked 
(which may be hard to increase in high-performing individuals).  However, research 
has demonstrated the 6MWT is a reliable test to measure functional capacity, and 
advantages of this test are that it is representative of daily functioning (i.e., walking 
places), avoids the impact of unfamiliarity with assessment equipment used in 
VO2max tests (e.g., treadmills, cycle ergometers) and requires minimal equipment 
(254).  Additionally, it is unclear if predictive aerobic fitness equations used with 
sub-maximal tests are reliable in breast cancer survivors (47; 164).  For upper-body 
strength, a 1-RM test may have provided a more accurate assessment of change, 
limiting the impact of fatigue that may accompany a 4-6 RM test.  However, 1-RM 
testing in unconditioned individuals, even when properly supervised, may induce 
greater muscle soreness and potential concern about lymphoedema worsening, and 4-
6RM has shown to be a reliable alternative to maximal testing (41; 91).  Advantages 
of the selected tests are that they were clinically appropriate, with minimal 
equipment requirements or safety risks.  They are also easily transferred out of the 
clinic and can be performed, for example, at a participant’s home if needed. 
 
There are also some notable strengths to this study.  The study used intention-to-treat 
analysis, as well as had adequate power for analysis of the primary outcome, 
lymphoedema status, specifically BIS and circumferences.  Intention-to-treat analysis 
includes data from all participants completing baseline assessment and 
randomisation, regardless of compliance.  This method minimises bias resulting from 
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loss of participants (26; 170; 176; 177).  It also aims to maximise the chance 
randomisation produces equivalent groups that allow for unbiased comparisons of 
treatment (264).  A consequence of intervention research is the risk of poor 
adherence affecting results, whereby benefits of the intervention may be downplayed 
(110). Conversely, excluding data from non-complying individuals may overestimate 
the efficacy of an intervention (121; 139; 280).  Use of intention-to-treat analysis 
also helped conserve sample size by including data regardless of adherence.  
 
This study also assessed other physical and psychosocial outcomes beyond 
lymphoedema, with findings highlighting the importance of resistance-based exercise 
for strength improvements in this vulnerable group of breast cancer survivors with 
additional co-morbidities.  Both groups improved aerobic fitness, supporting the 
cross-over effect, whereby resistance-based exercise can produce cardiovascular 
benefits.  Additionally, no exercise specificity effects (i.e., one mode best) related to 
improvements in quality of life or exercise barriers self-efficacy, with both 
resistance- and aerobic-based exercise groups demonstrating benefits in these 
outcomes by post-intervention.  Given both modes of exercise were equivalent in 
lymphoedema effect, knowing if modes differ in other benefits has important 
implications for exercise prescription.  As each woman has different additional 
survivorship concerns, exercise mode prescription can be individualised towards 
improving these issues, without losing lymphoedema benefits.  For example, women 
with significant strength loss can be prescribed resistance-based exercise to gain 
strength and lymphoedema benefits, while women who need to improve lower-body 
muscular endurance could be assigned to either exercise mode. 
 
4.4.8 Implications for clinical practice 
Unique to this study was the inclusion of a 12-week unsupervised follow-up period, 
with no supportive contact from the researcher.  Unsupervised components have 
been used in other studies (3; 244), but participants in these studies commonly had 
continued access to fitness trainers who encouraged adherence.  Unsupervised self-
maintenance of regular exercise is essential if exercise is to be used as an effective 
long-term treatment strategy for lymphoedema.  Despite significant reduction from 
the average minutes they exercised during the supervised intervention, the findings 
from our study suggest that the majority of women were able to maintain fitness, 
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exercise barriers self-efficacy and QoL gains from an initially supervised component.  
As such, healthcare practitioners may be able to help lay a foundation for longer-
term exercise participation and accrual of benefits by providing patients with initial 
exercise supervision.    
 
Of clinical interest is the finding that exercise barriers self-efficacy levels did not 
reflect objectively measured behaviour.  At baseline, women in the exercise 
intervention varied in their reported self-efficacy level.  However, similar adherence 
to exercise was observed between those reporting low, moderate and high exercise 
barriers self-efficacy.  As highlighted earlier, some participants still reported low 
exercise adherence during the follow-up period, despite high average levels of 
exercise barriers self-efficacy.  It is feasible that, while women may be confident to 
overcome most barriers and exercise overall, the presence of certain specific barriers 
(e.g., lack of motivation or someone encouraging exercise) may be particularly 
detrimental for participation.  This is supported by Rogers and colleagues (233) 
findings that physical activity participation was negatively affected by not only lower 
exercise barriers self-efficacy, but also factors such as lacking an exercise partner or 
role model.  Therefore, it may be important for healthcare professionals to discuss 
each specific identified barrier with patients struggling to adhere to exercise, as 
opposed to overall self-efficacy level. 
 
An important consideration for exercise intervention research in women with breast 
cancer-related lymphoedema is the ease of translating the program into practice.  
That is, women in this study received 18 one-on-one, predominantly home-based 
supervised exercise sessions as part of the intervention.  This design has significant 
time, convenience and financial implications.  Some participants reported they would 
have preferred a gradual reduction of supervised exercise to fortnightly, as it would 
be more convenient and provide them a better opportunity to transition to completely 
unsupervised exercise.  While sessions were provided to participants free of cost, this 
is usually not feasible outside of research programs and it may not be financially 
viable for some individuals to participate in a similar fee-for-service exercise 
program.  Additionally, women that were located outside of the Brisbane area were 
deemed ineligible based on location, even if other criteria were met.  Therefore, even 
if women are confident and motivated to exercise (i.e., high exercise barriers self-
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efficacy), maintenance of regular exercise may still be limited if a program does not 
take into account factors such as schedule flexibility, financial implications and 
program reach (e.g., whether individuals in rural locations must travel or can receive 
alternate forms of ‘supervision’).  Also necessary to consider is required location of 
exercise, aiming to ensure women are able to exercise in comfortable conditions, 
reducing potential body image concerns related to exercising in a public place where 
their compression garment or visible limb size differences might attract undesired 
attention (115).        
 
4.4.9 Recommendations for future research 
Overall, resistance- and aerobic-based exercise were found equally beneficial in their 
role in lymphoedema management.  Additionally, both modes produced significant 
improvements in areas such as muscular and aerobic fitness and QoL, even in a 
cohort with 49% of participants reporting sufficient physical activity levels at 
baseline.  Clearly this research has highlighted a number of important findings. 
Nonetheless, given the limitations described above, this research is preliminary.  
Replication of the results in a larger, controlled trial with blinded assessors is 
necessary before translation into practice can be recommended.   
 
This research also evaluated the association between exercise participation and self-
efficacy, assessing if self-efficacy levels are improved by participation in an initially 
supervised exercise program, and if baseline self-efficacy is related to program 
adherence.  Findings highlighted that confidence to overcome barriers of exercise 
(i.e., self-efficacy) improves with both resistance- and aerobic-based exercise 
participation.  Also, amount of supervision may need to be adjusted based on 
individual exercise barriers experienced.  Directions for future research are outlined 
below:   
 
• Are the effects of exercise mode similar in other breast cancer-related 
lymphoedema sub-groups, particularly those with earlier (i.e., stage one) 
lymphoedema or with lower baseline physical activity levels? 
• Do changes in other outcomes, such as fatigue and depression, vary between 
exercise modes?  
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• Does a program combining resistance- and aerobic-based exercise produce 
greater benefits than either mode in isolation? 
• Do women better maintain exercise in the longer-term with a more 
personalised decline in supervision (e.g., reducing sessions sooner, or more 
gradual reduction to once a fortnight then monthly)? 
• Does self-efficacy level affect exercise participation in other populations, 
particularly those with other types of cancer-related lymphoedema? 
• Are the effects of exercise modified by baseline self-efficacy?  That is, do 
individuals with low versus moderate versus high exercise barriers self-
efficacy differ in the benefit they gain from exercise participation, the mode 
of exercise or in the time it takes to accrue benefits? 
• Does self-efficacy level correlate with longer-term exercise maintenance?  
Additionally, if individuals have a low baseline self-efficacy level, does 
additional supervision help improve it, and are improvements associated with 
longer-term maintenance or are improvements lost once supervision 
concludes?  
 
As an extension to analyses contributing to this PhD, some of these questions can 
and will be addressed through secondary data analysis of study data in the future.  It 
is plausible that a combined resistance- and aerobic-based exercise program with 
greater personal support to minimise barriers may produce the most benefits in 
women with lymphoedema.  However, the first step is to get women confidently 
engaging in regular exercise.  Given the results of this study, prescription of 
preferred exercise mode may provide a foundation from which a more targeted 
exercise prescription designed to address individual survivorship concerns can occur. 
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Chapter 5: Conclusion 
As highlighted by this and past research, exercise program limitations and 
considerations exist when working with individuals with breast cancer-related 
lymphoedema.  This research contributes to the knowledge on important factors to 
consider and potential ways to overcome common issues.  These include helping 
individuals overcome general and lymphoedema-related exercise barriers, as well as 
providing clearer guidance on what mode of exercise to perform to lymphoedema-
related, and other physical and psychosocial, benefits.  As highlighted by the 
research findings, one significant challenge is helping breast cancer survivors with 
lymphoedema gain confidence to engage in regular exercise.  Exercise barriers self-
efficacy may be negatively impacted by certain characteristics, such as experience of 
lymphoedema-related symptoms, with a need to address them for each patient 
individually and adjust exercise prescription accordingly.  Additionally, results from 
this research suggest helping participants start exercising may significantly improve 
self-efficacy, even in women with high baseline physical activity levels and low 
symptom number and severity.  As such, helping women minimise barriers and start 
exercising may conversely improve their self-efficacy and further reduce barriers, 
with the potential for this to then translate into assisting women to become regular, 
long-term exercisers.      
 
Further guidance on what exercise prescription to give women with breast cancer-
related lymphoedema has also resulted from this study, with findings contributing to 
the existing literature suggesting that exercise, both resistance- and aerobic-based, is 
safe for women with breast cancer-related lymphoedema.  Certain exercise types 
may instigate greater change in certain outcomes compared with other types (e.g., 
resistance-based exercise may be optimal for improving upper-body strength, 
compared to aerobic-based exercise).  However, both modes of exercise are effective 
at improving a range of physiological outcomes, and of particular significance to 
women with lymphoedema, QoL.  Therefore, getting women to perform either mode 
of exercise should be the focus of healthcare professionals working with women with 
breast cancer-related lymphoedema.  While exercise prescription should ultimately 
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take into account individual survivorship needs (e.g., the need to preserve and/or 
improve strength, reduce fatigue, improve aerobic fitness, improve ROM 
limitations), the first step should be to assist women to become sufficiently active.  
As highlighted by this work, doing so may first require understanding and addressing 
of the exercise barriers they face.  Given both exercise modes are safe with respect to 
lymphoedema, prescription can first be guided by individual preference, as well as 
which mode presents the least barriers for the individual.  Once this foundation, as 
well as exercise confidence, is established, programs can be modified to optimise a 
woman’s recovery and longer-term function, health, QoL and survival.  
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University Human Research Ethics Committee
HUMAN ETHICS APPROVAL CERTIFICATE
NHMRC Registered Committee Number EC00171
Date of Issue: 29/9/14 (supersedes all previously issued certificates)
Miss Jena BuchanDear
This Approval Certificate serves as your written notice that the proposal has met the requirements of the National 
Statement on Ethical Conduct in Human Research and has been approved on that basis.  You are therefore 
authorised to commence activities as outlined in your proposal application, subject to any specific and standard 
conditions detailed in this document.
Project Details
Category of Approval:
Approved From: 21/11/2014
Approval Number: 1100001471
Human Negligible-Low Risk
Project Title:
Approved Until:21/11/2011 (subject to annual reports)
Examine barriers to exercise in people with secondary lymphoedema following cancer 
treatment
Chief Investigator: Miss Jena Buchan
Investigator Details
Other Staff/Students:
Investigator Name Type Role
Dr Sandi Hayes Internal Supervisor
Dr Robyn Box External Supervisor
Conditions of Approval
Specific Conditions of Approval:
No special conditions placed on approval by the UHREC.  Standard conditions apply.
5. Stop any involvement of any participant if continuation of the research may be harmful to that person, and 
immediately advise the Research Ethics Coordinator of this action;
6. Advise the Research Ethics Coordinator of any unforeseen development or events that might affect the 
continued ethical acceptability of the project;
7. Report on the progress of the approved project at least annually, or at intervals determined by the Committee;
8. (Where the research is publicly or privately funded) publish the results of the project is such a way to permit 
scrutiny and contribute to public knowledge; and
Standard Conditions of Approval:
The University's standard conditions of approval require the research team to:
1. Conduct the project in accordance with University policy, NHMRC / AVCC guidelines and regulations, and the 
provisions of any relevant State / Territory or Commonwealth regulations or legislation;
2. Respond to the requests and instructions of the University Human Research Ethics Committee (UHREC); 
3. Advise the Research Ethics Coordinator immediately if any complaints are made, or expressions of concern 
are raised, in relation to the project;
4. Suspend or modify the project if the risks to participants are found to be disproportionate to the benefits, and 
immediately advise the Research Ethics Coordinator of this action;
RM Report No. E801 Version 4.4 Page 1 of 2
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University Human Research Ethics Committee
HUMAN ETHICS APPROVAL CERTIFICATE
NHMRC Registered Committee Number EC00171
Date of Issue: 29/9/14 (supersedes all previously issued certificates)
Modifying your Ethical Clearance:
Requests for variations must be made via submission of a Request for Variation to Existing Clearance Form 
(http://www.research.qut.edu.au/ethics/forms/hum/var/var.jsp) to the Research Ethics Coordinator.  Minor 
changes will be assessed on a case by case basis.
It generally takes 7-14 days to process and notify the Chief Investigator of the outcome of a request for a 
variation.
Major changes, depending upon the nature of your request, may require submission of a new application.
9. Ensure that the results of the research are made available to the participants.
Audits:
All active ethical clearances are subject to random audit by the UHREC, which will include the review of the 
signed consent forms for participants, whether any modifications / variations to the project have been approved, 
and the data storage arrangements.
Further information regarding your ongoing obligations regarding human based research can be found via the 
Research Ethics website http://www.research.qut.edu.au/ethics/ or by contacting the Research Ethics 
Coordinator on 07 3138 2091 or ethicscontact@qut.edu.au
If any details within this Approval Certificate are incorrect please advise the Research Ethics Unit within 10 days 
of receipt of this certificate.
End of Document
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Dear!potential!participant,!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!
You!are!invited!to!participate!in!a!research!project!currently!being!undertaken!at!the!Queensland!
University!of!Technology,!entitled:!“Examining!barriers!to!exercise!in!people!with!secondary!lymphoedema!
following!cancer!treatment.”!!There!is!mounting!evidence!that!suggests!participating!in!exercise!does!not!
initiate!or!exacerbate!lymphoedema.!!However,!given!limited!guidelines,!many!people!may!be!unaware!of!
what!they!can!and/or!should!be!doing.!!This!study!aims!to!examine!what!barriers!to!exercise!are!
commonly!faced!by!individuals!with!lymphoedema!through!the!use!of!a!questionnaire.!
!
Researchers!at!QUT!have!not!been!provided!with!your!name!or!contact!details.!!You!are!receiving!this!
letter!and!questionnaire!as!you!are!either!currently!receiving!or!have!previously!received!lymphoedema!
treatment!by!Dr!Robyn!Box.!!Dr!Box!has!agreed!to!send!this!letter!and!accompanying!questionnaire!to!you,!
on!our!behalf,!ensuring!that!your!details!remain!confidential!and!to!enable!you!to!independently!decide!
whether!to!participate!or!not.!!Your!participation!in!this!project!is!voluntary,!will!incur!no!costs!to!you!and!
does!not!ask!for!any!identifying!information.!!Should!you!choose!to!participate,!we!ask!that!you!complete!
the!enclosed!questionnaire!and!return!it!to!us!using!the!preKpaid!envelope!within!two!weeks.!!Your!
completion!and!return!of!the!questionnaire!implies!you!are!consenting!to!participate.!!
!
Following!completion!of!the!study,!the!results!will!be!analysed!and!prepared!for!potential!publication!and!
presentation!at!a!national!lymphoedema!conference.!We!look!forward!to!hearing!back!from!you!and!thank!
you!for!your!support!in!our!research!endeavours.!!
!
Kind!regards,!
Jena!Buchan!
PhD!Student,!School!of!Public!Health!
Queensland!University!of!Technology!
 
Phone +61 7 3138 5879  Queensland University of Technology  
Facsimile +61 7 3138 3369  IHBI, School of Public Health  
www.icanhop.com.au  Victoria Park Rd, Kelvin Grove, QLD, Australia, 4059  
 [Type!a!quote!from!the!document!or!the!
summary!of!an!interesting!point.!You!can!
position!the!text!box!anywhere!in!the!
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PARTICIPANT(INFORMATION(FOR(QUT(
RESEARCH(PROJECT(
Examining(barriers(to(exercise(in(people(with(secondary(lymphoedema(
following(cancer(treatment(
QUT(Ethics(Approval(Number(1100001471(
RESEARCH(TEAM(!
!Principal!
Researcher:!
Jena!Buchan,!PhD!student,!QUT!
Associate!
Researchers:!
Dr!Sandi!Hayes,!Faculty!of!Health,!QUT!
Dr!Robyn!Box,!QLD!Lymphoedema!&!Breast!Oncology!Physiotherapy!
DESCRIPTION(
This!project!is!being!undertaken!as!part!of!a!PhD!study!for!Jena!Buchan.!!The!purpose!of!this!project!is!to!
identify!the!barriers!to!exercise!most!commonly!faced!by!people!with!secondary!lymphoedema!following!
treatment!for!cancer.!You!are!invited!to!participate!in!this!study!as!you!have!received!or!are!receiving!
lymphoedema!treatment!from!Dr!Robyn!Box.!
PARTICIPATION(
Your!participation!in!this!project!is!entirely!voluntary.!If!you!do!agree!to!participate,!you!can!withdraw!
from!the!project!at!any!time!without!comment!or!penalty.!Any!identifiable!information!already!obtained!
from!you!will!be!destroyed.!Your!decision!to!participate,!or!not!participate,!will!in!no!way!impact!upon!
your!current!or!future!relationship!with!QUT!and!Qld!Lymphoedema!and!Breast!Oncology!Physiotherapy,!
and!eligibility!to!be!included!in!future!studies.!!
Participation!will!involve!completing!a!questionnaire,!which!will!take!approximately!10!minutes!of!your!
time.!!The!questions!included!will!ask!you!to!rate!on!a!scale!from!0Q100%!how!confident!you!are!to!
exercise!when!faced!with!certain!barriers!(0%=not!at!all!confident,!100%=extremely!confident).!!These!
barriers!include!items!such!as!“When!I!am!tired”!and!“When!my!affected!body!part!is!painful.”!!If!you!
agree!to!participate,!you!are!encouraged!to!answer!all!questions!to!the!best!of!your!ability.!!However,!
you!may!choose!to!skip!any!questions!you!do!not!feel!comfortable!answering.!!There!are!also!some!
demographic!questions,!which!will!be!used!to!explore!whether!certain!personal!characteristics,!such!as!
age,!influence!exercise!barriers.!
EXPECTED(BENEFITS(
It!is!expected!that!the!results!of!this!project!will!help!identify!key!barriers!to!exercise!for!people!with!
secondary!lymphoedema!following!cancer!treatment.!!Identifying!these!barriers!will!help!the!researchers!
develop!an!exercise!intervention!trial!that!considers!these!concerns!and!implements!strategies!to!
overcome!these!issues.!There!are!no!related!costs!to!participation!in!this!study,!except!that!of!your!time!
in!completing!the!questionnaire.!!
RISKS(
There!are!no!inherent!risks!associated!with!this!study!and!many!of!the!questions!included!have!been!
previously!completed!by!women!with!breast!cancer.!!The!questions!are!not!considered!sensitive.!!In!the!
rare!instance!that!you!feel!distress!completing!the!questionnaire,!it!is!anticipated!that!this!distress!will!
be!minimal!and!shortQterm,!and!you!are!free!to!stop!completing!the!questionnaire!and!not!return!it!to!us!
at!any!stage.!!
QUT!provides!limited!free!counselling!for!research!participants!of!QUT!projects!who!may!experience!
discomfort!or!distress!as!a!result!of!their!participation!in!the!research.!!Should!you!wish!to!access!this!
service!please!contact!the!Clinic!Receptionist!of!the!QUT!Psychology!Clinic!on!3138!0999.!!Please!indicate!
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to!the!receptionist!that!you!are!a!research!participant.!
PRIVACY(AND(CONFIDENTIALITY(
No!identification!is!necessary!on!the!questionnaire,!ensuring!your!responses!are!kept!anonymous!and!
confidential.!!All!data!will!be!kept!nonQidentifiable!to!ensure!your!privacy!and!confidentiality.!!
Additionally,!Dr!Robyn!Box!and!the!study!researchers!will!have!no!method!of!tracking!who!does!and!does!
not!respond.!!
CONSENT(TO(PARTICIPATE(
The!return!of!the!completed!questionnaire!is!accepted!as!an!indication!of!your!consent!to!participate!in!
this!project.!!If!you!choose!to!participate,!we!ask!that!you!complete!the!enclosed!background!
information!and!questionnaire!and!return!them!to!us!using!the!enclosed!replyQpaid!envelope!within!two!
weeks.!
QUESTIONS(/(FURTHER(INFORMATION(ABOUT(THE(PROJECT(
If!have!questions!or!require!further!information!please!contact!the!study’s!chief!investigator!using!the!
details!below.!!
Jena!Buchan,!PhD!student,!Chief!investigator!
!
Dr!Sandi!Hayes,!Supervisor,!Faculty!of!
Health,!QUT!
3138!5677!!!!!!!0421!486!874!!!!!!!
jena.buchan@qut.edu.au!!
3138!9645!!!!!!!!!!!
sc.hayes@qut.edu.au!!
CONCERNS(/(COMPLAINTS(REGARDING(THE(CONDUCT(OF(THE(PROJECT(
QUT!is!committed!to!research!integrity!and!the!ethical!conduct!of!research!projects.!!However,!if!you!do!
have!any!concerns!or!complaints!about!the!ethical!conduct!of!the!project!you!may!contact!the!QUT!
Research!Ethics!Unit!on!3138!5123!or!email!ethicscontact@qut.edu.au.!The!QUT!Research!Ethics!Unit!is!
not!connected!with!the!research!project!and!can!facilitate!a!resolution!to!your!concern!in!an!impartial!
manner.!
Thank"you"for"helping"with"this"research"project.""Please"keep"this"sheet"for"your"
information.(
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Examining barriers to exercise in people 
with secondary lymphoedema following 
cancer treatment 
 
Questionnaire instructions 
 
 
This booklet contains the questions regarding barriers to exercise, as well as some 
questions about your personal characteristics to determine if factors such as age 
influence exercise barriers.  When completing the questions related to your 
lymphoedema and associated symptoms, please try to respond based on your current 
situation. 
 
The questionnaire you are being asked to complete seeks to determine how confident 
you are to exercise when faced with certain barriers.  It has a scale from 0 to 100%, with 
0% relating to “not at all confident” and 100% with “extremely confident.”  Even if you 
are not currently exercising, please try to respond to each question to the best of your 
ability, circling only ONE number.  If there are any questions that make you 
uncomfortable answering, you may skip them.  Incomplete questionnaires will still be of 
use to the study. 
 
If you are uncertain about any of the questions, please do not hesitate to contact either 
Jena Buchan (3138 5677 or 0421 486 874) or Dr Sandi Hayes (3138 9645).  You will 
not be required to provide any personal details during this call. 
 
Thank you for the taking the time to help us in our research endeavours relating to 
lymphoedema following cancer treatment. 
 
 
 ( (
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Before you start, please write today’s date:  _____  /  ______ /  ______ 
   
1 Age:   
 ___________ years  
   
2 Are you: 
 Female  Male  
   
3 Current marital status:    
 Married  Divorced  Widowed  
 Single  Partner   
     
4 Do you have children?    
  Yes  If yes, continue below 
  No  If no, go to question 5 
   
 How many children are younger than 5 years?    
 
 How many children are aged between 5 and 14 
years?   
 
  
 How many children are older than 14 years?    
   
 How many children, of any age, are living in 
your care?   
 
   
5 Currently, what is your main work arrangement? (please tick one box) 
 Employed/Self-employed – full-time  
 Employed/Self-employed – part-time  
 Employed/Self-employed – casual  
 Full-time home duties  
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 Student  
 Unemployed or looking for work  
 Retired  
 Permanently ill/unable to work  
 Unpaid work in a family business or farm  
 Unpaid voluntary worker  
 Other (please specify)  _______________________________________  
   
6 What side do you consider your dominant side (usually the hand that you write with)? 
 Right  Left  Both   
7 Please complete the following table regarding your lymphoedema: 
 Where? 
(mark with 
an ‘x’ all 
that apply) 
When were you 
diagnosed? (approx. 
# of months / years 
after cancer 
treatment) 
Who diagnosed you?  
(physiotherapist, surgeon, 
GP, massage therapist, 
self, other) 
right arm    
right hand    
right 
breast 
   
right trunk    
right leg    
right foot    
left arm    
left hand    
left breast    
left trunk    
left leg    
left foot    
groin area    
head/neck    
Other 
(list) 
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8 
 
What kind of cancer were you diagnosed with?  
 Breast  Cervix  
 Prostate  Vulva  
 Uterus  Bowel  
 Ovary  Melanoma  
 Other (please 
specify) 
  
_________________________ 
 
 
9 When were you first diagnosed with cancer?      
 
_______  /  _______  /  __________ 
 
 
10 What treatment have you had for your cancer? 
   
Yes No 
Don’t 
know 
 Surgery      
 Chemotherapy     
 Radiation therapy     
 Hormone therapy     
 Other (please specify) 
_______________________ 
 
   
 
 
11 Please complete the following table providing information about your current experience of the following lymphoedema-related symptoms. 
 
Very 
little/ 
Little 
Somewhat/ 
Moderately 
Quite a 
lot/ 
Very 
much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
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Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
      
Tingling (pins & 
needles) 
   Not applicable  
      
Pain    Not applicable  
      
Limited range of 
movement 
   Not applicable  
(
The next questions are about any physical activities that you may have done in 
the last week:(
 
1. In the last week, how many times have you walked 
continuously, for at least 10 minutes, for recreation, exercise 
or to get to or from places? 
 
times 
    
2. What do you estimate was the total time that you spent walking in this way 
in the last week? 
 In hours and/or minutes:    
 
   minutes 
  
 
  hours 
  
      
3. In the last week, how many times did you do any vigorous 
gardening or heavy work around the yard, which made you 
breathe harder or puff and pant? 
 
times 
    
4. What do you estimate was the total time that you spent doing vigorous 
gardening or heavy work around the yard in the last week? 
 In hours and/or minutes:    
 
   minutes 
  
 
  hours 
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The next questions exclude household chores, gardening or yardwork: 
 
5. In the last week, how many times did you do any vigorous 
physical activity which made you breathe harder or puff and 
pant? (e.g. jogging, cycling, aerobics, competitive tennis) 
 
times 
    
6. What do you estimate was the total time that you spent doing this vigorous 
physical activity in the last week? 
 In hours and/or minutes:    
 
   minutes 
  
 
  hours 
  
      
7. In the last week, how many times did you do any other more 
moderate physical activities that you have not already 
mentioned? (e.g. gentle swimming, social tennis, golf) 
 
times 
    
8. What do you estimate was the total time that you spent doing these 
activities in the last week? 
 In hours and/or minutes:    
 
   minutes 
  
 
  hours 
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Using the scale from 0-100%, indicate how confident you are that you could exercise in each of the following situations.  Even if you are 
not currently exercising, please read and respond to each question by circling one number for each situation. 
**Please note, “affected”=body segment(s) with lymphoedema 
Not at all 
Confident 
Slightly 
Confident 
Moderately Confident Very  
Confident 
Extremely  
Confident 
When I am worried about my 
appearance. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment feels heavy. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is painful. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is numb or tingling. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is swollen. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I fear making my 
lymphoedema worse. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am unsure what 
exercise advice to follow. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not certain if I am 
doing an exercise correctly. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am lifting/moving 
heavy objects a few times. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am lifting/moving 
light objects repetitively. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 
!
!
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 Using the scale from 0-100%, indicate how confident you are that you could exercise in each of the following situations.  Even if 
you are not currently exercising, please read and respond to each question by circling one number for each situation 
Not at all 
Confident 
Slightly 
Confident 
Moderately Confident Very  
Confident 
Extremely  
Confident 
When I lack the discipline to 
exercise. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am nauseated. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When exercise is not a 
priority. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When the weather is bad. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am tired. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not interested in 
exercising. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I lack time. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I do not enjoy 
exercising. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I do not have 
someone to encourage me 
to exercise. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
!
!
!
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!
!
!
!
All!data!collected!from!this!questionnaire!will!remain!confidential!and!
anonymous.!!However,!should!you!wish!to!receive!information!on!additional!
studies!at!QUT!that!you!may!be!eligible!for,!you!have!the!option!of!surrendering!
your!anonymous!status!and!providing!us!with!contact!details.!!Please!note!only!
the!lead!researcher!will!be!aware!of!your!identity.!!Any!publications!that!may!
result!from!this!study!will!maintain!your!results!as!anonymous!to!protect!your!
confidentiality.!!!
!
Should!you!wish!to!receive!information!about!additional!studies,!please!provide!
us!with!one!of!the!following!to!contact!you:!
!
Email:___________________________________!
!
Name!and!mailing!address:__________________!
!
___________________________________________!
!
___________________________________________!
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APPENDIX 3: STUDY ONE FEEDBACK 
SURVEY 
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!
!
!
!
!
!
!
Dear!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!
Thank!you!for!your!recent!participation!in!the!research!project!currently!being!undertaken!at!
the!Queensland!University!of!Technology,!entitled:!“Examining!barriers!to!exercise!in!people!
with!secondary!lymphoedema!following!cancer!treatment.”!!I!am!in!the!process!of!analysing!
the!information!you!and!others!have!provided!and!will!present!this!information!at!the!
Australasian!Lymphology!Association!Conference!in!May.!!!
!
I!am!hoping!to!gain!participant!feedback!related!to!the!study!questionnaire!so!as!to!better!
ensure!it!adequately!presents!the!common!barriers!to!exercise!those!with!lymphoedema!may!
face.!!Please!feel!under!no!obligation!to!further!participate,!as!your!assistance!up!to!this!point!
of!the!study!has!been!highly!useful!and!appreciated.!!Should!you!wish!to!provide!feedback,!
however,!I!ask!that!you!complete!the!attached!questions!at!your!convenience.!!Feedback!
provided!will!be!utilised!to!further!develop!the!questionnaire!to!ensure!it!provides!relevant!
and!beneficial!information!to!healthcare!professionals.!!!!!
!
I!look!forward!to!hearing!back!from!you!and!thank!you!for!your!support!in!our!research!
endeavours!here!at!QUT.!!Have!a!wonderful!start!to!autumn!!
!
Kind!regards,!
Jena!Buchan!
PhD!Student,!School!of!Public!Health!
Queensland!University!of!Technology!
 
Phone +61 7 3138 5879  Queensland University of Technology  
Facsimile +61 7 3138 3369  IHBI, School of Public Health  
www.icanhop.com.au  Victoria Park Rd, Kelvin Grove, QLD, Australia, 4059  
 !
!
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Thank you for taking the time to provide valuable feedback related to the 
questionnaire you recently filled out.  The section of the questionnaire we are 
seeking to gain feedback on has been attached to serve as reference in assisting your 
response to the following questions. 
 1) Please(rate,(from(1/5((with(1=very(unclear(and(5=easy(to(understand),(how(informative(and(clear(you(found(the(questionnaire(instructions:(
“Using the scale from 0-100%, indicate how confident you are that you could 
exercise in each of the following situations.  Even if you are not currently 
exercising, please read and respond to each question by circling one number 
for each situation.  **Please note, ‘affected’=body segment(s) with 
lymphoedema.” 
  1-5:  _______________________ 
Suggestions for improvement: 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
__________________________________________ 
 2) Please(tell(me(what(may/does(prevent(you(from(exercising.((Feel(free(to(list(or(give(specific(examples(of(situations(or(symptoms(you(may(encounter.((The(original(scale(has(been(provided(as(a(guide,(but(do(not(feel(limited(by(this.((We(are(working(to(ensure(as(many(potential(barriers(as(possible(are(addressed(in(the(scale.(
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
________ 
 3) Are(there(other(symptoms/problems(you(face(that(may(not(personally(limit(your(exercise(participation,(but(may(be(relevant(to(others(with(lymphoedema(and(beneficial(to(include(in(this(questionnaire?((________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________(
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 4) Are(there(any(questions(that(you(feel(were(irrelevant,(repetitive(or(unrelated(to(possible(barriers(to(exercise(for(those(with(lymphoedema?((________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________((5) Do(you(feel(a(“not(applicable”(option(would(be(a(valuable(addition(to(the(scale?((_____________________________________________________________________________________(
 6) Any(other(additional(comments/suggestions?(
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______ 
 
Once again, thank you so much for your valuable time and participation in 
helping with my PhD study! 
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APPENDIX 4: PARTICIPANT 
DEMOGRAPHIC, MEDICAL AND 
LYMPHOEDEMA-RELATED 
CHARACTERISTICS 
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Variables collected 
 
1) Demographic 
a. Age 
b. Gender (male/female) 
c. Marital status (married/single/divorced/partner/widowed) 
d. Children (yes/no; number, ages, how many living in care) 
e. Employment (full-time/part-time/casual/home 
duties/student/unemployed or looking for work/retired/permanently ill 
or unable to work/unpaid work in family business or farm/unpaid 
voluntary worker/other) 
2) Medical 
a. Type of cancer 
(breast/prostate/uterus/ovary/cervix/vulva/bowel/melanoma/other) 
b. Date of diagnosis 
c. Treatment (surgery/chemotherapy/radiation therapy/hormone 
therapy/other) 
3) Lymphoedema-related 
a. Dominant side (right/left/both) 
b. Lymphoedema location 
c. Time with lymphoedema 
d. Who diagnosed lymphoedema 
e. Symptoms experienced (swelling/heaviness/tightness/aching/ 
tenderness/stiffness/weakness/numbness/tingling/pain/limited range 
of movement) 
f. Severity of symptom (very little-little/somewhat-moderate/quite a lot-
very much/not applicable) 
 
Variable re-categorisation 
 
Prior to statistical analyses, variables were re-categorised as following: 
 
• Marital status was condensed into two categories, “married/de facto” and 
“single/widowed/divorced.”   
•  Employment status was coded as “paid employment,” 
“volunteer/unemployed/unpaid work” and “retired.”  
• Information on children was categorised as “no children,” “children at 
home,” or “children living out of home/unknown ages.”  When information 
was not provided on age or location of children, they were categorised in the 
“children living out of home/unknown ages.”  
• Time living with lymphoedema was categorised as “<2 years,” “2-5 years” or 
“>5 years.”  
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• Cancer type was categorised as “breast,” “gynaecological” and “other” due to 
the spread of respondents, and in keeping with previous research that 
traditionally has focused on breast or gynaecological patients separately.   
• For reporting lymphoedema symptoms in relation to descriptive 
characteristics of respondents, the categories of “very little/little” and 
“somewhat/moderately” were combined and re-labelled “little/some” due to 
similar mean lymphoedema-specific ESE scores for most of the variables.  
For additional data analyses, variable categories were re-labelled as: “very 
little/little”= “mild,”  “somewhat/moderately”= “moderate,” and “quite a 
lot/very much”= “severe.”   
• Chemotherapy and radiation therapy were re-coded into a combined variable: 
“chemotherapy only,” “radiation only,” “both” or “neither.” 
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APPENDIX 5: THE ACTIVE AUSTRALIA 
SURVEY 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendices 163 
 
Physical activity levels 
The Active Australia survey was utilised to assess weekly physical activity 
participation.  This survey, devised by the Australian Institute of Health and Welfare 
(15), uses eight questions to assess number of sessions and time spent in various 
physical activities.  Total number of sessions and time spent engaged in activity is 
calculated and reported as “sedentary” (physical activity=0 minutes), “insufficient” 
(physical activity <150 min OR physical activity ≥ 150 min and number of sessions 
< 5) or “sufficient” (physical activity ≥150 min AND number of sessions ≥ 5).   
 
Session number is determined by adding the number of walking, moderate activity 
and vigorous activity sessions reported, not including gardening and yardwork.  Total 
activity time is calculated by adding time spent walking and undertaking moderate 
activity and twice the time spent undertaking vigorous activity, again excluding 
gardening and yardwork.  This is done as vigorous activity is of a higher intensity, 
and therefore considered to accrue greater health benefits (Armstrong et al., 2000).   
The Active Australia survey has demonstrated good test-retest reliability and validity 
(intraclass correlations=0.71-0.86; Spearman’s Rho=0.54-0.77; Kappa 
statistics=0.52) (15; 45). 
 
 
 
The AA Survey 
The next questions are about any physical activities that you may have done 
in the last week: 
 
1. In the last week, how many times have you walked 
continuously, for at least 10 minutes, for recreation, 
exercise or to get to or from places? 
 
times 
    
2. What do you estimate was the total time that you spent walking in this 
way in the last week? 
 In hours and/or minutes:    
 
   minutes 
  
 
  hours 
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3. In the last week, how many times did you do any 
vigorous gardening or heavy work around the yard, which 
made you breathe harder or puff and pant? 
 
times 
    
4. What do you estimate was the total time that you spent doing vigorous 
gardening or heavy work around the yard in the last week? 
 In hours and/or minutes:    
 
   minutes 
  
 
  hours 
  
      
The next questions exclude household chores, gardening or yardwork: 
 
5. In the last week, how many times did you do any 
vigorous physical activity which made you breathe harder 
or puff and pant? (e.g. jogging, cycling, aerobics, 
competitive tennis) 
 
times 
    
6. What do you estimate was the total time that you spent doing this 
vigorous physical activity in the last week? 
 In hours and/or minutes:    
 
   minutes 
  
 
  hours 
  
      
7. In the last week, how many times did you do any other 
more moderate physical activities that you have not 
already mentioned? (e.g. gentle swimming, social tennis, 
golf) 
 
times 
    
8. What do you estimate was the total time that you spent doing these 
activities in the last week? 
 In hours and/or minutes:    
 
   minutes 
  
 
  hours 
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APPENDIX 6: EXERCISE BARRIERS SELF-
EFFICACY SCALES (GENERAL BARRIERS, 
ORIGINAL LYMPHOEDEMA-SPECIFIC, 
FINAL COMBINED SCALE) 
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 Using the scale from 0-100%, indicate how confident you are that you could exercise 
in each of the following situations.  Even if you are not currently exercising, please 
read and respond to each question by circling one number for each situation 
Not at all 
Confident 
Slightly 
Confident 
Moderately Confident Very  
Confident 
Extremely  
Confident 
When I lack the discipline 
to exercise. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am nauseated. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When exercise is not a 
priority. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When the weather is bad. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am tired. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not interested 
in exercising. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I lack time. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I do not enjoy 
exercising. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I do not have 
someone to encourage 
me to exercise. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 
 
  
Appendices 167 
Using the scale from 0-100%, indicate how confident you are that you could exercise  
in each of the following situations.  Even if you are not currently exercising,  
please read and respond to each question by circling one number for each situation. 
**Please note, “affected”=body segment(s) with lymphoedema 
Not at all 
Confident 
Slightly Confident Moderately Confident Very  
Confident 
Extremely  
Confident 
When I am worried about my 
appearance. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment feels heavy. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is painful. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is numb or tingling. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body 
segment is swollen. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I fear making my 
lymphoedema worse. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am unsure what 
exercise advice to follow. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not certain if I am 
doing an exercise correctly. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am lifting/moving 
heavy objects a few times. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
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Using the scale from 0-100%, indicate how confident you are that you could exercise in each of the following 
situations (‘exercise’ is planned physical activity undertaken for health benefits, e.g. lifting weights, planned 
walks, swimming).  Even if not currently exercising, please read and respond to each question by circling one 
number for each situation. 
 Not at all 
Confident 
Slightly Confident Moderately Confident Very  
Confident 
Extremely  
Confident 
When I am worried about my 
appearance (e.g. due to swelling and/or 
compression garment). 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am experiencing lymphoedema-
related symptoms (e.g. pain, heaviness, 
numbness/ tingling, swelling). 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I fear making my lymphoedema 
worse. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am unsure what exercise advice 
to follow. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not certain if I am doing an 
exercise correctly. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I lack the discipline to exercise. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am nauseated. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When exercise is not a priority. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When the weather is bad. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am tired. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not interested in exercising. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I lack time. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I do not enjoy exercising. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I do not have someone to 
encourage me to exercise. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
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Demographic characteristics and exercise barriers self-efficacy  
The physical activity variable had statistically and clinically significant (7+ points) 
differences between categories for general exercise barriers self-efficacy scores.  
Specifically, individuals categorised as sedentary (31.4 [17.1, 45.7]) had lower self-
efficacy levels than those reporting insufficient (49.8 [42.9, 56.8]) and sufficient 
physical activity levels (50.0 [44.0, 52.1]; p<0.05) (Table 1).  Two variables, gender 
and children in care, had clinically significant differences between categories.  
Lower exercise barriers self-efficacy scores were observed in females (47.2 [43.2, 
51.3]) compared to males (65.0 [31.8, 98.2]), and respondents with children living at 
home (43.6 [36.4, 50.9]) compared to those with children living out of home (51.1 
[44.9, 57.3]).  However, none of these differences were supported statistically, and 
no significant differences were found for the remaining variables.  
 
Table 1 Associations between general exercise barriers self-efficacy and 
demographic characteristics (N=109) 
Variable n    mean (95% CI) p-value 
Age (years) 109           0.08 (Pearson r) 0.39 
Gender  
  Male  
  Female  
 
5 
104 
 
65.0 (31.8, 98.2) 
47.2 (43.2, 51.3) 
 
0.07 
Marital Status  
  Married/de facto 
  Single/widowed/divorced 
 
80 
29 
 
49.4 (44.9, 53.9) 
44.3 (35.3, 53.3) 
 
0.27 
Employment status 
  Paid employment 
  Unemployed/retired  
 
67 
42 
 
49.0 (44.0, 54.0) 
46.5 (39.4, 53.7) 
 
0.56 
Children in carea 
  No children 
  Children at home 
  Children living out of home 
 
22 
38 
47 
 
46.4 (38.4, 54.4) 
43.6 (36.4, 50.9) 
51.1 (44.9, 57.3) 
 
0.26 
Total physical activity1 
  Sedentary 
  Insufficient  
  Sufficient 
 
11 
37 
61 
 
31.4 (17.1, 45.7) 
49.8 (42.9, 56.8) 
50.0 (44.0, 52.1) 
 
0.02* 
*p<0.05; aN=107; CI=confidence intervals; 1sedentary (no physical activity), insufficient (< 150 min 
OR ≥ 150 min and < 5 sessions), sufficient (≥ 150 min and ≥ 5 sessions 
 
For lymphoedema-specific exercise barriers self-efficacy, a clinically significantly 
(4+ points) lower exercise barriers self-efficacy was seen in females (50.2 [45.8, 
54.7]) compared to males (62.6 [28.5, 96.7]) (Table 2).  Additionally, lower self-
efficacy was reported by individuals who were sedentary (36.0 [20.9, 51.1]) 
compared to those categorised as insufficiently (51.4 [44.5, 58.3]) or sufficiently 
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active (53.1 [47.1, 59.2]).  However, these differences were not supported 
statistically, and no significant differences were found for the remaining variables.   
 
Table 2 Associations between lymphoedema-specific exercise barriers self-efficacy 
and demographic characteristics (N=109) 
Variable n mean (95% CI) p-value 
Age (years) 109 0.032 (Pearson r) 0.74 
Gender  
  Male  
  Female  
 
5 
104 
 
62.6 (28.5, 96.7) 
50.2 (45.8, 54.7) 
 
0.24 
Marital Status  
  Married/de facto 
  Single/widowed/divorced 
 
80 
29 
 
51.8 (46.7, 56.9) 
48.1 (39.3, 56.9) 
 
0.46 
Employment status 
  Paid employment 
  Unemployed/retired 
 
67 
42 
 
50.6 (45.2, 55.9) 
51.2 (43.5, 58.9) 
 
0.89 
Children in carea 
  No children 
  Children at home 
  Children living out of home 
 
22 
38 
47 
 
49.5 (39.2, 59.8) 
49.5 (42.1, 56.9) 
51.1 (45.9, 54.5) 
 
0.94 
Total physical activity1 
  Sedentary 
  Insufficient  
  Sufficient 
 
11 
37 
61 
 
36.0 (20.9, 51.1) 
51.4 (44.5, 58.3) 
53.1 (47.1, 59.2) 
 
0.07 
aN=107; CI=confidence intervals; 1sedentary (no physical activity), insufficient (< 150 min OR ≥ 150 
min and < 5 sessions), sufficient (≥ 150 min and ≥ 5 sessions 
 
 
Medical characteristics and exercise barriers self-efficacy 
Clinically significant differences in general exercise barriers self-efficacy were 
observed for cancer type, whereby lower self-efficacy was reported by individuals 
with breast (47.3 [42.9, 51.6] and gynaecological cancers (47.5 [33.2, 61.8]), 
compared to those with ‘other’ cancer (54.5 [36.2, 76.8]), although findings were not 
supported statistically (Table 3).  No other clinically relevant or statistically 
significant associations were observed between medical variables and general 
exercise barriers self-efficacy.   
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Table 3 Associations between general exercise barriers self-efficacy and medical 
characteristics (N=109) 
Variable n mean (95% CI) p-value 
Cancer type 
  Breast  
  Gynaecological 
  Other 
 
86 
14 
9 
 
47.3 (42.9, 51.6) 
47.5 (33.2, 61.8) 
54.5 (36.2, 76.8) 
 
0.47 
Chemotherapy and Radiation Therapy 
  Chemotherapy only 
  Radiation therapy only 
  Both 
  Neither 
 
12 
12 
78 
7 
 
51.1 (37.1, 65.2) 
51.7 (34.1, 69.3) 
46.7 (42.1, 51.4) 
51.2 (34.9, 67.4) 
 
0.79 
Hormone therapy  
  Yes  
  No  
 
54 
55 
 
45.5 (40.3, 50.8) 
50.5 (44.3, 56.7) 
 
0.22 
Other treatment 
  Yes  
  No 
 
16 
93 
 
43.3 (30.2, 56.4) 
48.9 (44.6, 53.1) 
 
0.33 
CI=confidence intervals; NA=not applicable  
 
For lymphoedema-specific self-efficacy, lower scores were reported by those with 
gynaecological cancer (40.0 [27.6, 52.4]) compared to breast (52.7 [47.9, 57.5]) and 
‘other’ cancers (49.7 [27.8, 71.6]), and those who did not receive chemotherapy or 
radiation (48.6 [27.0, 72.0]) compared to those receiving only chemotherapy (53.8 
[38.0, 69.7]) (Table 4).  Self-efficacy was also clinically lower in individuals 
receiving ‘other’ treatment (45.4 [32.1, 58.6]) compared to participants who did not 
(51.8 [45.1, 56.4]).  However, none of these associations were supported statistically.   
 
Table 4 Associations between lymphoedema-specific exercise barriers self-efficacy 
and medical characteristics (N=109) 
Variable n mean (95% CI) p-value 
Cancer type 
  Breast  
  Gynaecological 
  Other 
 
86 
14 
9 
 
52.7 (47.9, 57.5) 
40.0 (27.6, 52.4) 
49.7 (27.8, 71.6) 
 
0.157 
Surgery  
  Yes  
  No 
 
108 
1 
 
50.7 (46.3, 55.1) 
67.0 (NA) 
 
NA 
Chemotherapy and Radiation Therapy 
  Chemotherapy only 
  Radiation therapy only 
  Both 
  Neither 
 
12 
12 
78 
7 
 
53.8 (38.0, 69.7) 
51.7 (31.5, 72.0) 
50.4 (46.5, 55.2) 
48.6 (27.0, 70.2) 
 
0.958 
Hormone therapy  
  Yes  
  No  
 
54 
55 
 
49.2 (43.4, 55.0) 
52.4 (45.7, 59.1) 
 
0.472 
Other treatment 
  Yes  
  No 
 
16 
93 
 
45.4 (32.1, 58.6) 
51.8 (47.1, 56.4) 
 
0.308 
CI=confidence intervals; NA=not applicable 
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Lymphoedema-related characteristics and exercise barriers self-efficacy 
Clinically and statistically significant differences were observed in general exercise 
barriers self-efficacy related to number and severity of symptoms.  Lower self-
efficacy was observed in participants with 5 or more symptoms (43.3 [38.3, 48.3]) 
compared to those with 3 to 4 symptoms (53.7 [45.3, 62.0]) and 1 to 2 symptoms 
(61.6 [52.1, 71.1]; p<0.01) (Table 5).   Self-efficacy was also lower in individuals 
reporting severe symptoms (72.7 [35.8, 49.7]) compared to respondents with 
moderate (49.3 [44.1, 54.5]) and mild symptoms (60.4 [48.2, 72.6]; p<0.05).  No 
other clinically or statistically significant differences were observed in general 
exercise barriers self-efficacy scores. 
 
Table 5 Associations between general exercise barriers self-efficacy and 
lymphoedema-related characteristics (N=109) 
Variable n mean (95% CI) p-value 
Time with lymphoedema  
  < 2 years 
  ≥ 2 years 
 
43 
66 
 
51.0 (44.9, 57.1) 
46.1 (40.7, 51.6) 
 
0.25 
Lymphoedema location  
  Upper-body  
  Lower-body  
 
87 
22 
 
47.0 (42.7, 51.3) 
52.1 (40.9, 63.3) 
 
0.32 
Lymphoedema on dominant side  
  Yes  
  No  
 
50 
58 
 
50.3 (44.2, 56.3) 
46.1 (40.5, 51.7) 
 
0.31 
Number of symptoms 
  1-2 
  3-4 
  5+ 
 
17 
20 
72 
 
61.6 (52.1, 71.1) 
53.7 (45.3, 62.0) 
43.3 (38.3, 48.3) 
 
<0.01* 
Severity of symptoms 
  Mild 
  Moderate 
  Severe 
 
14 
51 
44 
 
60.4 (48.2, 72.6) 
49.3 (44.1, 54.5) 
42.7 (35.8, 49.7) 
 
0.02* 
*p<0.05; CI=confidence intervals; r=Pearson correlation coefficient  
 
Four variables had clinically significant differences in lymphoedema-specific 
exercise barriers self-efficacy scores: time with lymphoedema, lymphoedema 
location, number of symptoms and severity of symptoms.  Having lymphoedema for 
over 5 years (46.8 [35.6, 57.9]) was associated with lower self-efficacy compared to 
having it for 2 to 5 years (51.9 [44.9, 58.9]) or less than 2 years (51.9 [45.1, 58.6]) 
(Table 6).  Lower-body lymphoedema was associated with lower self-efficacy 
compared to upper-body lymphoedema (44.7 [33.9, 55.6] versus 52.4 [47.6, 57.1], 
respectively).  Self-efficacy was also lower in individuals with 5 or more symptoms 
(47.2 [42.3, 52.2]) versus those with 1 to 2 (58.6 [46.6, 70.7]) and 3 to 4 symptoms 
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(57.0 [44.2, 69.8]), and in individuals with severe (49.1 [41.9, 56.3]) and moderate 
symptoms (49.7 [43.4, 56.0]) compared to participants with mild symptoms (60.4 
[47.6, 73.1]).  None of these differences were statistically significant, and no other 
clinically or statistically significant differences were observed in the remaining 
variables.  
 
Table 6 Associations between lymphoedema-specific exercise barriers self-efficacy 
and lymphoedema-related variables (N=109) 
Variable n mean (95% CI) p-value 
Time with lymphoedema  
  < 2 years 
  ≥ 2 years 
 
43 
66 
 
51.9 (45.1, 58.6) 
50.1 (44.3, 56.0) 
 
0.70 
Lymphoedema location  
  Upper-body  
  Lower-body  
 
87 
22 
 
52.4 (47.6, 57.1) 
44.7 (33.9, 55.6) 
 
0.17 
Lymphoedema on dominant side  
  Yes  
  No  
 
50 
58 
 
51.3 (45.2, 57.4) 
50.4 (44.0, 56.9) 
 
0.85 
Number of symptoms 
  1-2 
  3-4 
  5+ 
 
17 
20 
72 
 
58.6 (46.6, 70.7) 
57.0 (44.2, 69.8) 
47.2 (42.3, 52.2) 
 
0.07 
Severity of symptoms 
  Mild 
  Moderate 
  Severe 
 
14 
51 
44 
 
60.4 (47.6, 73.1) 
49.7 (43.4, 56.0) 
49.1 (41.9, 56.3) 
 
0.25 
*p<0.05; CI=confidence intervals; r=Pearson correlation coefficient 
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Abstract 
Background 
No tool exists to measure self-efficacy for overcoming lymphedema-related exercise 
barriers in individuals with cancer-related lymphedema. However, an existing scale 
measures confidence to overcome general exercise barriers in cancer survivors. 
Therefore, the purpose of this study was to develop, validate and assess the reliability 
of a subscale, to be used in conjunction with the general barriers scale, for 
determining exercise barriers self-efficacy in individuals facing lymphedema-related 
exercise barriers. 
Methods 
A lymphedema-specific exercise barriers self-efficacy subscale was developed and 
validated using a cohort of 106 cancer survivors with cancer-related lymphedema, 
from Brisbane, Australia. An initial ten-item lymphedema-specific barrier subscale 
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was developed and tested, with participant feedback and principal components 
analysis results used to guide development of the final version. Validity and test-
retest reliability analyses were conducted on the final subscale. 
Results 
The final lymphedema-specific subscale contained five items. Principal components 
analysis revealed these items loaded highly (>0.75) on a separate factor when tested 
with a well-established nine-item general barriers scale. The final five-item subscale 
demonstrated good construct and criterion validity, high internal consistency 
(Cronbach’s alpha = 0.93) and test-retest reliability (ICC = 0.67, p < 0.01). 
Conclusions 
A valid and reliable lymphedema-specific subscale has been developed to assess 
exercise barriers self-efficacy in individuals with cancer-related lymphedema. This 
scale can be used in conjunction with an existing general exercise barriers scale to 
enhance exercise adherence in this understudied patient group. 
Keywords 
Lymphedema, Self-efficacy, Barriers, Cancer, Exercise, Physical activity 
Background 
Cancer-related lymphedema is reported as one of the most feared and problematic 
cancer survivorship concerns [1,2]. A potentially chronic condition, it typically 
presents as swelling in the limbs, trunk, head, neck or groin, depending on the cancer 
type. Lymphedema following breast cancer occurs in approximately 20% of women 
within 18 months of treatment [3], with additional new cases presenting beyond this 
period [2,4]. While incidence rates for lymphedema in other cancers are limited, a 
meta-analysis found that, overall, approximately 15% of those with melanoma, 
sarcoma, genitourinary, gynecological or head/neck cancer subsequently developed 
cancer-related lymphedema [5]. 
Participating in regular exercise during and following cancer treatment is considered 
effective for counteracting treatment-related morbidity, improving function and 
quality of life, and possibly improving cancer-specific and overall survival [6-9]. 
Exercise may also help manage lymphedema, but research is predominately limited 
to breast cancer-related lymphedema [10]. However, despite growing evidence on 
the importance of engaging in exercise post-cancer, findings from breast cancer 
studies suggest that approximately 55% do not engage in nationally recommended 
levels of physical activity [11,12], and nearly 60% report declines in physical activity 
following their cancer diagnosis [13]. Further, the proportion of women engaging in 
sufficient levels of physical activity is even lower for women who have lymphedema 
[14,15]. Yet, participation in physical activity has been associated with less 
exacerbation of lymphedema-related symptoms in breast cancer survivors [16]. 
Understanding exercise barriers and self-efficacy for individuals with cancer-related 
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lymphedema will aid international physical activity behaviour change strategies post-
cancer diagnosis. Moreover, this information can be used to enhance adherence in 
the exercise and cancer efficacy trials needed in those cancer types for which less is 
known about the effects of exercise on lymphedema (e.g., gynaecologic, head and 
neck). 
Exercise barriers self-efficacy is a term used to describe the confidence to overcome 
barriers and partake in exercise [17], with higher physical activity levels observed in 
individuals reporting greater self-efficacy to overcome such barriers [18-20]. 
Common general exercise barriers identified by healthy and clinical populations 
include time, motivation, social support and weather [17,21-24]. These common 
barriers may be even greater for cancer survivors due to potentially increased time 
pressures created by cancer-related medical appointments and treatment requirements 
[25]. However, cancer survivors also encounter unique barriers to exercise that arise 
as a consequence of their cancer and its treatment. These may include the presence of 
treatment-related side effects such as nausea or fatigue, reduced functional capacity 
or uncertainty about what exercise is safe [15,24,26]. Lymphedema-related barriers, 
such as the presence of swelling, pain and altered sensation in the affected body area, 
as well as feelings of fear and uncertainty about making the lymphedema worse, may 
also exist [15,27,28]. While a scale exists measuring the impact of general barriers 
on exercise barriers self-efficacy, there is no current tool including lymphedema-
related exercise barriers. Therefore, the purpose of this study was to develop, validate 
and assess the reliability of a lymphedema-specific subscale for measuring exercise 
barriers self-efficacy in individuals with cancer-related lymphedema. 
Methods 
Ethical approval for this study was obtained from the Queensland University of 
Technology Research Ethics Unit, Brisbane, Australia (Approval # 1100001471). 
This research has been performed in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki. 
Scale development 
A convenience sample of men and women with cancer-related lymphedema was 
recruited through a local private physiotherapy practice specializing in treatment of 
lymphedema. Eligibility criteria included a diagnosis of secondary lymphedema due 
to cancer treatment. Eligible clinic patients were mailed a study information letter 
and questionnaire by clinic staff to ensure researcher blinding and patient 
confidentiality. Invited patients were informed that participation was voluntary and 
could not be tracked, and consent was implied by return of the questionnaire in the 
provided reply-paid envelope. Participants were also given the opportunity to provide 
details if they wished to be contacted about providing scale feedback and other future 
research. A follow-up letter and additional copy of the questionnaire was sent out 
approximately one month after the initial mailing to maximise response rate. 
Initially, ten lymphedema-specific barriers were included. These barriers were 
identified following review of qualitative and quantitative exercise and lymphedema 
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research [10,27,29-33], and consultation with experts (i.e., allied health professionals 
and researchers experienced in exercise and lymphedema; backgrounds in exercise 
science, psychology, lymphedema management, cancer survivorship and 
physiotherapy). The barrier identification process highlighted that individuals with 
cancer-related lymphedema face condition-related barriers, as well as general 
exercise barriers. Therefore, the lymphedema-specific items were designed to be 
used as a subscale for a previously validated nine-item exercise barriers self-efficacy 
scale assessing general barriers (internal consistency, Cronbach’s alpha = 0.95; test-
retest reliability, r = 0.89, p < 0.001) [17], which was also included in the survey. 
The format of the ten-item lymphedema-specific subscale followed the same format 
as this pre-existing general self-efficacy validated scale [17]. Therefore, participants 
were asked to indicate their confidence to overcome barriers (nine general and ten 
lymphedema-specific) on a scale ranging from 0% (not at all confident) to 100% 
(extremely confident), with 10% intervals. As is standard procedure for the general 
self-efficacy scale, responses were then categorised as 0-20% = not at all confident; 
20-40% = slightly confident; 40-60% = moderately confident; 60-80% = very 
confident; 80-100% = extremely confident. Additionally, a follow-up survey mail-
out was done to participants that provided contact details expressing interest in future 
research participation, enabling participants to provide feedback on scale structure 
and whether there were any relevant barriers missed. 
Scale refinement 
Construct validity of the ten-item lymphedema-related subscale was assessed by 
measuring its correlation with the pre-existing general barriers scale [17]. A principal 
components analysis was done to determine if all ten items loaded on a single factor. 
Data from validity testing and factor analysis were then used, in conjunction with 
participant feedback, to help determine which items to include in the final subscale. 
Testing of final scale 
Once revised, validity and reliability testing was completed on the revised 
lymphedema-specific subscale using a different convenience sample of women with 
stable, unilateral breast cancer-related lymphedema. These participants were women 
who had partaken in previous research studies conducted by study investigators, and 
who had notified us that they were interested in participating in future research. 
Participants completed the final scale on two occasions, with a two-week interval 
before repeat assessment. To conduct validity testing, three additional self-report 
questionnaires were completed, on quality of life, upper-body function and physical 
activity levels. Quality of life was measured using Functional Assessment of Cancer 
Therapy-Breast + 4 (FACT-B + 4). This scale, designed specifically for breast cancer 
patients, has been shown to have sufficient test-retest reliability (r = 0.97) and good 
internal consistency (alpha coefficient = 0.62 to 0.88) [34]. Upper-body function was 
assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) 
questionnaire, a validated tool that measures the impact of upper-limb limitations on 
daily life (alpha = 0.96) [35]. The Active Australia survey was used to assess weekly 
physical activity participation. Total number of sessions and time spent engaged in 
activity is calculated and reported as “sedentary” (physical activity = 0 minutes), 
“insufficient” (physical activity < 150 min OR physical activity ≥ 150 min and 
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number of sessions < 5) or “sufficient” (physical activity ≥ 150 min AND number of 
sessions ≥ 5). The Active Australia survey has demonstrated good test-retest 
reliability and validity (intra-class correlations = 0.71-0.86; Spearman’s Rho = 0.54-
0.77; Kappa statistics = 0.52) [36,37]. 
Statistical analysis 
Frequencies were run for all items on the original and final version of the 
lymphedema-specific subscale, to check for any invalid values and potential outliers. 
As is standard procedure for the general exercise barriers self-efficacy scale [38], if 
participants missed individual items, and as long as responses for less than 33% of 
items were missing, the mean of remaining items was imputed to allow calculation of 
the total scale score. When participants missed more than 33% of items, their data 
were excluded from analysis. 
Principal components analysis with direct oblimin rotation was completed for final 
subscale analyses. To validate the subscale, we correlated scores from the 
lymphedema-specific subscale with the ten-item general barriers scale. Correlations 
were also calculated between the lymphedema-specific subscale and quality of life 
(FACT-B + 4;) and upper-body function (DASH) (construct [discriminant] validity) 
scores, as well as physical activity levels (criterion validity; one-way ANOVA). We 
expected low correlations between the scale and quality of life and upper-body 
function, given the differences in these constructs. However, higher self-efficacy 
levels were expected in participants reporting higher physical activity levels. The 
internal consistency (i.e., Cronbach’s coefficient alpha) and test-retest reliability 
statistics (i.e., intraclass correlation coefficients [ICC] and paired-sample t-tests) 
were also calculated. Intraclass correlation coefficients were used to determine how 
well repeated measurements resembled one another (i.e., how consistent participants 
were in responding), and paired-sample t-tests were used to examine if changes in 
response were statistically significant from initial to repeat assessment for any item. 
Results 
Participant characteristics 
Responses from 68 (64%) of the original sample were received, with their data being 
used for psychometric assessment of the original lymphedema-specific subscale (ten 
items), while 38 participants (93% of the second sample) provided data for 
psychometric testing (five items) of the revised subscale. The data and feedback 
collection processes are outlined in Figure 1. 
Figure 1 Participant response flow. 
Table 1 presents an overview of participant demographic and medical characteristics 
of the two convenience samples. Briefly, sample one and two were similar in age 
(mean [95%CI]: 59.6 [57.1,62.1] and 56.3 [53.1,59.5] years, respectively) and the 
majority were employed (64.7% and 57.9%, respectively) and lived with a partner 
(married, de facto or serious partner; 77.9% and 63.2%, respectively). The majority 
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of respondents reported participating in some weekly physical activity (91.2% and 
86.8%, respectively). Key differences between samples were that all individuals from 
the second sample had lymphedema following breast cancer, compared with only 
66% of those in the first sample. Further, compared with sample two, more 
respondents in sample one had lymphedema for longer than five years (sample one: 
25%; sample two: 13%). 
Table 1 Descriptive characteristics of participants 
Variable Original scale sample Final scale sample 
(N = 68) (N = 38) 
n (%) n (%) 
Age (year) 
Age, mean (95% CI) 59.6 (57.1,62.1) 56.3 (53.1,59.5) 
Gender 
Male 5 (7.4) 0 (0) 
Female 63 (92.6) 38 (100) 
Marital Status 
Married/de facto 53 (77.9) 24 (63.2) 
Single/widowed/divorced 15 (22.1) 14 (36.8) 
Employment status 
Paid employment 44 (64.7) 22 (57.9) 
Unemployed/retired/unpaid work 24 (35.3) 16 (42.1) 
Total physical activitya 
Sedentary 6 (8.8) 5 (13.2) 
Insufficient 21 (30.9) 13 (34.2) 
Sufficient 41 (60.3) 20 (52.6) 
Cancer 
Breast 45 (66.2) 38 (100) 
Gynaecological 14 (20.6) 0 (0) 
Other (skin, bowel, prostate) 9 (13.2) 0 (0) 
Duration with lymphedema 
<2 years 26 (38.2) 16 (42.1) 
2-5 years 25 (36.8) 17 (44.7) 
>5 years 17 (25.0) 5 (13.2) 
CI = confidence intervals; min = minutes. 
asedentary = no weekly physical activity; insufficient = < 150 min OR ≥ 150 min and < 5 sessions per week; 
sufficient = ≥ 150 min and ≥ 5 sessions per week. 
Original subscale 
Results from the principal components analysis on the original ten-item 
lymphedema-specific subscale (Table 2) suggested items loaded on two factors, 
which accounted for 73.5% of the total variance. Eight items loaded well on the first 
factor (0.67 to 0.88), and two items (“when I am lifting/moving heavy objects a few 
times” and “when I am lifting/moving light objects repetitively”) loaded on the 
second factor (0.90 and 0.95). Scores on the general and lymphedema-specific scales 
were strongly correlated, indicating good construct validity (Pearson’s r = 0.72, p < 
0.01). 
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Table 2 Original lymphedema-specific exercise barriers self-efficacy subscale 
Using the scale from 0-100%, indicate how confident you are that you could exercise in each of the following situations. Even if you are not currently exercising, please 
read and respond to each question by circling one number for each situation. 
 Not at all Confident Slightly Confident Moderately Confident Very Confident Extremely 
Confident 
When I am worried about my appearance. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body segment feels heavy. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body segment is painful. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When my affected body segment is numb or tingling. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I fear making my lymphoedema worse. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am unsure what exercise advice to follow. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not certain if I am doing an exercise correctly. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am lifting/moving heavy objects a few times. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am lifting/moving light objects repetitively. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
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Twenty-one respondents (20%) from sample one provided feedback on the subscale 
and suggested inclusion of items that dealt with lack of time and/or motivation, work 
and family commitments, exacerbation of lymphedema symptoms, embarrassment, 
pain, lack of confidence, and limited advice following treatment. Since most of these 
suggestions are already covered by the general self-efficacy scale, it highlighted the 
necessity for concurrent assessment of general and lymphedema-specific exercise 
barriers self-efficacy. Respondents also suggested clarifying the question on 
embarrassment about appearance (whether this was lymphedema-related or general, 
due to for example obesity or being unfit) and suggested defining the term ‘exercise’, 
which is used in the questionnaire instructions. Of note, 4 of the 21 respondents 
providing feedback had a cancer type other than breast (i.e., gynecological, bowel) 
with suggestions for additional barriers being similar for breast and non-breast cancer 
survivors. 
Final subscale 
By considering results from the factor analysis and participant feedback, the original 
ten items in the lymphedema-specific subscale were reduced to a five-item subscale 
(Table 3) to be used in conjunction with the nine-item general exercise barriers self-
efficacy scale. Three of the five items reflect original, unchanged items: “when I fear 
making my lymphedema worse,” “when I am not certain I am doing an exercise 
correctly,” and “when I am unsure what exercise advice to follow.” In line with 
participant feedback, the appearance barrier question was reworded to clarify that it 
was related to worry regarding swelling and compression garment use (“when I am 
worried about my appearance [e.g., due to swelling and/or compression garment]”) 
and the four original items about side-effects as a barrier (heaviness, swelling, 
numbness/tingling and pain) were collapsed into a single item. The two items loading 
on a separate factor in the original subscale principal components analysis were 
removed (Table 4), also guided by participant feedback suggesting these items were 
only relevant in certain situations (i.e., during resistance-based exercise). 
Table 3 Final lymphedema-specific exercise barriers self-efficacy subscale 
Using the scale from 0-100%, indicate how confident you are that you could exercise in each of the 
following situations (‘exercise’ is planned physical activity undertaken for health benefits, e.g. lifting 
weights, planned walks, swimming). Even if not currently exercising, please read and respond to each 
question by circling one number for each situation. 
 Not at all 
Confident 
Slightly 
Confident 
Moderately 
confident 
Very 
Confident 
Extremely 
Confident 
When I am worried about my 
appearance (e.g. due to swelling and/or 
compression garment). 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am experiencing 
lymphoedema-related symptoms (e.g. 
pain, heaviness, numbness/ tingling, 
swelling). 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I fear making my lymphoedema 
worse. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am unsure what exercise 
advice to follow. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not certain if I am doing an 
exercise correctly. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
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Table 4 Paired-sample t-test values for test-retest reliability of final five-item 
lymphedema-specific subscale 
Scale Item Test-retest mean 
difference (95% CI) 
t-score p-value 
Total scale 0.79 (−5.28, 6.87) −0.266 0.792 
When I am worried about my appearance −3.75 (−10.53, 3.03) 1.129 0.268 
When I am experiencing lymphedema-related 
symptoms 
3.75 (−5.49, 12.99) −0.828 0.414 
When I fear making my lymphedema worse 2.50 (−6.84, 11.84) −0.546 0.589 
When I am unsure what exercise advise to follow 2.09 (−5.15, 9.33) −0.589 0.560 
When I am not certain if I am doing an exercise 
correctly 
−0.63 (−8.50, 7.25) 0.162 0.872 
CI = confidence intervals. 
Scale structure: Results of the principal components analysis applied to data 
collected from the second sample showed that items loaded on two significant factors 
(that is, the nine-item general exercise barriers self efficacy items loaded on factor 
one and the five items from the lymphedema-specific subscale loaded on factor two), 
and together accounted for 76.6% of the total variance. Factor loadings for the nine 
items of the general self-efficacy scale [30] and the five-item lymphedema-specific 
subscale ranged from 0.60 to 0.95 and 0.64 to 0.97, respectively. 
Validity: The final lymphedema subscale was strongly correlated with the ten-item 
general barriers scale, indicating good construct validity (Pearson’s r = 0.61, p < 
0.01). The lymphedema-specific scale was poorly associated with quality of life 
(FACT-B + 4) and upper-body function (DASH) (Pearson’s r = 0.31 and Pearson’s r 
= −0.34, respectively). Criterion validity testing showed individuals classified as 
both insufficiently active (>0 min but < 150 min OR ≥ 150 min and < 5 sessions 
weekly) and sufficiently active (≥150 min and ≥ 5 sessions weekly) had higher self-
efficacy scores (mean [SD]: 62.1 [15.7] and 56.7 [23.9], respectively) than 
individuals performing no physical activity (42.4 [30.4]), though this difference was 
not supported statistically (p = 0.24). 
Reliability: Cronbach’s alpha score of the final subscale was high (alpha = 0.93), 
indicating strong internal consistency. Participants answered the scale consistently at 
the test and re-test time-points, with their overall score of the first and second 
completion correlating highly (ICC = 0.67, p < 0.001). Test-retest correlations of 
individual items ranged from 0.44 to 0.65 (p < 0.01 for all). Paired-sample t-test 
showed no statistically significant change from initial to repeat assessment for any 
item (Table 4). 
Conclusions 
This study has led to the development of a valid and reliable exercise barriers self 
efficacy scale to assess confidence in ability to exercise when faced with barriers 
experienced by individuals with cancer-related lymphedema. This scale combines ten 
general exercise barriers, a pre-existing scale developed by Rogers and colleagues 
[17], with five lymphedema-specific barriers, a subscale developed in this study. The 
subscale correlated highly with the general self-efficacy scale, but formed a distinct 
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separate factor, indicating the importance of lymphedema-specific barriers to 
exercise. 
This study addresses a key gap in the evidence, as previously only scales that assess 
general exercise barriers in breast cancer survivors [17,39] or ‘healthy’ populations 
[40] were available. Initial validity testing conducted as part of this study is 
promising. As has been demonstrated in general [18] and cancer [41] populations 
with the general exercise barriers self-efficacy scale, participants who had lower self-
efficacy engage in less activity compared with those who report higher self-efficacy. 
Importantly, the scale does not overlap with the measurement of other constructs, 
such as quality of life and upper-body function. 
Reliability testing yielded an alpha coefficient of 0.93 for the final lymphedema-
specific subscale. This is a high value and similar to those found for other exercise 
barriers self-efficacy scales [17,39]. It may indicate that the five items within the 
lymphedema-specific scale are too similar and further items are needed that cover 
other lymphedema-related barriers not yet described, or may be a reflection of the 
homogeneity of samples in the previous, as well as our, studies. Nevertheless, 
additional barriers were not identified when feedback was obtained from the sample 
completing the original ten-item subscale. Test-retest reliability for the subscale was 
good (ICC = 0.67), with values for individual items ranging between 0.44 and 0.65. 
The overall mean differences for each item from test to retest ranged from 0.6 to 3.8 
points and all responses remained within the same category; for example participants 
were still ‘moderately confident’ on the initial and re-test scale for any given item. 
These findings are consistent with those found by Rogers and colleagues [17], in 
their validity and reliability testing of the original nine-item general barriers scale. In 
practice, these findings suggest that the total scale score is robust, but that it is not 
ideal to focus on results from any one specific item within the scale. 
It should be noted that scale construction and validity and reliability testing was 
undertaken using two, relatively small (N = 68 and N = 38), convenient and likely 
homogenous samples (66% and 100% of sample one and two respectively were 
women with breast cancer-related lymphedema and >75% of the samples had 
lymphedema for less than five years). Additionally, no data were available on non-
respondents, so it cannot be determined how representative this sample was of the 
general lymphedema population. Both sample size and homogeneity have important 
implications for results of the principal components analysis, with further testing 
warranted in a larger, more diverse population to confirm items still load on a single 
lymphedema barrier self-efficacy factor. Nonetheless, the initial subscale 
development process collected barriers reported by survivors with breast and non-
breast cancer-related lymphedema. Specifically, we were able to make use of 
qualitative data collected from focus groups and telephone interviews exploring how 
individuals with cancer-related lymphedema (16 in focus groups of 2–4 participants, 
13 completing telephone interviews) construct their experience in daily life [33]. 
Participants in this qualitative work included men and women with lymphedema 
following treatment for breast, gynecological or ‘other’ cancers. As part of this 
qualitative work, participants were questioned about potential barriers of 
participation in physical activity with issues raised incorporated into the original 
 186 Appendices 
subscale. This information was further supplemented by consultation of specialists in 
the field (dealing with patients with upper- and lower-limb lymphedema), an 
extensive literature search and incorporation of written participant feedback 
following completion of our original subscale. Our results showed, in looking at 
characteristics of participants providing feedback, there were no key differences in 
feedback received from people with breast versus other cancer-related lymphedema. 
As such, it is feasible that the lymphedema-specific barriers included are relevant to, 
and representative of the barriers faced by, individuals with lymphedema following 
cancer other than breast. 
Using the new lymphedema-specific subscale along with the existing general barriers 
self-efficacy scale by Rogers and colleagues’ [17] will allow healthcare professionals 
and patients to identify low self-efficacy for overcoming exercise barriers when 
cancer-related lymphedema is a concern. In turn, this should assist patients and their 
support team in identifying ways to overcome barriers and improve exercise uptake 
and adherence. The addition of the lymphedema-specific scale in future exercise 
interventions involving people with cancer-related lymphedema may also be useful 
to help guide individual program design. Baseline measurements of overall self-
efficacy levels at the start of an exercise intervention can be used to identify 
participants that may be at risk of poorer adherence [12,19] and to guide and 
individualize the level of support during exercise interventions or programing. 
Alternatively, researchers could assess whether baseline self-efficacy levels influence 
the effect of exercise interventions or whether participation in an exercise 
intervention has the potential to increase self-efficacy levels. In summary, this work 
extends the research in exercise barriers self-efficacy in the general cancer 
population into the understudied area of cancer-related lymphedema. In doing so, 
future research in this area could assist those with cancer-related lymphedema to 
become more confident in overcoming barriers and engaging in exercise, ultimately 
improving their physical and psychosocial well-being. 
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Table 7 Studies comparing resistance- and aerobic-based exercise in women with 
breast cancer 
Study Intervention Outcomes Limitations 
Yeun and 
Sword, 
2007 
(299) 
*N=22 post-treatment breast 
cancer survivors 
*12-week program, 3x/week 
*moderate-intensity home-
based exercise 
*UC (n=7) vs. RES (n=8) vs. 
AER (n=7) 
RES=improved 
functional capacity 
(6MWT) 
 
AER=reduced fatigue 
(Piper Fatigue Scale) 
*small-scale pilot study 
*no report on adverse 
events 
*only information on 
lymphoedema stated no 
RES participants had the 
condition at baseline   
Schwartz 
et al., 
2007 
(253) 
*N=66 breast cancer patients 
undergoing chemotherapy 
*6-month program, 4x/week 
*moderate-intensity home-
based exercise 
*UC (n=23) vs. RES (n=21) 
vs. AER (n=22) 
Both groups improved 
strength compared to UC 
 
AER=improved aerobic 
fitness and minimised 
BMD decline compared 
to RES or UC 
*36 off 66 participants 
were regular exercisers at 
baseline 
*21% of RES participants 
also reported AER 
*no report on adverse 
events 
*lymphoedema 
information only provided 
about RES group (no 
worsening) 
Courneya 
et al., 
2007 (73) 
*N=242 breast cancer patients 
undergoing chemotherapy 
*duration of chemo 
(median=17 weeks), 3x/week 
*moderate-intensity gym-
based exercise 
*UC (n=82) vs. RES (n=82) 
vs. AER (n=78) 
Both groups improved 
self-esteem, fatigue, 
anxiety, depression and 
QoL compared to UC 
 
RES=improved strength 
(vs UC and AER) and 
lean body mass (vs UC) 
 
AER=improved aerobic 
fitness (vs UC) 
 
No adverse events or 
development of 
lymphoedema 
*variation in intervention 
length 
UC=usual care; RES=resistance-based exercise; AER=aerobic-based exercise; 6MWT=6-Minute 
Walk Test; BMD=bone mineral density; QoL=quality of life 
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University Human Research Ethics Committee
HUMAN ETHICS APPROVAL CERTIFICATE
NHMRC Registered Committee Number EC00171
Date of Issue: 6/6/13 (supersedes all previously issued certificates)
Miss Jena BuchanDear
A UHREC should clearly communicate its decisions about a research proposal to the researcher and the final 
decision to approve or reject a proposal should be communicated to the researcher in writing.  This Approval 
Certificate serves as your written notice that the proposal has met the requirements of the National Statement on 
Research involving Human Participation and has been approved on that basis.  You are therefore authorised to 
commence activities as outlined in your proposal application, subject to any specific and standard conditions        
detailed in this document.
Within this Approval Certificate are:
                    * Project Details
                    * Participant Details
                    * Conditions of Approval (Specific and Standard)
Researchers should report to the UHREC, via the Research Ethics Coordinator, events that might affect continued 
ethical acceptability of the project, including, but not limited to:
(a) serious or unexpected adverse effects on participants; and
(b) proposed significant changes in the conduct, the participant profile or the risks of the 
       proposed research.
Further information regarding your ongoing obligations regarding human based research can be found via the 
Research Ethics website http://www.research.qut.edu.au/ethics/ or by contacting the Research Ethics Coordinator 
on 07 3138 2091 or ethicscontact@qut.edu.au
If any details within this Approval Certificate are incorrect please advise the Research Ethics Unit within 10 days of 
receipt of this certificate.
Project Details
Category of Approval:
Approved From: 2/05/2016
Approval Number: 1300000103
Human - Committee
Project Title:
Approved Until:2/05/2013 (subject to annual reports)
The effects of aerobic- versus resistance-based exercise on breast cancer-related 
lymphoedema
Experiment Summary: Evaluate and compare the effects of aerobic-versus resistance-based exericise to 
usual care on lymphoedema, lymphoedema-related symptoms and quality of life.
Chief Investigator: Miss Jena Buchan
Investigator Details
Other Staff/Students:
Investigator Name Type Role
A/Prof Sandi Hayes Internal Supervisor
A/Prof Monika Janda Internal Supervisor
Dr Robyn Box External Supervisor
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University Human Research Ethics Committee
HUMAN ETHICS APPROVAL CERTIFICATE
NHMRC Registered Committee Number EC00171
Date of Issue: 6/6/13 (supersedes all previously issued certificates)
Participant Details
Participants:
Approximately 60
Location/s of the Work:
IHBI, participant's home and private physiotherapy practices
Conditions of Approval
Specific Conditions of Approval:
None apply
Modifying your Ethical Clearance:
Requests for variations must be made via submission of a Request for Variation to Existing Clearance Form 
(http://www.research.qut.edu.au/ethics/forms/hum/var/var.jsp) to the Research Ethics Coordinator.  Minor changes 
will be assessed on a case by case basis.
It generally takes 7-14 days to process and notify the Chief Investigator of the outcome of a request for a variation.
Major changes, depending upon the nature of your request, may require submission of a new application.
5. Stop any involvement of any participant if continuation of the research may be harmful to that person, and 
immediately advise the Research Ethics Coordinator of this action;
6. Advise the Research Ethics Coordinator of any unforeseen development or events that might affect the 
continued ethical acceptability of the project;
7. Report on the progress of the approved project at least annually, or at intervals determined by the Committee;
8. (Where the research is publicly or privately funded) publish the results of the project is such a way to permit 
scrutiny and contribute to public knowledge; and
9. Ensure that the results of the research are made available to the participants.
Standard Conditions of Approval:
The University's standard conditions of approval require the research team to:
1. Conduct the project in accordance with University policy, NHMRC / AVCC guidelines and regulations, and the 
provisions of any relevant State / Territory or Commonwealth regulations or legislation;
2. Respond to the requests and instructions of the University Human Research Ethics Committee (UHREC); 
3. Advise the Research Ethics Coordinator immediately if any complaints are made, or expressions of concern 
are raised, in relation to the project;
4. Suspend or modify the project if the risks to participants are found to be disproportionate to the benefits, and 
immediately advise the Research Ethics Coordinator of this action;
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HUMAN ETHICS APPROVAL CERTIFICATE
NHMRC Registered Committee Number EC00171
Date of Issue: 6/6/13 (supersedes all previously issued certificates)
Audits:
All active ethical clearances are subject to random audit by the UHREC, which will include the review of the signed 
consent forms for participants, whether any modifications / variations to the project have been approved, and the 
data storage arrangements.
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Phone +61 7 3138 5677   Queensland University of Technology  
Mobile: 0421 486 874    IHBI, School of Public Health  
 Email: jena.buchan@qut.edu.au  Victoria Park Rd    
 www.icanhop.com.au  Kelvin Grove, QLD, Australia, 4059 
  !
!!Dear!potential!participant!!Researchers!at!Queensland!University!of!Technology!(QUT)!are!conducting!a!study!on!exercise!for!women!with!breast!cancer?related!lymphoedema.!!Supervised!and!progressive!exercise!is!considered!to!be!safe!and!beneficial!for!women!with!breast!cancer?related!lymphoedema.!!The!potential!benefits!include:!
• Improved!functioning!
• Decreased!lymphoedema?related!symptoms!
• Potential!decrease!of!lymphoedema!flare?ups!
• Improved!quality!of!life!!However,!we!don’t!know!whether!certain!types!of!exercise!lead!to!greater!lymphoedema?related!benefits!than!other!types.!!!Women!who!have!been!diagnosed!with!lymphoedema!in!one!arm,!who!live!in!the!Brisbane!area!and!who!have!completed!all!their!breast!cancer!treatment!are!invited!to!partake!in!a!study!that!is!designed!to!evaluate!whether!one!type!of!exercise!is!more!beneficial!for!women!with!breast!cancer?related!lymphoedema!than!other!forms.!!This!study!would!require!you!to:!
• participate!in!a!12?week!program!of!weekly!exercise!sessions!or!follow?up!phone!calls!(at!a!time!and!location!convenient!to!you),!
• attend!3!data!collection!sessions!(approximately!60!minutes!in!duration)!at!QUT’s!Kelvin!Grove!campus!at!the!start!and!end!of!the!12?week!program!and!for!a!12?week!follow?up,!and!
• complete!a!questionnaire!(approximately!30!minutes!in!duration)!at!the!start!and!end!of!the!study.!!Please!read!the!enclosed!‘Participant!Information!and!Consent!Form’!for!more!detailed!information.!!If!you!are!eligible!but!unable!or!not!interested!in!participating,!please!consider!completing!and!returning!the!blue!‘I!do!not!wish!to!participate’!form!and!short!questionnaire!at!the!end!of!this!packet.!!The!information!you!provide!here!will!help!us!to!better!understand!how!applicable!these!findings!will!be!for!all!women!with!breast!cancer?related!lymphoedema.!!!Please!do!not!hesitate!to!contact!me!using!the!details!provided!below!with!any!questions!or!concerns!you!may!have.!!Kind!regards,!!Jena!Buchan,!AEP!Chief!investigator!PhD!Student!Institute!of!Health!and!Biomedical!Innovation!&!School!of!Public!Health!and!Social!Work!
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PARTICIPANT INFORMATION 
 
Full Project Title:  The effect of aerobic- versus resistance-based exercise 
on breast cancer-related lymphoedema 
 
Principal researcher:  Ms Jena Buchan, PhD student, Institute of Health 
and Biomedical Innovation (IHBI) & School of Public Health and Social Work, 
QUT 
 
Associate researchers:  Associate Professor Sandi Hayes, IHBI & School of 
Public Health and Social Work, QUT; Associate Professor Monika Janda, 
IHBI & School of Public Health and Social Work, QUT; Dr. Robyn Box, QLD 
Lymphoedema & Breast Oncology Physiotherapy  
 
 
The Participant Information sheet is 3 pages long and has 3 additional forms 
(2 copies of each) attached: ‘consent form’, ‘revocation of consent form’ and 
‘I do not wish to take part form’. The orange-coloured forms are copies for 
you to keep, while the relevant yellow copy is to be signed and returned to 
research staff (using the reply-paid envelope enclosed).  Please make sure 
you have all the pages.  
 
1. Your Consent 
You are invited to take part in a research project.  This Participant 
Information document contains detailed information about this research 
project.  Its purpose is to explain to you as openly and clearly as possible all 
the procedures involved in this project before you decide whether or not to 
take part in it.  
 
2. Purpose and Background 
This study will evaluate and compare the effects of aerobic- versus 
resistance-based exercise to usual care on lymphoedema, lymphoedema-
related symptoms (e.g. decreased fitness, impaired functioning, changes in 
weight, strength loss), and quality of life.  Women will be asked to participate 
in a 12-week intervention (or usual care) and will be assessed pre- and post-
intervention and 12 weeks post-intervention.  Results will help us to better 
understand whether participating in certain exercise types provide greater 
lymphoedema-related benefits over other types or usual care. 
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3. Procedures 
All eligible women diagnosed with unilateral (one side only) breast cancer-
related lymphoedema and meeting study inclusion criteria are being invited to 
participate.  Agreeing to take part in the study means that you are willing to 
be randomly assigned to one of three groups, two of which will partake in a 
12-week exercise program (either aerobic- or resistance-based exercise) and 
the remaining being a usual care control group. 
 
Each participant randomly assigned to the exercise groups will work one-on-
one with the study investigator, who is an Accredited Exercise Physiologist 
(AEP) and current PhD student at QUT.  The AEP will assist participants to 
achieve optimal levels of weekly exercise while continuing their current 
lymphoedema care.  Participants will partake in weekly 50-minute personal 
training sessions at their specified location (e.g. your home) over a 12-week 
duration, twice a week during weeks 1-4 and once a week during weeks 5-
12.  They will also be asked to complete additional exercise on their own 
each week. Participation in the usual care group will involve continuing usual 
lymphoedema care and receiving a weekly phone call from the study 
investigator during the first 4 weeks, followed by fortnightly calls during the 
remaining 8 weeks.  Participants randomly assigned to this group will also 
have the option to participate in a personalised exercise program following 
the study. 
 
All participants will complete 3 data collection sessions, scheduled just prior 
to commencing the 12-week program, immediately following participation and 
at a 12-week follow-up (week 24).  During these testing sessions, 
approximately 60 minutes in duration, lymphoedema, aerobic and muscular 
fitness and body composition will be assessed.  Additionally, participants will 
be asked to complete questionnaires assessing quality of life, upper-body 
function and exercise barriers, which will take approximately 30 minutes to 
complete.  Data collection sessions will be conducted at QUT’s Kelvin Grove 
campus during times convenient to you.   
 
4. Possible Benefits 
All women will be allowed and encouraged to continue any other 
lymphoedema-related care they currently receive.  This study will in no way 
prevent you from taking part in any other activity (in addition to routine 
standard care) that you choose to participate in, which may, or may not, be 
related to recovery after breast cancer or your lymphoedema treatment.    
 
We know that regular exercise can be beneficial for your health.  However, 
we don’t know which types of exercise provide lymphoedema-related 
benefits.  We can therefore not guarantee that you will receive any benefits.  
 
5. Possible Risks 
Possible risks, side effects and discomforts include injury to muscles or 
bones. These are risks of taking part in any exercise program.  However, this 
risk is reduced as the exercise program has been specially designed and is 
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watched over by experts with experience in exercise to people treated for 
cancer. Participants will be asked to advise the researchers if any concerns 
arise, so that problems can be promptly dealt with and managed at that time. 
 
6. Privacy, Confidentiality and Disclosure of Information 
We will be asking you to provide information about your breast cancer and 
lymphoedema diagnosis and treatment and basic demographic information.  
This information will not be disclosed to anyone other than the study 
researchers and will remain confidential and anonymous.  Also, your results 
from the study will only be revealed to the researchers and yourself.  We 
intend to give you feedback on the results of the project when available.  
When the results of the study are published or presented, we will ensure that 
you will remain anonymous. 
 
7. Results of Project 
When you join this research project, you will be invited to let the researchers 
know if you are interested in hearing about the final results of the research. 
The contact details you provide at that time will be used to send a brief report 
to you if you wish. 
 
8. Further Information or Any Problems 
If you need more information or if you have any problems about this project 
(or, for example, any side effects), you can contact the researcher (Ms Jena 
Buchan, 3138 5677/ 0421 486 874; jena.buchan@qut.edu.au), her 
supervisor (Associate Professor Sandi Hayes, 3138 9645; 
sc.hayes@qut.edu.au) or your treating physiotherapist/healthcare 
professional. 
 
9. Participation is Voluntary 
Taking part in any research project is voluntary. If you do not wish to take 
part you are not obliged to. If you decide to take part and later change your 
mind, you are free to withdraw from the project at any stage.  Your decision 
to take part or not take part, or to take part and then withdraw, will not affect 
your clinical treatment, your relationship with those treating you or your 
relationship with your health practitioner.   
Before you make your decision, the researcher will be available to answer 
any questions you have about the research project. You can ask for any 
information you want.  You may also wish to discuss the project with your 
healthcare team or with a relative.  Sign the Consent Form only after you 
have had a chance to ask your questions and have received satisfactory 
answers.  If you decide to withdraw from this project, please notify the 
researcher.  
 
10. Ethical Guidelines and other issues 
This project will be carried out according to the National Statement on Ethical 
Conduct in Research Involving Humans (June 1999) produced by the 
National Health and Medical Research Council of Australia. This statement 
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has been developed to protect the interests of people who agree to 
participate in human research studies. 
This study has been reviewed and approved by the Queensland University of 
Technology Human Research Ethics Committee.   
 
Please contact the number below if you have any concerns or complaints 
about the ethical conduct of the project.  
• Queensland University of Technology: Human Research Ethics 
Committee, Research Ethics Officer, Gardens Point Campus, 
Brisbane, Qld, 4001 or telephone (07) 3138 2340; 
 
11. Reimbursement for your costs 
You will not be paid for taking part in this project.  To cut down costs 
(financial and time), the exercise sessions will be held at a convenient 
location to you.  Additionally, women assigned to the exercise groups will be 
provided with exercise equipment if needed.   
 
12. Final instructions 
If you are interested and eligible to participate, please contact the researcher 
using the information provided below, or return the ‘Expression of interest’ 
form using the enclosed reply-paid envelope and the researcher will contact 
you.  Following contact, if you are deemed eligible for participation, you will 
be asked to sign and bring the ‘Consent Form (Researcher’s copy)’ to your 
initial session.  If you do not wish to take part in this study, you do not have to 
take any further steps.  However, if you would like to provide basic 
information to help determine if differences exist between those women 
declining participation and those partaking in the study, please complete the 
‘I do not wish to participate’ form and accompanying questionnaire.  This can 
be returned using the enclosed reply-paid envelope.  
 
Researcher contact details: 
Ms Jena Buchan, AEP and PhD student, Institute of Health and Biomedical 
Innovation & School of Public Health and Social Work 
Phone: 3138 5677 
Mobile: 0421 486 874 
Email: jena.buchan@qut.edu.au                                                                    
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Consent Form 
 
Project Title: The effect of aerobic- versus resistance-based exercise 
on breast cancer-related lymphoedema 
 
I have: 
• read,&or&have&had&read&to&me,&and&I&understand&the&Participant&Information;&&&
• freely&agreed&to&participate&in&this&project&according&to&the&conditions&in&the&Participant&Information;&&
 
• had&any&questions&or&queries&answered&to&my&satisfaction&
 
• understood&that&the&project&is&for&the&purpose&of&research&and&not&for&treatment;&
 
• understood&that&the&confidentiality&of&information&will&be&maintained&and&safeguarded;&and&
 
• given&permission&for&medical&practitioners,&other&health&professionals,&and/or&treating&hospital,&to&release&information&concerning&my&disease&and&treatment&which&is&needed&for&this&trial&and&understand&that&such&information&will&remain&confidential.&
 
I will be given a copy of the Participant Information and Consent Form to keep. 
 
The researcher has agreed not to reveal my identity and personal details if 
information about this project is published or presented in any public form. 
 
Participant’s name (printed):__________ __________________ 
 
Signature: _____________________________________________     
Date: ____________________ 
 
 
Name of witness 
(printed):_______________________________________________________ 
 
Signature: _____________________________________________     
Date: ____________________ 
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‘I do not wish to participate’ Form 
 
Project Title: The effect of aerobic- versus resistance-based exercise on breast 
cancer-related lymphoedema 
 
I DO NOT wish to participate in the research project named above. 
 
I understand that this refusal WILL NOT jeopardise my relationship with 
Queensland University of Technology or my treating lymphoedema 
specialist. 
 
Participant’s name 
(printed):_________________________________________________ 
 
Signature: _____________________________________________    
 Date: ____________________ 
 
 
Please find some questions on the following pages (front and back of 
pages).  You are under no obligation to complete these questions.  
However, it would be most helpful to the researcher if you would 
complete this section so that we can compare the characteristics of those 
who decide not to take part with those who do.  This helps us understand 
how relevant our findings are to all individuals with cancer-related 
lymphoedema.  Even if you are uncomfortable answering certain 
questions, an incomplete survey will still be of use to us. 
 
Please note that these questions have been placed on separate paper from 
your name and signature.  This allows us to separate the information you 
provide from your name once the form is returned to us.  In turn, your 
confidentiality is maintained as this information becomes de-identified 
and will never be used in association with your name. 
 
 
 
If you have any questions, please contact Jena Buchan at 3138 5677 or 
jena.buchan@qut.edu.au. 
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1 What is your date of birth?                      ____ /____ / ____ 
 
      2    What is your gender? (please circle one)        FEMALE / MALE 
 
3 Where is your lymphoedema located? (please tick all that apply)  
  Right Left Both  
 Hand…………………………………………………..     
 Arm…………………...............................................     
 Breast………………...............................................     
 Upper trunk (shoulder to waist)………………..     
 Lower trunk (waist to hips).................     
 Groin (include genital region)……………………….     
 Upper leg………………………………………..…….     
 Lower leg…………………………………………..….     
 Foot…………………………………………………….     
 Other (specify): 
 
    
4 When were you diagnosed with 
lymphoedema? 
_____(month)/______(year)   
     
5 Who diagnosed you?    ________________________________   
       
  
6 
How would you best describe your lymphoedema? (please tick only 
one) 
 Single episode (had it but is now resolved)…...   
 Recurrent (comes and goes)……………………   
 Fluctuates (gets better and worse)…………….   
 Stable and persistent (almost always there)….   
 
  
7 
 
 
What treatment(s) do you routinely use to manage your lymphoedema? 
(please tick all that apply) 
 Complex physical therapy……………………………………     
 Manual lymphatic drainage (administered by professional)     
 Manual lymphatic drainage (self-massage)…..……………     
 Compression bandages………………………………………     
 Compression garment………………………………………     
 Laser 
therapy………………………………………………………… 
    
 Pneumatic pump……………………………………………..     
 
 
Other (please 
specify):__________________________________ 
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      8    Please complete the following table providing information on your current   
      experience of the following lymphoedema-related symptoms. (please tick 
      one box for each question) 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
Not 
applicable 
Swelling     
Heaviness     
Tightness     
Aching     
Tenderness     
Stiffness     
Weakness     
Numbness     
Tingling (pins & 
needles) 
    
Pain     
Limited range of 
movement 
    
 
  9 When were you diagnosed with cancer? _____/_____/_____  
 
10 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
What type of cancer were you diagnosed with? (please tick relevant 
box) 
Breast………......  Vulvar ………..  
Uterine………….  Melanoma……  
Ovarian…………  Bowel…………  
Cervical…………  Prostate…..….  
Other (specify): 
 
 
 
Please tick relevant box for each question 
 Right Left Both 
What side was your treatment for cancer?...    
What hand do you normally write with?.......    
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12 
 
 
What treatment have you had for your cancer?  
(please tick relevant box for each question) 
  Yes-
completed 
Yes-
undergoing 
No Don’t 
know 
 Surgery………….........     
 Chemotherapy….........     
 Radiation therapy…….     
 Hormone therapy (e.g. 
Tamoxifen, aromatase 
inhibitors, etc)………… 
    
 Herceptin………….......     
 Other (please specify): 
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13 
To help us understand the difficulties that individuals with different personal 
circumstances experience, we would be grateful if you could provide us with 
answers to the last few questions: 
 
What is the highest educational qualification you have completed? (Please tick 
one only) 
 Year 10 or less……………………………………......   
 Year 11………………………………………………   
 Year 12………………………………………………   
 Trade or business certificate………………………   
 Apprenticeship………………………………………...   
 Associate or undergraduate diploma……………….   
 Bachelor degree………………………………………   
 Post Graduate diploma………………………………   
 Masters degree or Doctorate……………………......   
 Other (please specify):    
          
14 Which ONE of the following best describes your current living arrangement? 
(please tick only one) 
 Living alone with no children……………………………...............   
 Single parent living with one or more children……………………   
 Single and living with friends or relatives…………………………   
 Couple (married or defacto) living with no children………………   
 Couple (married or defacto) living with one or more children…..   
      
 
Other (please specify):    
     
15 
 
 
Do you have private health insurance?  (please tick only one) 
No……………………………………...  
 Yes, hospital only…………………….  
 Yes, extras only………………………  
 Yes, hospital + extras………………..  
 
Thank you for completing this section. 
 
If you would like to be contacted for participation in future research, please 
provide us with some/all of the following information: 
 
Name:_______________________________________ 
Address:_____________________________________ 
____________________________________________ 
Email:_______________________________________ 
Phone/mobile:________________________________ 
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Revocation of Consent Form 
 
Project Title: The effect of aerobic- versus resistance-based exercise 
on breast cancer-related lymphoedema 
 
I hereby wish to WITHDRAW my consent to participate in the research 
project named above. 
 
I understand that this withdrawal WILL NOT jeopardise my relationship 
with Queensland University of Technology or my treating lymphoedema 
specialist. 
 
Participant’s name 
(printed):__________________________________________________ 
 
Signature: _____________________________________________    
Date: ____________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you have any questions, please contact Jena Buchan at 3138 5677 or jenabuchan@qut.edu.au 
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APPENDIX 12: STUDY TWO PARTICIPANT 
QUESTIONNAIRE 
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Project Title   Exercise for breast cancer-related lymphoedema 
Principal 
Researcher 
Ms Jena Buchan, Accredited Exercise Physiologist (AEP) 
and PhD Student, IHBI & School of Public Health and Social 
Work, QUT  
  
Survey Instructions: 
 
Thank you for taking the time to complete this survey.  Below is a list of 
instructions that should help make this task easier:   
 
• To reduce the time required to complete the survey, we have used 
boxes that can be marked for your answers.  Simply respond to the 
question by placing a tick in the box that corresponds to your answer.  
There are some questions which will require a short written answer, 
but these have been kept to a minimum.  The questionnaire should 
take approximately 30 minutes to complete. 
 
• Sometimes your answer to one question will allow you to skip over 
other questions.  Please read the ‘go to’ statements carefully to make 
sure that you answer all the appropriate questions.  If at any time you 
are uncertain about what to do, or cannot answer a question, just 
leave it until we talk to you and we will help you at that time.  
Otherwise, you can phone Jena on 3138 5677. 
 
• A fully completed survey will provide us with valuable information.  
However, if you are uncomfortable answering certain questions, you 
are able to skip these, and move on to the next.  An incomplete survey 
will still be of use to us. 
 
• The last part of this survey includes standardised questionnaires.  
Unfortunately, we are unable to modify the questions within these 
questionnaires.  Please follow the directions provided within each 
questionnaire.  Also, we would greatly appreciate it if you could 
answer all questions (or as many as you feel comfortable with), even 
when there may be some questions that you have previously 
answered in a different questionnaire or when you find some 
questions are not applicable to you.  Just give us the closest response 
that reflects how you are feeling.     
 
Office Use only 
ID#: 
Test phase #: 
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1 What is your date of birth?        ____ /____ / ____ 
 
2 Are you currently working? No    If no, go to question 4 
  Yes  
 
Yes, full-time….  
     Yes, part-time.….  
     Yes, casual…...  
     Yes, other …..…  
3 When were you diagnosed with breast cancer? ____/_____/_____  
   
4 What treatment have you had for your breast cancer? 
 (please tick relevant box for each question) 
 
  Yes-
completed 
Yes-
undergoing 
No Don’t know 
 Surgery………………...     
 Chemotherapy………...     
 Radiation therapy……..     
 Hormone therapy (e.g. 
Tamoxifen, aromatase 
inhibitors, etc)…..…….. 
    
 Herceptin………………     
 Other (please specify): 
 
    
 
5 
 
During any surgical procedure, were the lymph nodes under your armpit/s 
removed? (Please tick only one) 
 I did not have surgery…………………………...    
 Yes, sentinel node biopsy only…………………    
 Yes, all of them were removed…………………    
 Yes, some of them were removed………………    
 Yes, but unsure how many were removed……    
 Don’t know………………………………………    
 No……………………………………………………   
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6 Please tick relevant box for each question Right Left Both  
What hand do you normally write with?..............    
 What side was your treatment for breast cancer?     
 What side is your lymphoedema on?.................     
 
7 Where is your lymphoedema located? (please tick all that apply)  
  Right Left Both  
 Hand………………….     
 Arm…………………...     
 Breast………………...     
 Trunk…………………     
8 When were you diagnosed with 
lymphoedema? 
____(month)/_____(year)   
     
9 Who diagnosed you?  _________________________________   
       
10 How would you best describe your lymphoedema? (please tick only 
one) 
 Single episode (had it but is now resolved)..   
Recurrent (comes and goes)………………..   
Fluctuates (gets better and worse)…………   
Stable and persistent (almost always there)   
 
11 
 
What treatment(s) do you routinely use to manage your lymphoedema? 
(please tick all that apply) 
 Complex physical therapy…………………………………............     
 Manual lymphatic drainage (administered by professional)……     
 Manual lymphatic drainage (self-massage)…..…………………     
 Compression bandages………………………………………….....     
 Compression garment……………………………………………....     
 Laser therapy………………………………………………………...     
 Pneumatic pump………………………………………………….....     
 Other (please specify):_______________________________ 
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12 Please complete the following table providing information on your current  
     experience of the following lymphoedema-related symptoms. (please tick  
     one box for each question) 
  Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
Not 
applicable 
Swelling...............................     
Heaviness............................     
Tightness.............................     
Aching..................................     
Tenderness..........................     
Stiffness..............................     
Weakness............................     
Numbness..........................     
Tingling (pins & needles).....     
Pain.....................................     
Limited range of movement     
 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following question asks about your hands.  We’re interested in 
the differences you have noticed over the past 3 months. 
 
During the past three months did your right and left hands seem to 
be different sizes from one another?      No     Yes      (IF NO, 
go to question 14) 
 
 a) Which hand appeared larger, your right hand or your left 
hand?                 Right      Left     
 
 b) In what month and year did you first notice this difference in 
size? 
       Month/year     /           Don’t know/not sure         
 
 c) Did this difference in hand size appear suddenly or gradually? 
      Suddenly      Gradually      Don’t know/not sure         
Refused          
 
d) During the past three months, would you say that, on average, 
the difference in the size of your hands was: 
     Very slight; you are the only person who would notice     
  Noticeable to people who knew you well, but not to strangers   
    Very noticeable 
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14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
 
 
 e) During the past three months, did the amount of difference 
between your hands change from day to day, or was it pretty 
steady? 
               Change       Steady      
 
f) Is the one hand still larger than the other? 
 Yes (go to question 14)        No  !In what month  and year 
did your hands return to being their normal size? 
                                   Month/year     /    Don’t know  
------------------------------------------------------------------------------------------- 
The following question asks about your lower arms (from your wrist 
to your elbow).  We’re interested in the differences you have noticed 
over the past 3 months. 
 
During the past three months did your right and left lower arms 
seem to be different sizes from one another?      No     Yes      
(IF NO, go to question 15) 
 
a) Which lower arm appeared larger, your right lower arm or your left 
lower arm?                Right      Left     
 
b) In what month and year did you first notice this difference in size? 
            Month/year     /           Don’t know/not sure  
       
 
c) Did this difference in lower arm size appear suddenly or 
gradually? 
Suddenly      Gradually      Don’t know/not sure     
Refused          
 
d) During the past three months, would you say that, on average, 
the difference in the size of your lower arms was: 
      Very slight; you are the only person who would notice     
      Noticeable to people who knew you well, but not to strangers
    Very noticeable                                                                         
 
e) During the past three months, did the amount of difference 
between your lower arms change from day to day, or was it pretty 
steady?                        Change       Steady       
 
f) Is the one lower arm still larger than the other? 
Yes (go to question 15)         No  !In what month and year 
did your lower arms return to being their normal size? 
                          Month/year     /    Don’t know  
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-------------------------------------------------------------------------------------------  
The following question asks about your upper arms (from your 
elbow to your shoulder).  We’re interested in the differences you 
have noticed over the past 3 months. 
 
During the past three months did your right and left upper arms 
seem to be different sizes from one another?      No     Yes      
(IF NO, go to question 16) 
 
a) Which upper arm appeared larger, your right upper arm or your 
left upper arm?                 Right      Left     
 
b) In what month and year did you first notice this difference in size? 
            Month/year     /            Don’t know/not sure         
 
c) Did this difference in upper arm size appear suddenly or 
gradually? 
Suddenly      Gradually      Don’t know/not sure     
Refused          
 
d) During the past three months, would you say that, on average, 
the difference in the size of your upper arms was: 
     Very slight; you are the only person who would notice     
     Noticeable to people who knew you well, but not to strangers
    Very noticeable 
 
e) During the past three months, did the amount of difference 
between your upper arms change from day to day, or was it pretty 
steady?                   Change       Steady       
 
f) Is the one upper arm still larger than the other? 
Yes (go to question 16)         No   !In what month and year 
did your upper arms return to being their normal size? 
                     Month/year     /    Don’t know  
------------------------------------------------------------------------------------------- 
The following question asks about your torso.  We’re interested in 
the differences you have noticed over the past 3 months. 
 
During the past three months did your right and left sides of your 
torso seem to be different sizes from one another?      
                No     Yes      (IF NO, go to question 17) 
 
a) Which side of your torso appeared larger, the right side of your 
torso or the left side of your torso?  Right      Left     
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b) In what month and year did you first notice this difference in size? 
       Month/year     /           Don’t know/not sure         
 
c) Did this difference in torso size appear suddenly or gradually? 
Suddenly      Gradually      Don’t know/not sure     
Refused          
 
d) During the past three months, would you say that, on average, 
the difference in the size of your right and left torso was:                
    Very slight; you are the only person who would notice     
     Noticeable to people who knew you well, but not to strangers 
    Very noticeable 
 
e) During the past three months, did the amount of difference 
between your right and left sides of your torso change from day to 
day, or was it pretty steady?       Change       Steady       
 
f) Is the one side of your torso still larger than the other? 
Yes (go to question 17)         No  !In what month and year 
did the sides of your torso return to being their normal size? 
                 Month/year     /    Don’t know  
------------------------------------------------------------------------------------------- 
NOTE for Question 17 (on the following page): 
If a, b, c, or d = YES, Read: Here are some ways that people notice 
that their hands, arms, or sides of their torso are different from each 
other.  For each way that is mentioned, please fill in the circle if this 
was something you noticed during the past three months. 
 
If a, b, c, or d = NO, Read: During the past three months, did you 
notice any difference between your right and left hands or arms or 
sides of your torso in any of the following: 
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During'the'past'3'months,'did'you'notice:' Was'that'your'
right'or'left'side?'
How'often'did'this'occur'
during'the'past'3'months?'
How'severe'was'it'during'the'
past'3'months?'
How'much'did'it'distress'or'bother'
you'during'the'past'3'months?'
'
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Your'rings'got'too'tight'on'one'side'''''''''''No' ''''Yes'' '''''' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Your'watch'got'too'tight''''''''''''''''''''''''''''''No' ''''Yes'' ''''' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Your'bracelets'got'too'tight'on'one'side'''No' ''''Yes'' '''''' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Your'clothing'was'too'tight'on'one'side'''No' ''''Yes'' ''''' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
One'side'was'puffy'compared'to'the'other'
''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''No' ''''Yes'' ''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
You'couldn’t'see'the'knuckles'of'the'hand'on'one'side'
''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''No' ''''Yes'' ''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
You'couldn’t'see'the'veins'in'the'hand'on'one'side'
''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''No' ''''Yes'' ''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Your'skin'felt'different'on'one'side;'for'example,'firmer'or'
‘leathery’'or'some'other'way''''''''''''''''''''''No' ''''Yes'' ''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Your'hand'or'arm'felt'tired,'thick'or'heavy'on'one'side'
''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''No' ''''Yes'' ''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
You'had'pain'in'your'hand'or'arm'on'one'side'
''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''No' ''''Yes'' ''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
You'noticed'indentions'in'the'skin'of'your'hand'when'you'
leaned'against'something''''''''''''''''''''''''''''No' ''''Yes'' '''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
After'exercise,'your'hand'or'arm'swelled'on'one'side'
'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''No' ''''Yes'' ''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
You'had'difficulty'writing''''''''''''''''''''''''''''No' ''''Yes'' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
You'noticed'the'difference'in'some'other'way.''If'YES,'how?'
'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''No' ''''Yes'' ''''
' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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18 Have you had any of the following conditions?  If yes, please state the 
approximate date you were first diagnosed with this condition. (please tick 
all that apply) 
  
      Yes No Don’t 
know 
Date of 
diagnosis 
 Heart attack (coronary, myocardial 
infarction) 
    
 Angina pectoris………………………………     
 High blood pressure…………………………     
 High cholesterol………………………………     
 Other heart condition (specify): _________     
 Stroke…………………………………………..     
 Diabetes……………………………………….     
 Asthma…………………………………………     
 Chronic bronchitis……………………………     
 Emphysema of the lungs…………………     
 Stomach or duodenal ulcer…………………     
 Migraine headaches………………………….     
 Osteoporosis…………………………………..     
 Rheumatoid arthritis. ………………………     
 Depression…………………………………….     
 Cancer beside breast (specify): _________     
 Other prolonged serious illness (specify): 
______________________ 
    
       
       
19 Below is a list of statements that other people with your illness have said are 
important. By circling one (1) number per line, please indicate how true each 
statement has been for you during the past 7 days. 
 
 
 
PHYSICAL WELL-BEING 
Not 
at 
all 
A 
little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
 I have a lack of 
energy............................... 
0 1 2 3 4 
 I have nausea........................................... 0 1 2 3 4 
 Because of my physical condition, I have 
trouble meeting the needs of my family..... 
 
0 
 
1 
 
2 
 
3 
 
4 
 I have pain................................................. 0 1 2 3 4 
 I am bothered by side effects of treatment 0 1 2 3 4 
 I feel ill....................................................... 0 1 2 3 4 
 I am forced to spend time in bed............... 0 1 2 3 4 
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SOCIAL/FAMILY WELL-BEING 
Not 
at 
all 
A 
little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
 I feel close to my friends............................ 0 1 2 3 4 
 I get emotional support from my family..... 0 1 2 3 4 
 I get support from my friends..................... 0 1 2 3 4 
 My family has accepted my illness............ 0 1 2 3 4 
 I am satisfied with family communication 
about my illness 
0 1 2 3 4 
 I feel close to my partner (or the person 
who is my main support) ........................ 
 
0 
 
1 
 
2 
 
3 
 
4 
 Regardless of your current level of sexual activity, please answer the following question, 
using the same scale as above. If you prefer not to answer it, please check this box and go 
to the ‘Emotional Well-being’ section. 
     
 I am satisfied with my sex life……… 0 1 2 3 4 
 
 By circling one (1) number per line, please indicate how true each 
statement has been for you during the past 7 days. 
  
EMOTIONAL WELL-BEING 
Not 
at all 
A 
little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
 I feel sad...................................... 0 1 2 3 4 
 I am satisfied with how I am 
coping with my illness 
0 1 2 3 4 
 I am losing hope in the fight 
against my illness……………. 
0 1 2 3 4 
 I feel nervous................................ 0 1 2 3 4 
 I worry about dying....................... 0 1 2 3 4 
 I worry that my condition will get 
worse...................................... 
0 1 2 3 4 
  
FUNCTIONAL WELL-BEING 
     
 I am able to work (include work at 
home)................ 
0 1 2 3 4 
 My work (include work at home) 
is fulfilling............. 
0 1 2 3 4 
 I am able to enjoy life.................. 0 1 2 3 4 
 I have accepted my illness.......... 0 1 2 3 4 
 I am sleeping well........................ 0 1 2 3 4 
 I am enjoying the things I usually 
do for fun.......... 
0 1 2 3 4 
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 I am content with the quality of 
my life right now..... 
0 1 2 3 4 
  
ADDITIONAL CONCERNS 
     
 I have been short of breath....... 0 1 2 3 4 
 I am self-conscious about the 
way I dress....... 
0 1 2 3 4 
 One or both of my arms are 
swollen or tender.... 
0 1 2 3 4 
 I feel sexually attractive.............. 0 1 2 3 4 
 I am bothered by hair loss........... 0 1 2 3 4 
 I worry that other members of my 
family might someday get the 
same illness I have........... 
 
0 
 
1 
 
2 
 
3 
 
4 
 I worry about the effect of stress 
on my illness........ 
0 1 2 3 4 
 I am bothered by a change in 
weight................... 
0 1 2 3 4 
 I am able to feel like a woman...... 0 1 2 3 4 
 I have certain parts of my body 
where I experience pain……… 
 
0 
 
1 
 
2 
 
3 
 
4 
       
 On which side(s) was your breast operation?           Left          Right   
(please circle) 
 Movement of my arm on this side is 
painful............ 
0 1 2 3 4 
 I have a poor range of arm 
movement on this side. 
0 1 2 3 4 
 My arm on this side feels numb..... 0 1 2 3 4 
 I have stiffness of my arm on this 
side.................... 
0 1 2 3 4 
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20 These questions ask about your symptoms as well as your ability to 
perform certain activities.  Please answer every question, based on your 
condition during the past 7 days, by circling the appropriate number.  If you 
did not have the opportunity to perform an activity in the past week, please 
make your best estimate on which response would be the most accurate. It 
doesn’t matter which hand or arm you use to perform the activity; please 
answer based on your ability regardless of how you perform the task.  
 
 
 
 
 
 
Please rate your ability to do the following activities in the last week by 
circling the number below the appropriate response. 
 
  
  No 
difficulty 
Mild 
difficulty 
Moderate 
difficulty 
Severe 
difficulty 
Unable 
 Open a tight or new jar. 1 2 3 4 5 
 Write………………… 1 2 3 4 5 
 Turn a key………….. 1 2 3 4 5 
 Prepare a meal………. 1 2 3 4 5 
 Push open a heavy door 1 2 3 4 5 
 Place an object on a 
shelf above your head… 
 
1 
 
2 
 
3 
 
4 
 
5 
 Do heavy household 
chores (e.g. wash walls, 
wash floors)………....... 
 
1 
 
2 
 
3 
 
4 
 
5 
 Garden or do yard work 1 2 3 4 5 
 Make a bed………… 1 2 3 4 5 
 Carry a shopping bag or 
briefcase. 
1 2 3 4 5 
 Carry heavy object 
(>10lb/ 4.5kg) 
 
1 
 
2 
 
3 
 
4 
 
5 
 Change a lightbulb 
overhead 
1 2 3 4 5 
 Wash or blow dry your 
hair 
1 2 3 4 5 
 Wash your back……… 1 2 3 4 5 
 Put on a pullover 
sweater 
1 2 3 4 5 
 Use a knife to cut food 1 2 3 4 5 
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  No 
difficulty 
Mild 
difficulty 
Moderate 
difficulty 
Severe 
difficulty 
Unable 
 Recreational activities 
which require little effort 
(e.g. cardplaying, 
knitting, etc) 
 
1 
 
2 
 
3 
 
4 
 
5 
 Recreational activities in 
which you take some 
force or impact through 
your arm, shoulder or 
hand (e.g., golf, 
hammering, tennis, 
etc)… 
 
 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
 Recreational activities in 
which you move your 
arm freely (e.g., playing 
frisbee, badminton, etc) 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 Manage transportation 
needs (getting from one 
place to another) 
 
1 
 
2 
 
3 
 
4 
 
5 
 Sexual activities…… 1 2 3 4 5 
       
 During the past 7 days, to what extent has your arm, shoulder or hand 
problem interfered with your normal social activities with family, friends, 
neighbours or groups? (circle number) 
  Not at all Slightly Moderately Quite a bit Extremely 
  1 2 3 4 5 
  
 During the past 7 days, were you limited in your work or other regular daily 
activities as a result of your arm, shoulder or hand problem? (circle 
number) 
  Not limited 
at all 
Slightly 
limited 
Moderatel
y limited 
Very 
limited 
Unable 
  1 2 3 4 5 
       
 Please rate the severity of the following symptoms in the past 7 days.  
(circle number) 
  None Mild Moderate Severe Extreme 
 Arm, shoulder or hand 
pain..…… 
1 2 3 4 5 
 Arm, shoulder or hand pain 
when you performed any 
specific activity 
 
 
1 
 
2 
 
3 
 
4 
 
5 
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 Tingling (pins and needles) 
in your arm, shoulder or 
hand...…… 
 
1 
 
2 
 
3 
 
4 
 
5 
 Weakness in your arm, 
shoulder or hand…..……. 
 
1 
 
2 
 
3 
 
4 
 
5 
 Stiffness in your arm, 
shoulder or hand.……….... 
 
1 
 
2 
 
3 
 
4 
 
5 
       
 During the past 7 days, how much difficulty have you had sleeping 
because of the pain in your arm, shoulder or hand? (circle number) 
  No difficulty Mild 
difficulty 
Moderate 
difficulty 
Severe 
difficulty 
So much 
difficulty that I 
can’t sleep 
   1 2 3 4 5 
 
 
 I feel less capable, less confident or less useful because of my arm, 
shoulder or hand problem. (circle number) 
  Strongly 
disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly 
agree 
  1 2 3 4 5 
  
 
 
21 The following questions relate to the impact of your arm, shoulder or 
hand problem on playing your musical instrument or sport or both.  If 
you play more than one sport or instrument (or play both), please 
answer with respect to that activity which is most important to you.  
Please indicate the sport or instrument which is most important to you: 
 
  
 If you do not play a sport or instrument, please 
tick this box… and go to question 22 
  
 Otherwise, please continue with question 21: 
 
  
 Please circle the number that best describes your physical ability in 
the past 7 days.  
 Did you have any 
difficulty: 
No 
difficulty 
Mild 
difficulty 
Moderate 
difficulty 
Severe 
difficulty 
Unable 
       
 Using your usual 
technique for playing 
your instrument or 
sport? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
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 Playing your musical 
instrument or sport 
because of arm, 
shoulder or hand pain?  
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 Playing your musical 
instrument or sport as 
well as you like? 
 
1 
 
2 
 
3 
 
4 
 
5 
 Spending your usual 
amount of time 
practising or playing 
your instrument or 
sport?  
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
       
22 
 
 
The following questions ask about the impact of your arm, shoulder or 
hand problem on your ability to work (including homemaking if that is 
your main work role). Please indicate what your job/work 
is:_____________________________________ 
   If you do not work, please tick this box and go to question 23.  
Otherwise, please continue with question 22. 
  
 Please circle the number that best describes your physical ability in 
the past 7 days.   
  
Did you have any 
difficulty: 
No 
difficulty 
Mild 
difficulty 
Moderate 
difficulty 
Severe 
difficulty 
Unable 
       
 Using your usual 
technique for work?  
 
1 
 
2 
 
3 
 
4 
 
5 
 Doing your usual work 
because of arm, shoulder 
or hand pain?....... 
 
1 
 
2 
 
3 
 
4 
 
5 
 Doing your work as well 
as you would like? … 
 
1 
 
2 
 
3 
 
4 
 
5 
 Spending your usual 
amount of time doing your 
work? … 
 
1 
 
2 
 
3 
 
4 
 
5 
 
23 
   
 
The next questions are about any physical activities that you may 
have done in the last 7 days: 
  
  
a)  In the last 7 days, how many times have you walked 
continuously, for at least 10 minutes, for recreation, exercise or to 
get to and from places? 
 
  
     times   
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b) What do you estimate was the total time that you spent walking 
in this way in the last 7 days? 
 
  
 In hours and/or minutes     
    Minutes  
      
    Hours   
      
 c) In the last 7 days, how many times did you do any vigorous 
gardening or heavy work around the yard, which made you breathe 
harder or puff and pant?  
 
 
    Times   
 
 
 
d) What do you estimate was the total time that you spent doing 
vigorous gardening or heavy work around the yard in the last 7 
days? 
 
In hours and/or minutes 
 
  
    Minutes  
      
   Hours   
 
24 
 
The next questions exclude household chores, gardening or 
yardwork: 
 
  
 a) In the last 7 days, how many times did you do any vigorous 
physical activity which made you breathe harder or puff and pant? 
(e.g. jogging, cycling, aerobics, competitive tennis) 
 
  
    Times   
      
 b) What do you estimate was the total time that you spent doing 
vigorous physical activity in the last 7 days? 
 
In hours and/or minutes 
 
  
     Minutes   
      
   Hours   
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c) In the last 7 days, how many times did you do any other 
moderate physical activities that you have not already mentioned? 
(e.g. gentle swimming, social tennis, golf) 
 
   Times   
      
 d) What do you estimate was the total time that you spent doing 
these activities in the last 7 days? 
 
In hours and/or minutes 
 
  
    Minutes  
      
   Hours   
 
 
 
e) In the last 7 days, how many times did you do any moderate to heavy 
strength training (such as hand-held weights of more than 5 lbs/2.3 kg, 
weight machines, or push-ups)? 
   
   Times 
 
f) What do you estimate was the total time that you spent doing these 
activities in the last 7 days? 
 
In hours and/or minutes 
 
   Minutes 
   
  Hours 
 
g) In the last 7 days, how many times did you do light strength training 
(such as hand-held weights of 5 lbs/2.3 kg or less or elastic bands)? 
 
  Times 
 
h) What do you estimate was the total time that you spent doing these 
activities in the last 7 days? 
 
In hours and/or minutes 
 
   Minutes 
   
  Hours 
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25 
 
The scale on the following page asks about your confidence to perform 
exercise in a variety of situations.  Please read the instructions at the top 
of the scale and complete to the best of your ability.   
 232 Appendices 
Using the scale from 0-100%, indicate how confident you are that you could exercise in each of the following situations (‘exercise’ is planned physical activity 
undertaken for health benefits, e.g. lifting weights, planned walks, swimming).  Even if not currently exercising, please read and respond to each question by 
circling one number for each situation. 
 Not at all 
Confident 
Slightly Confident Moderately Confident Very  
Confident 
Extremely  
Confident 
When I am worried about my 
appearance (e.g. due to swelling and/or 
compression garment). 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am experiencing lymphoedema-
related symptoms (e.g. pain, heaviness, 
numbness/ tingling, swelling). 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I fear making my lymphoedema 
worse. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am unsure what exercise advice 
to follow. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not certain if I am doing an 
exercise correctly. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I lack the discipline to exercise. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am nauseated. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When exercise is not a priority. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When the weather is bad. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am tired. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I am not interested in exercising. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I lack time. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I do not enjoy exercising. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
When I do not have someone to 
encourage me to exercise. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
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26 
To help us understand the difficulties that women with different personal 
circumstances experience, we would be grateful if you could provide us 
with answers to the last few questions: 
 
What is the highest educational qualification you have completed? 
(Please tick one only) 
 Year 10 or less……………………………………......   
 Year 11………………………………………………   
 Year 12………………………………………………   
 Trade or business certificate………………………   
 Apprenticeship………………………………………...   
 Associate or undergraduate diploma……………….   
 Bachelor degree………………………………………   
 Post Graduate diploma………………………………   
 Masters degree or Doctorate……………………......   
 Other (please specify):    
    
27 Which ONE of the following best describes your current living 
arrangement? (please tick only one) 
 Living alone with no children…………………………   
 Single parent living with one or more children……   
 Single and living with friends or relatives…………..   
 Couple (married or defacto) living with no children   
 Couple (married or defacto) living with one or more 
children………………………………………………… 
  
 Other (please specify):   
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Do you have private health insurance?  (please tick 
only one) 
No……………………………………...  
 Yes, hospital only……………………  
 Yes, extras only……………………...  
 Yes, hospital + extras……………….  
 
 
Thank you for completing the survey!! 
 
 
Please bring this survey with you to your next data 
collection session. 
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APPENDIX 13: ‘WHEN NOT TO EXERCISE’ 
GUIDELINES 
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When not to exercise 
You should not take part in an exercise session if any of the following conditions are 
present: 
 
• A"temporary"minor"illness,"such"as"a"cold"or"viral"infection,"or"if"you"are"
feeling"unusually"unwell"
• Experienced"chest"pain"
• Unusual'fatigability"and/or"muscle"weakness"
• Recurring"leg"pain"or"cramps"
• Bone,"back"or"neck"pain"of"recent"origin"
• Vomited"within"the"last"24"hours"
• Feel"disoriented"or"confused"
• Feel"dizzy"or"have"blurred"vision"or"faintness"
• Sudden"onset"of"difficulty"in"breathing"
• Known"blood"counts"that"are"below"normal"
• Any"other"unusual"sensation"
 
Please record any of these occurrences in the section for that 
corresponding day (see previous page) so that follow-up can be 
undertaken if needed and we can monitor occurrences. 
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APPENDIX 14: STUDY TWO SECONDARY 
OUTCOME SAMPLE SIZE TABLES
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Table 8.  Details on studies used in sample size calculation based on body composition 
Study informationa Measurement Baseline mean (SD) Expected follow-up 
mean (MCID) 
Estimated 
sample sizeb 
Limitations as relevant to 
current study 
Courneya et al. (73) 
N=242 women undergoing 
chemotherapy for breast cancer 
 DXA 
1) %BF: 38.8 (9.0)% 
 
2) LBM: 40.8 (4.9) kg 
1) 36.8% (2 units) 
 
2) 43.2 kg (5%) 
1) 764 
 
2) 156 
Women did not have breast 
cancer-related 
lymphoedema 
 
Participants still undergoing 
chemotherapy  
Ahmed et al. (3) 
N=45 post-treatment breast cancer 
survivors with (n=13) or at risk of 
lymphoedema  
DXA 
1) %BF: 43.7 (8.5)% 
 
2) LBM: 37.9 (5.0) kg 
1) 41.7% (2 units) 
 
2) 39.8 kg (5%) 
1) 680 
 
2) 260 
Only 13 participants had 
lymphoedema 
Schmitz et al. (244) 
N=141 post-treatment breast cancer 
survivors with lymphoedema  
DXA 
1) %BF: 39.6 (5.4)% 
 
2) LBM: 49.1 (7.7) kg 
1) 37.6% (2 units) 
 
2) 51.6 kg (5%) 
1) 274 
 
2) 348 
 
Schmitz et al. (243) 
N=154 post-treatment breast cancer 
survivors at risk of lymphoedema 
DXA 
1) %BF: 39.3 (6.0)% 
 
2) LBM: 47.3 (7.3) kg 
1) 37.3% (2 units) 
 
2) 49.7 kg (5%) 
1) 336 
 
2) 348 
Participants did not have 
lymphoedema 
Turner et al. (281) 
N=10 post-treatment breast cancer 
survivors, n=2 with lymphoedema 
DXA LBM: 54.7 (7.5) kg 57.4 kg (5%) 290 
Only 2 women had 
lymphoedema 
 
aall information extracted from control group when available; bbased on 80% power, two-tailed p<0.05 with 20% attrition 
SD=standard deviation; %BF=percent body fat; LBM=lean body mass; DXA=dual energy x-ray absorptiometry; MCID=minimal clinically important difference
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Table 9. Details on studies used in sample size calculation based on upper-body and handgrip strength 
Study informationa Measurement Baseline 
mean (SD) 
Expected follow-
up mean (MCID) 
Estimated 
sample sizeb 
Limitations as relevant to current study 
Upper-body strength      
Courneya et al. (73) 
N=242 women undergoing 
chemotherapy for breast cancer 
1-RM chest 
press 22.8 (7.8) kg 26.8 (4) kg 146 
Women did not have cancer-related lymphoedema 
 
Participants still undergoing chemotherapy 
Cheema and Gaul (57) 
N=27 post-treatment breast cancer 
survivors, n=3 with lymphoedema  
1-RM chest 
press 29.8 (6.6) kg 33.8 (4) kg 104 
Only 3 women had lymphoedema 
Ahmed et al. (3) 
N=45 post-treatment breast cancer 
survivors with (n=13) or at risk of 
lymphoedema  
1-RM chest 
press 25.4 (5.9) kg 29.4 (4) kg 82 
Only 13 participants had lymphoedema 
Schmitz et al. (244) 
N=141 post-treatment breast cancer 
survivors with lymphoedema 
1-RM chest 
press 17.7 (6.6) kg 21.7 (4) kg 100 
 
Schmitz et al. (243) 
N=154 post-treatment breast cancer 
survivors at risk of lymphoedema 
1-RM chest 
press 18.6 (5.9) kg 22.6 (4) kg 82 
No participants had lymphoedema at baseline 
Lane et al. (171) 
N=16 post-treatment breast cancer 
survivors with no history of 
lymphoedema 
1-RM chest 
press 55.3 (13.6) kg 59.3 (4) kg 434 
No participants had lymphoedema at baseline 
Rajotte et al.. (223) 
N=221 post-treatment cancer 
survivors, n=2 with lymphoedema 
1-RM chest 
press 45.9 (31.9) kg 49.9 (4) kg 2388 
Not limited to breast cancer survivors 
 
Only 2 participants had lymphoedema at baseline  
Handgrip strength       
Portela et al. (222) 
N=34 post-treatment breast cancer 
survivors with no history of 
lymphoedema 
Handgrip 
dynamometer 17.1 (6.8) kg 23.6 (6.5) kg 40 
Participants did not have lymphoedema 
Culos-Reed et al. (204) 
N=38 post-treatment cancer survivors Handgrip dynamometer 30.5 (7.3) kg 37.0 (6.5) kg 48 
No mention of lymphoedema presence 
 
Not limited to breast cancer survivors 
aall information extracted from control group when available; bbased on 80% power, two-tailed p<0.05 with 20% attrition 
SD=standard deviation; MCID=minimal clinically important difference; RM=repetition maximum 
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Table 10. Details on studies used in sample size calculation  based on aerobic fitness 
Study informationa Measurement Baseline mean (SD) Expected follow-
up mean (MCID) 
Estimated 
sample sizeb 
Limitations as relevant to current study 
Anderson et al. (9) 
N=104 breast cancer survivors 
within 3 months of having 
completed surgery 
6MWT 538.0 (97.2) m 563.0 (25) m 568 
Purposely excluded women with 
lymphoedema 
 
Some participants still undergoing treatment 
Rajotte et al. (223) 
N=221 post-treatment cancer 
survivors, n=2 with lymphoedema 6MWT 444.5 (147.8) m 469.5 (25) m 1316 
Not limited to breast cancer survivors 
 
Only 2 participants had lymphoedema at 
baseline  
Culos-Reed et al. (204) 
N=38 post-treatment cancer 
survivors 6MWT 663.1 (167.8) m 688.1 (25) m 1694 
No mention of lymphoedema presence and not 
limited to breast cancer survivors 
 
Significant difference at baseline between 
control group and intervention group for 
distance walked 
aall information extracted from control group when available; bbased on 80% power, two-tailed p<0.05 with 20% attrition 
SD=standard deviation; MCID=minimal clinically important difference; 6MWT=6-minute walk test 
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Table 11. Details on studies used in sample size calculation based on self-reported upper-body functioning  
Study informationa Measurement Baseline 
mean (SD) 
Expected follow-
up mean (MCID) 
Estimated 
sample sizeb 
Limitations as relevant to current study 
Portela et al. (222) 
N=34 post-treatment breast cancer survivors 
Spanish 
version of 
DASH 
18.0 (16.1) 8.0 (10 points) 98 
Participants did not have lymphoedema at 
baseline 
Cormie et al. (64) 
N=62 post-treatment breast cancer survivors 
with lymphoedema 
DASH 16 (14) 6 (10 points) 74 
 
Jönsson and Johansson (154) 
N=35 post-treatment breast cancer survivors 
with lymphoedema 
DASH 16 (11) 6 (10 points) 46 
 
aall information extracted from control group when available; bbased on 80% power, two-tailed p<0.05 with 20% attrition 
SD=standard deviation; MCID=minimal clinically important difference; DASH=Disabilities of the Arm, Shoulder and Hand 
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Table 12. Details on studies used in sample size calculation based on quality of life 
Study informationa Measurement Baseline mean 
(SD) 
Expected 
follow-up mean 
(MCID) 
Estimated 
sample sizeb 
Limitations as relevant to current study 
Anderson et al. (9) 
N=104 breast cancer survivors 
within 3 months of having 
completed surgery 
FACT-B 103.7 (22.1) 110.7 (7 points) 374 
Purposely excluded women with 
lymphoedema 
 
Some participants still undergoing treatment 
Portela et al. (222) 
N=34 post-treatment breast cancer 
survivors 
Spanish version of 
FACT-B 109.9 (22.5) 116.9 (7 points) 388 
Participants did not have lymphoedema at 
baseline 
Stan et al. (267) 
N=15 post-treatment breast cancer 
survivors, n=1 with lymphoedema 
FACT-B 101.8 (14.1) 108.8 (7 points) 154 
Only 1 participant had lymphoedema 
Turner et al. (281) 
N=10 post-treatment breast cancer 
survivors, n=2 with lymphoedema 
FACT-B 98.1 (17.4) 105.1 (7 points) 232 
Only 2 women had lymphoedema 
aall information extracted from control group when available; bbased on 80% power, two-tailed p<0.05 with 20% attrition 
SD=standard deviation; MCID=minimal clinically important difference; FACT-B=Functional Assessment of Cancer Therapy-Breast 
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